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Summary 
 
Osteoprotegerin (OPG), Receptor Activator of Nuclear Factor ᴋB (RANK) and RANK ligand 
(RANKL), are members of the tumour necrosis factor receptor superfamily (TNFRSF), signal 
transducers which have pleiotropic actions. Each family member has unique structural 
attributes shown to couple them directly to specific signalling pathways involved in cell 
proliferation, differentiation and survival. Previous studies have clinically correlated OPG, 
RANK and RANKL expression, at both transcript and protein levels, with increasing cancer 
tumour burden, metastatic bone involvement and androgen status, however the 
mechanisms by which these molecules exert their effects remain elusive. This study aimed 
to establish what influence targeting OPG, RANK and RANKL expression may have on 
osteotrophic prostate and breast cancer cells in vitro and to subsequently explore the 
effect(s) Hepatocyte Growth Factor (HGF) and Bone Matrix Extract (BME) might also exert 
on cancer cell behaviour following manipulation of these molecules.  
The current study utilised 2 prostate cancer cell lines with varying androgen status, 
metastatic potential and bone metastasis phenotypes. Initial screening showed that the more 
aggressive osteolytic PC-3 cells expressed OPG, whilst weakly metastatic mixed-osseous 
LNCaP cells had very low expression. Whilst RANK was present in both cell lines, RANKL 
expression was only detected in the LNCaP cells. Reduction of OPG expression in the PC-3 
cells resulted in increased cell invasion in vitro, which was further enhanced when treated 
with BME. No other cellular traits were affected by targeting OPG directly, however, cell 
migration was enhanced when the manipulated cells were exposed to the representative 
bone microenvironment. In contrast the addition of a recombinant form of OPG to LNCaP 
cells resulted in decreased cell invasion, a trend which was reversed when combined with 
BME. Combination of OPG and BME treatment reduced the migratory response of LNCaP 
cells, whilst combination of OPG and HGF were pro-migratory. The targeting of RANK in 
PC-3 cells affected cell proliferation and matrix adhesion in vitro though the addition of HGF 
or BME appeared to have no further direct influence on these manipulated cells. Targeting of 
the RANKL expression with a neutralising monoclonal antibody had little effect on cancer 
cell behaviour; however combined exposure with HGF or BME resulted in similar behaviour 
patterns seen under the OPG treatments.  
In our breast cancer cohort, RANK and RANKL expression were correlated with bone 
metastases and survival rates. Though OPG did not appear to be associated with grading, 
data also implied a role in overall survival. In the aggressive osteolytic MDA-MB-231 breast 
cancer cells, reduced OPG expression resulted in increased motility and invasion, traits 
which were little affected upon exposure to HGF or BME. In contrast the targeting of RANK 
expression in MDA-MB-231 cells resulted in reductions in all the cancer cell behaviours 
studied, but again these appeared unaffected under the influence of HGF or BME.  
The complexity of the bone environment underpins the vast number of soluble factors, 
signalling pathways and transcription regulators which can influence osteotrophic cancer 
cells. As indicated by the licensing of Denosumab, one therapeutic approach is not suitable 
for all osteotrophic cancers. Therefore further elucidation into the intricacies of these 
interactions is needed.  
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General Introduction 
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1.1 Prostate  
The prostate gland, found exclusively in mammals, is a partly glandular partly 
muscular organ, the size and shape of a walnut, which completely surrounds the 
prostatic portion of the urethra. It is located within the lower pelvis deep to the 
superior fascia of the urogenital diaphragm, inferior to the urinary bladder and 
anterior to the rectum. 
 
1.1.1 Formation and morphogenesis 
Prostate formation is a feature of embryogenesis which occurs through epithelial 
budding from the urogenital sinus. The prostate gland originates from the 
intermediate region, known as the pelvic part.  The maturation time of the prostate 
gland, the lengthening and branching of prostatic ducts, differs greatly within the 
population, largely occurring in response to testosterone metabolites, including 
dihydrotestosterone (DHT),  secreted from the developing testes during puberty (Vis 
and Schroder 2009a).  
DHT is the primary intracellular, intraprostatic androgen which plays an essential 
role in prostate development and growth due to its high binding affinity for the 
androgen receptor (AR) and its capability of stabilising the ligand-androgen receptor 
complex (Vis and Schroder 2009b).  DHT exhibits differing functions dependent on 
the individual’s developmental stage. In utero, DHT is vital for normal differentiation 
of external male genitalia and the prostate whilst during puberty DHT is responsible 
for facial hair, acne and prostate growth (Marks 2004, Imperato-McGinley 2002).  
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1.1.2 Structure  
The prostate gland is enclosed within a fibrous capsule. It consists of several 
glandular and non-glandular regions formed by the urethra and the ejaculatory ducts 
that extend through the gland (Martini and Nath 2009). The capsule consists of 
prostatic stromal smooth muscle which gradually extends into fibrous tissue that 
terminates with loose connective and adipose tissue. Extensive bands of smooth 
muscle course throughout the prostate to form a meshwork that supports the 
glandular tissue. Prostate anatomy was first defined by McNeal as three distinct 
morphological regions: the peripheral zone; transition zone and the central zone 
(Figure 1.1) (McNeal 1969, 1988b). Each zone has different pathological 
tendencies; benign hyperplasia (BPH) develops in the transition zone whilst prostate 
cancer tends to originate in the peripheral zone (Table 1.1) (McNeal 1988a).   
 
1.1.3 Function 
Contraction of the prostatic smooth muscle results in expulsion of the contents of 
the gland, and provides part of the propulsive force needed to ejaculate semen. 
Discharge from the prostate makes up approximately 40% of the volume of the 
semen (Martini and Nath 2009). The thin, milky prostatic secretion assists spermatic 
motility by acting as a liquefying agent. Its alkalinity also protects the sperm during 
their passage through the acidic environment of the female vagina. The prostate 
also secretes several enzymes including acid phosphatase, which is often 
measured clinically to assess prostate function and possibly highlight the presence 
of cancer (Ludwig and Weidner 2000, Zielie et al 2004).  
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1.3 Natural history and pathophysiology of prostate cancer 
1.3.1 Natural history 
Prostate cancer is generally age-related and tends to be very slow growing with a typical doubling time of 3-4 years.  
 
 
 
 
 
 
 
 
 
 
A B 
Figure 1.1 - Prostate Anatomy 
Prostate has three distinct morphological zones shown in the frontal (A) and sagittal (B) planes, highlighting the three distinct regions identified by McNeal (Figure 
adapted from Kirby 2003) 
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Table 1.1 - Anatomical mass of the individual zones in the prostate, their location 
and the incidence of prostate related conditions that originate in each zone (adapted 
from Crawford 2009) 
 
Zone Mass 
(%) 
Location % of cancer case 
origins 
Transition 5-10 Surrounds the urethra proximal 
and entry of the ejaculatory 
ducts 
BPH and 
~ 10-15% cancer 
cases 
Central 20-25 Below the proximal urethral 
segment. The ejaculatory duct 
passes through the central 
zone before entering the 
urethra 
~ 15-20% 
Peripheral 70-75 A double row of duct buds that 
laterally surrounds the central 
zone and occupies the apical 
region of the prostate 
~ 70% 
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1.1.4 Natural History and Pathophysiology  
The majority of prostate cancers remain clinically silent or are slow-progressing 
malignancies not associated with, or attributed as, cause of death. However, it is not 
yet possible to predict which of these histological cancers will progress to 
aggressive clinical disease requiring intervention and therapy. Autopsy data 
suggests that the prevalence of prostate cancer could be as high as 90% in men 
aged 70-90 (Guileyardo et al 1980, Yatani et al 1988, Sakr et al 1993). 
Retrospective data analysis from patient studies also found that highly or 
moderately differentiated tumours at time of diagnosis yielded an 87% 10 year 
disease-specific survival rate, whilst poorly differentiated tumours were associated 
with only a 34% survival rate (Chodak et al 1994, Johansson et al 2004).  
Early prostate tumourigenesis appears to be associated with a dysplasia starting 
with proliferative inflammatory atrophy, which progresses to prostatic intraepithelial 
neoplasia (PIN), which in turn may lead to some cases of carcinoma.  The majority 
of all prostate cancer cases are adenocarcinomas and very few have 
neuroendocrine morphology (Dunn and Kazer 2011). Most cases are multifocal, 
multicentric lesions of varying grades presenting in different zones of the prostate 
(Crawford 2009).  
 
1.1.4.1 Benign Prostatic Hyperplasia 
Benign Prostatic Hyperplasia (BPH) is a non-malignant overgrowth of the epithelium 
and fibromuscular tissue in the transition zone and periurethral area of the prostate 
(Kirby 2003, Crawford 2009). The development of BPH includes three pathologic 
stages: nodule formation, nodule enlargement and diffuse expansion of the 
transition zone and periurethral tissue (Bostwick et al 2004).  In younger men (<70 
years) diffuse expansion and nodule formation predominates. However, in older 
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men the presence of epithelial proliferation and expansive growth of existing 
nodules occurs, possibly due to aberrant stimulation by androgens and other 
hormones (Berry et al 1984, Bostwick et al 2004). Histologically, BPH includes 
expansion of the basal layer, stromal hyperplasia, including fibrosis, and associated 
inflammation ((McNeal 1978, McNeal 1988a) (Figure 1.2). 
 
 1.1.4.2 Prostatic Intraepithelial Neoplasia  
Prostatic Intraepithelial Neoplasia (PIN) is characterised by the multi-layering of 
luminal epithelial cells and a disappearing basal epithelial cell layer (Figure 1.3) 
(Kirby 2003). PIN is often referred to as the precancerous end of a continuum of 
cellular proliferations within the epithelial lining of prostatic ducts, ductules and acini, 
whilst cytologic changes mimic cancer by nuclear and nucleolar enlargement 
(Bostwick 2000, Bostwick et al 2000). PIN, by retaining a fragmented basal layer, 
can coexist with cancer (Bostwick et al 2004).  Evidence suggests PIN are 
androgen dependent lesions which show heterogeneity and have a multifocal 
appearance, although obtaining tissue for study is difficult (Bostwick and Cheng 
2012). In normal prostate epithelium, luminal secretory cells are more sensitive to 
the absence of androgen than basal cells, indicating that PIN shares this androgen 
sensitivity. A marked decrease in high-grade PIN has been reported after androgen-
deprivation therapy compared with untreated lesions, also supporting this theory 
(Bostwick and Cheng 2012). The continuum that culminates in high-grade PIN and 
early invasive cancer is characterised by progressive basal cell layer disruption, 
abnormalities in secretory differentiation markers, increased cell proliferation, 
increased nuclear and nucleolar alterations, increased genetic instability and 
variation in DNA content (Bostwick and Brawer 1987).  
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Figure 1.2 – Benign Prostate Hyperplasia (BPH) Histology 
Histologically BPH is generally characterised by proliferation of stromal and epithelial 
components resulting in nodule formation. (A)  Histological evidence of hyperplastic 
nodules of epithelium and stroma. (B)  BPH basal cell hyperplasia showing stratified 
layers of compressed tall columnar cells. Double cell layers of LP34 positive and PSA 
positive luminal cells confirm benign nature of specimen (as shown by arrow head). (C) 
Histological example of epithelial hyperplastic nodules (D) Histological example of 
stromal overgrowth in hyperplastic nodules, generally periurethral, often situated 
beneath the urethral epithelium (adapted from Kirby 2003) 
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Studies have reported that PIN tends to occur predominantly in the peripheral zone 
of the prostate, or simultaneously in the transitional and peripheral zones, where 
most cancers arise (Epstein et al 1990, Quinn et al 1990). Appearance of high 
grade PIN lesions generally precedes the appearance of carcinoma by at least 10 
years, however PIN lesions do not produce high levels of prostate specific antigen 
(PSA), they are only detectable by biopsy (Bostwick and Cheng 2012). Several 
studies have made associations between PIN and prostate cancer on 
epidemiologic, clinical, genetic and molecular levels (Nagle et al 1991, Bostwick et 
al 1993, Montironi et al 1993). Cancerous prostates were shown to have 
significantly increased (82%) evidence of PIN compared to spontaneous cancerous 
prostates without any previous evidence of PIN lesions (43%) (McNeal and 
Bostwick 1986, McNeal et al 1986, Bostwick and Brawer 1987).    
 
1.2 Prostate cancer 
Amongst men in Western society, prostate cancer is a highly prevalent non-
cutaneous disease. Within the UK, it accounts for 25% of newly diagnosed male 
cancer cases per year (2010 – 41,700 diagnosed in UK) and it was fatal in 10,721 
cases (Cancer Research UK CancerStats, 2012).   The European age-standard 
incidence rate of prostate cancer is significantly higher in Wales (114.0/100,000 
male population), than in any other constituent part of the UK. Increasing incidence 
in developing parts of the world underwrites concerns for future healthcare systems 
and increasing financial burdens associated with cancer management and 
treatment, thus driving the need for a better understanding about this disease, its 
risk factors and its progression. 
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Figure 1.3 – Prostatic Intraepithelial neoplasia (PIN) Histology 
PIN may be a precursor for most prostate cancer cases; (A) Low grade PIN 
showing stratified epithelium and the nuclei are larger than those of the normal 
acini. (B) High grade PIN shows stratified epithelium, cells that have lost their 
polarity and nuclei are larger and contain nucleoli. The outer layer of basal cells 
can still be seen (adapted from Kirby 2003) 
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1.2.1 Epidemiology and risk factors 
There remains a need to identify risk factors and the multiple genetic changes which 
are involved in the development of prostate cancer, with particular emphasis on 
recognising those patients who will develop highly aggressive forms of the disease. 
Data suggests that more men will die with indolent prostate cancer than those who 
will die as a result of prostate cancer (Crawford 2009). However, as life expectancy 
increases, incidence of prostate cancer will continue to be a major health concern 
worldwide.  
 
1.2.1.1 Age 
Prostate cancer incidence and mortality is strongly correlated with increasing age. In 
the UK, between 2008 and 2010, 75% of prostate cancer cases were diagnosed in 
men over 65 years, whilst the under 50’s accounted for just 1% (Figure 1.4). 
 
1.2.1.2 Ethnicity 
The highest age adjusted incidence rate of prostate cancer is found within the 
African American community (272/100,000), almost twice as prevalent as in 
Caucasians, whilst the lowest age-adjusted incidence rate is found within Asian and 
Pacific Islanders communities (93.8/100,000). However these statistics do not 
always reflect the influence of migration. Evidence has shown when Japanese men 
relocated to the United States, or other western countries, their prostate cancer 
incidence statistics started to resemble those of the local (Caucasian) population 
(Dunn 1975, Locke and King 1980).  This can be further compounded by the age at 
time of relocation and the length of time spent in this environment which also 
correlated with increased risk (Shimizu et al 1991).  
12 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 - Age related incidence of prostate cancer 
Graph showing the average number of new prostate cancer cases per year and the age specific 
incidence within UK men between 2008 and 2010 (Cancer Research UK CancerStats, 
2012) 
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1.2.1.3 Family history 
Familial susceptibility was first associated with prostate cancer in the 1950’s, 
however it was not until the early 1990’s that the concept of hereditary prostate 
cancer was established and susceptible loci identified (Steinberg et al 1990, Carter 
et al 1992a). Two familial susceptibility loci have been mapped to the X 
chromosome, region 1q (Smith et al, 1996, Xu et al 1998). Through linkage 
analysis, subsequent research has highlighted several other susceptible 
chromosomal loci, though there are many contradicting studies in the literature 
(Table 1.2).  
Hereditary factors account for approximately 10% of diagnosed prostate cancer 
cases and are generally associated with early disease onset (Carter et al 1992a, 
Carter et al 1993). The risk of prostate cancer increases approximately two-fold for 
men with a first degree relative with prostate cancer, showing a stronger familial 
component than colon and breast cancer (Carter et al 1993, Bostwick et al 2004). 
This risk is further increased if relatives were diagnosed before the age of 60 years 
or if more than one first degree relative has been diagnosed (Gronberg et al 1999, 
Bratt et al 1999, Cotter et al 2002).  Several epidemiological studies have indicated 
that the risk of developing prostate cancer is stronger in brothers than it is in sons, 
suggesting environmental factors may also have a strong role (Narod et al 1995, 
Lesko et al 1996, Cerhan et al 1999, Bratt 2002, Bratt et al 2002). Also based on 
these observations a strong X-linked recessive inheritance has been suggested to 
affect some families.  
Several studies report an increased incidence of prostate cancer linked to men who 
have a first degree female relative with breast cancer (Thiessen 1974, Rodriguez et 
al 1998), though this remains contentious.  
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Table 1.2 – List of the main loci linked to prostate cancer (info from OMIM, Bratt 2002 and Brown et al 2004)
Loci Association Chromosomal 
location 
Reference(s) in favour Reference(s) against 
HPC1 Increased copy number in advanced 
prostate cancer specimens, not 
strongly linked with sporadic disease 
1q24 – 25 Smith et al 1996, Cher et al 1996,  Ahman et al 2000,  Latil et al 1997 
PCaP 
(HPC8) 
Pre-disposition to develop prostate 
cancer 
1q42.2-43 Berthon et al 1998, Cancel-Tassin 
et al 2001b 
Berry et al 2000a, Bergthorsson et al 
2000 
CAPB Early onset of prostate cancer 1p36 Gibbs et al 1999 Berry et al 2000a, Suarez et al 2000 
HPCX Recessive inheritance Xq27-28 Xu et al 1998, Farnham et al 2005 Bergothorsson et al 2000, Hsieh et al 
2001 
HPC3 
(HPC20) 
Later onset of disease 20q13 Berry et al 2000b, Zheng et al 
2001, Bock et al 2001 
Cancel-Tessin et al 2001a 
MSR1 Susceptibility to developing prostate 
cancer in both European and 
African-American men  
8p23-p22 Latil and Lidereau 1998, Xu et al 
2001, Xu et al 2002, Maier et al 
2005 
Wang et al 2003, Maier et al 2006 
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1.2.1.4 Diet 
Dietary components have also been proposed to have a role in prostate cancer 
incidence (Nelson 2003). Dietary differences among racial groups, socio- economic 
classes and geographic locations may contribute for some differences seen in 
prostate cancer epidemiology and biologic behaviour (Whittemore et al 1995, 
Crawford 2009). Gaziano and Heenekens (1995) found a positive association 
between prostate cancer risk and fat intake, especially polyunsaturated fat. Other 
studies have identified that obese men may be more susceptible to developing 
prostate cancer. Japanese men consume a relatively low-fat diet, however as the fat 
content of the Japanese diet has increased towards Western levels, the incidence of 
prostate cancer has also increased (Marks et al 2004). Early detection efforts and 
detection bias may account for some of this, though it is unlikely to account for all. 
Many vitamins have also been associated with prostate cancer risk (Bostwick et al 
2004).  Vitamin D deficiency has been implicated in prostate cancer development, 
as the hormonal form, 1-25-dihydroxyvitamin D, exhibited anti-proliferative and anti-
differentiative effects on prostate cancer cells as well as inhibiting cancer cell 
invasiveness (Bostwick et al 2004). Whilst a prospective study into the active form 
of Vitamin D, 1,25-dihydroxycholecalciferol, found an association between low 
serum levels and an increased risk of prostate cancer in elderly men, however, this 
did not translate to lower age groups (Corder et al 1993). The retinoids, including 
vitamin A, have also been shown to help regulate epithelial cell differentiation and 
proliferation, and therefore may also have a positive association with prostate 
cancer risk (Bostwick et al 2004, Tang and Gudas 2011).   
Many other studies have been conducted to examine the influence of dairy intake, 
red meat consumption and prostate cancer incidence (Rodriguez et al 2006, Park et 
al 2007b). Initially believed to be associated with the fat content of dairy products, a 
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more recent hypothesis is that the increased dietary calcium levels may suppress 
production of 1-25-dihydroxyvitamin D thereby increasing the risk of prostate cancer 
(Chan and Giovannucci 2001, Rodriguez et al 2003, Giovannucci 1998). 
This field however remains controversial and several studies have been conducted 
to analyse the prophylactic effects of vitamin supplements. As an antioxidant, 
Vitamin E (α-tocopherol) has been shown to inhibit prostate cancer cell growth 
through apoptosis (Fleshner et al 1999).  In a large, controlled clinical trial in Finland 
a daily intake of Vitamin E was shown to decrease the risk of prostate cancer by 
32% (Heinonen et al 1998, Knekt et al 1988).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
 
1.2.2 Grading and staging system 
At time of diagnosis, prostate carcinomas are scored, based on histological patterns 
using the Gleason grading system, first described in 1966 (Figure 1.5) (Gleason 
1966). Morphologically heterogeneous, prostate cancer behaves in accordance with 
the average morphology; therefore the two dominant grades are identified and 
combined to arrive at the reported total Gleason score (Table 1.3). As most lesions 
are multifocal, the most prominent histological pattern is assigned grade 1-5, whilst 
the other grade is assigned to the second most common pattern (Table 1.4) 
(Humphrey 1994).   
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Figure 1.5 – Prostate Cancer 
Staging 
Visual of the Gleason grading 
system devised between 1960 
- 1975. Patterns were 
arranged into five grades with 
numbers corresponding to 
increasing malignancy 
determined by mortality data.  
Histology specimen of 
Gleason grade 2 (A), 
Histology of Gleason grade 3 
specimen (B), Histology of 
Gleason grade 4 specimen(C)  
Histology of Gleason grade 5 
(D) 
(Adapted from Kirby 2003) 
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Table 1.3 – Total differentiation scores of prostate cancer (adapted from Che and      
Grignon 2002) 
  
 
 
 
 
Table 1.4 – Descriptions of the histology observed for each grade of the Gleason    
scoring system (adapted from Che and Grignon 2002) 
 
 
 
 
 
Total Grade classification Differentiation 
5-7 Intermediate grade, moderately 
differentiated 
 
8-10 
 
High grade, poorly differentiated 
Gleason Grade Description 
1 Acini which are consistent in size and 
well defined nodules 
2 Closely packed acini, less consistent 
in size 
3 An irregular mass of malignant acini 
typically small and angular which 
have started to infiltrate benign acini 
4 Malignant acini have fused to form 
irregular masses 
5 Sheets of anaplastic malignant cells 
with little evidence of gland formation 
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1.2.3 Screening and detection 
In most cases prostate cancer is slow growing and therefore may not result in 
clinical symptoms during a patient’s lifetime. However, tumours are frequently 
detected due to routine testing which can result in unnecessary clinical intervention 
causing adverse effects on the patient (Berry et al 1984, Holman et al 1999, Lilja et 
al 2008). When aggressive prostate cancer does progress it results in a burden to 
the patient’s health which translates into increased morbidity and mortality. 
Therefore great effort continues to develop effective detection markers, schemes 
and accurate prognostics which might be able to distinguish between indolent and 
aggressive prostate diseases (Abate-Shen and Shen 2000, Berrruti et al 2005).  
Currently the Prostate-Specific Antigen (PSA) test and the Digital Rectal 
Examination (DRE) are used as primary screening tools whilst Transrectal 
Ultrasound-guided biopsy (TRUS) is performed to confirm diagnosis.  
 
1.2.3.1 Guidelines for screening and early detection 
Efforts continue to educate men regarding the benefits and limitations of early 
detection and treatment of prostate cancer to enable them to make informed 
decisions about testing (Heidenreich et al 2011b).  Within the UK and other parts of 
the developed world, experts disagree on the usefulness of the PSA test (Detchokol 
and Frauman 2011). Alongside this, the economic burden and adverse effects of 
overtreatment mean that there is no widespread screening programme for prostate 
cancer. However, the American Cancer Society recommends PSA tests and DRE 
for men over 50 years old who have at least a 10-year life expectancy (Ulmert et al 
2008). 
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A recent study in the USA (Prostate, Lung, Colorectal and Ovary trial (PLCO)) found 
that there was no correlation between annual PSA and DRE assessments and a 
decline in mortality rates compared to those who had standard treatment with some 
monitoring (Andriole et al 2005, Andriole 2009, Andriole et al 2009). A similar large 
randomised study conducted in Europe (European Randomised Study of screening 
for Prostate Cancer (ERSPC)) initially supported the findings of the PLCO study. 
However more recent retrospective analysis from the ERSPC has shown that the 
relative risk of prostate cancer metastases and prostate cancer specific mortality 
was significantly lower in the screening arm than in the control group (Djavan 2011). 
For men in high risk groups, the American Urological Association recommends PSA 
testing should begin as early as 45 years, especially amongst African-American 
men with a first degree relatives diagnosed with prostate cancer before the age of 
65 years (Dunn and Kazer 2011).   
 
1.2.3.2 Prostate-Specific Antigen (PSA) test 
Elevated serum PSA levels have been associated with prostate cancer and 
therefore PSA is used as the standard screening tool for disease detection 
(Dimakakos et al 2014).  However, BPH, inflammation, TRUS, biopsy and 
transurethral prostatectomy also increase serum PSA levels, and thus its role as a 
specific marker for detecting prostate cancer remains under intense scrutiny 
(Stamey et al 1987, Hernandez and Thomson 2004, Ablin and Piana 2014). In men 
displaying elevated serum levels of PSA, 30-50% of cases were associated with 
BPH whilst only 25% of cases were prostate cancer related (Andriole Jr 2012, 
Schroder 2009). Further evidence has also demonstrated that serum PSA levels 
can be affected by several drugs including 5α-reductase inhibitors such as 
finasteride (Thompson et al 2006).  PSA serum levels detected within the range of 
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2.6-4.0ng/ml are associated with tumours that are generally significantly smaller and 
organ confined, compared with tumours detected when PSA serum levels are 
greater than 4.0ng/ml (Krumholtz et al 2002).  However serum levels of PSA do not 
correlate to tissue PSA expression levels at any stage of prostate cancer (Qiu et al 
1990). Whilst there is a lack of evidence, it is hypothesised that elevated serum PSA 
levels may be due to the loss of architecture in the normal prostate, which is integral 
to confining it to the prostate gland (Lilja et al 2008). Based on this theory it is serum 
PSA levels which are used to direct which management strategy is recommended 
for patients. For those who have a serum PSA level of less than 10ng/ml and low 
grade tumours active surveillance is recommended. However in patients with serum 
PSA levels of 10-20ng/ml and a life expectancy of 10 years radical prostecomy is 
indicated (Heidenreich et al 2011).   
To improve the utility of the PSA test, increased specificity and sensitivity for 
prostate cancer parameters such as PSA velocity or PSA density have been 
proposed and explored. Carter and colleagues found that a PSA velocity increase of 
0.75ng/ml/annum was significantly associated with clinical prostate cancer (Carter 
et al 1992b). More recent data highlights that these approaches have limited 
additional diagnostic use to the stand-alone PSA test as definitive diagnosis of 
prostate cancer still required needle biopsy of the prostate (O’Brien et al 2009, 
Vickers et al 2009, Lilja et al 2008).  
 
1.2.3.3 Other tumour markers 
Clinicians, pharmaceutical companies and research laboratories around the world 
continue to strive to identify new, specific and sensitive markers for prostate cancer.  
The best markers would have the potential to distinguish between BPH, PIN, 
indolent and malignant cancer with high sensitivity and specificity (Chodak 2006). 
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Potential tests should use a selection of positive and negative markers whilst also 
being easy to use, inexpensive, non-invasive and quick to analyse (Chodak 2006).   
Varambally et al (2005) showed that, in prostate cancer tissue samples, the 
equivalence between RNA transcript levels and protein products ranged between 
48% and 62%. This has resulted in more focused efforts to identify protein 
biomarkers involved in prostate cancer development.  
Prostate cancer antigen 3 (PCA3), is one of the most promising candidates to 
emerge. PCA3 RNA has been measured in urine sediment after prostatic massage 
(Deras et al 2008). Testing this biomarker as a prostate cancer marker currently 
continues to be experimental and data looks promising at a population level, 
however, using this test for isolating those patients more susceptible to aggressive 
disease remains questionable (Heidenreich et al 2011).   
Similarly, TMPRSS2:ERG gene fusion is frequently present in 50% of prostate 
cancer cases but is not detected in normal prostate tissue or BPH (Cerveira et al 
2006, Park et al 2010, van Leenders et al 2011). Non-invasive detection of this gene 
fusion has been achieved using real-time PCR on urinary sediment, with 93% 
specificity, for prostate cancer (Dimakakos et al 2014). This is a potential diagnostic 
candidate for the future, as it can also be used in combination with other markers 
(Hessels et al 2007, Salami et al 2013). 
 
1.2.3.4 Metastatic disease detection 
Autopsy data has shown that 90% of the metastatic prostate cancer cases 
metastasised to the bone, whilst the other 10% of detected metastases sites were in 
organs such as the lungs and liver (Bubendorf et al 2000). Hess et al (2006) 
concluded from their study, for 86% of patients, bone metastases were the only 
detected metastatic site.  This, combined with a study which demonstrated an 
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inverse relationship between spine and lung metastases, indicates the possibility of 
two independent metastatic patterns (Thobe et al 2011). Despite a variety of studies 
there remains no way of predicting the sub-group of prostate cancer patients which 
are at high risk of developing metastatic disease (Briganti et al 2014).  
Based on current clinical data from the European Association of Urology and 
European Society of Medical Oncology the combination of an increased PSA (≥15- 
20ng/ml) and a high biopsy Gleason score (˃7) enhances the possibility and 
presence of bone metastases (P˂0001) and dictates a bone scan and an MRI or CT 
for the possibility of soft tissue metastases (Crawford et al 2013). Primarily, 
diagnosis of bone metastases relies on radioactive bisphosphonates such as 
technetium-99m methylene-diphosphonate and conventional x-ray, though more 
modern approaches such as positron emission tomography-computed tomography 
(PET-CT) are providing more specific and sensitive screening, but are also 
associated with greater financial costs (Tombal and Lecouvet 2012).  
Nuclear scintigraphy has the ability to reveal bone metastases significantly earlier 
than that of conventional x-ray. For a reliable method of detecting and monitoring 
bone metastases nuclear medicine is used, however, upon detection of metastatic 
bone disease; treatment options remain limited (Storey and Torti 2007). 
 
1.2.4 Management  
Treatment of localised prostate cancer disease has made major advances in the 
last decade. If the cancer is detected at an early stage prior to it metastasising it can 
often be treated successfully by surgery or local irradiation, potentially curing the 
patient (Chambers et al 2002). Yet despite recent advances in bone targeted 
therapies, half of metastatic prostate cancer patients will die from the disease within 
30-35 months as treatment plans still do not ultimately prevent the formation of new 
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bone lesions, further morbidity and disease progression (Buijs and van der Pluijm 
2009,  Suva et al 2011). 
Patients who do not initially present with metastases at the time of primary 
diagnosis may already have metastases, though they may not be clinically 
apparent, which can further complicate therapy (Buijs and van der Pluijm 2009). 
Data has shown that in castration-resistant prostate cancer patients with no 
identifiable metastases at time of diagnosis, 33% developed bone metastases within 
2 years (Smith et al 2005). 
 
1.2.4.1 Treatment of localised disease 
The approach taken to treat localised prostate cancer disease varies greatly based 
on the harm-balance benefits to the patient. Advances are constantly being made in 
this area, attempting to minimise adverse effects on the patient both during therapy 
and with potential long term complications. The current main stays of prostate 
cancer treatment include surgery or localised irradiation (Table 1.5). 
 
1.2.4.2 Treatment of advanced disease 
Prostate cancer can be considered a chronic disease if treatments have slowed 
disease progression. However if the disease has metastasised currently further 
therapeutic interventions are rarely curative. Until recently the main-stay of 
metastatic prostate cancer treatments have focused on targeting the tumour cells by 
using androgen ablation or cytotoxic therapies. However, as understanding of the 
disease and the bone microenvironment has evolved newer, more selective 
targeted therapies have emerged.  Despite this, treatments so far have only had 
modest effects on patient survival (Ye et al 2007). 
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Table 1.5 – List of main management options of localised prostate cancer (Adapted 
from prostatecanceruk.org) 
 
Treatment 
 
Approach 
Monitoring Active surveillance Long term monitoring of slow growing 
prostate cancers which may never 
progress or cause symptoms 
 
Watchful waiting 
Surgery Radical prostatectomy Operation to remove the prostate gland. 
Suitable for patients where cancer is 
contained within the gland  but otherwise 
healthy 
 
Cyrosurgery Using freeze thawing to kill cancer cells in 
the prostate.  
 
Therapies Permanent seed 
brachytherapy 
Implant of a radioactive seed into the 
prostate gland. Can be used in 
combination with external beam 
radiotherapy and hormone therapy 
 
Hormone therapy Helps control prostate cancer by stopping 
the hormone testosterone from reaching 
the prostate cancer cells.  Not curative 
but helps to manage symptoms 
Can be used in combination with 
brachytherapy or radiotherapy 
 
Temporary brachytherapy Insertion of a high dose rate radiation for 
very short periods of time 
 
External beam radiotherapy Uses high energy x-ray beams to treat 
prostate cancer. Can be used in 
combination with permanent or temporary 
seed brachytherapy or after surgery 
 
High intensity focused 
ultrasound 
Uses high frequency ultrasound waves. 
Newer therapy, long term effects remain 
unknown 
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Transition to metastatic disease includes local invasion into the seminal vesicles, 
followed primarily by the development of bone metastasis.  The disturbance to 
normal bone turnover associated with bone metastases leads to debilitating 
skeletal-related events (SREs) including intractable pain, pathological fracture, 
spinal cord and nerve compression and hypercalcaemia (Coleman 2006). 
During all stages of prostate cancer, patients may suffer from generalised bone loss 
or localised decreases in bone integrity, as lower bone mineral density has been 
reported in hormone therapy naïve patients with early stage prostate cancer (Saad 
et al 2004). The risk with the current first line treatments for advanced disease is 
that most are associated with accelerated bone loss, a process which can contribute 
to SREs particularly to increased risk of fractures (Ye et al 2007). 
Androgen deprivation therapy, the most common intervention for prostate cancer 
treatment, is achieved by surgical ablation (orchiectomy) and/or pharmacological 
inhibition of gonadotrophin signalling e.g. luteinising-releasing or gonadotropin-
releasing hormone agonist. There has been strong evidence to support the idea that 
androgen deficiency can increase osteoclast-mediated bone resorption and affect 
the bone microenvironment, which may ultimately increase the risk of bone 
metastasis (Ye et al 2007). Initially, 75-80% of metastatic prostate cancer cases 
respond to androgen ablation therapy, which can help to alleviate bone pain, 
however this is only a palliative measure because the metastatic prostate cancer 
will eventually lethally progress, with hormone resistance (Ye et al 2007).  
Recent advances in hormone therapy have led to the approval of Abiraterone and 
Triptorelin, from NICE, for the treatment of advanced prostate cancer which had 
stopped responding to other hormone therapies. Both therapies, by blocking the 
synthesis of testosterone, result in decreases in serum PSA levels and reductions in 
tumour size (Attard et al., 2008, Reid et al 2010, Ploussard and Mongiat-Atrus 
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2013). Abiraterone has also been approved for use in combination with the 
chemotherapy agent prednisolone.  
After the development of hormone resistant prostate cancer, the systemic line of 
therapy is chemotherapy. A combination of docetaxel and prednisolone is now the 
standard of care for hormone resistant prostate cancer patients (Berthold et al 2005, 
Berthold et al 2008). Other ongoing clinical trials combining other chemotherapy 
agents such as calcitriol in combination with docetaxel are also underway (Beer et 
al 2007, Scher et al 2011). Though the signs are encouraging, survival benefits 
remain modest and more effective alternatives continue to be sought (Ye et al 
2007). 
For the majority of patients, external beam radiotherapy or radiopharmaceuticals 
provide palliation for localised metastatic bone pain (Storey and Torti 2007). 
Radiation therapy can temporarily control bone pain in 50-90% of treated patients 
and may prevent bone lesion progression, although repetitive treatments can result 
in cumulative toxicities. Strontium-89 is the prototypic example of a wide field bone 
targeted radioisotope, functioning as a calcium analogue, preferentially taken up at 
sites of bone formation (Porter et al 1993). As it subsequently decays over time, 
radioactive β particles are emitted throughout the tumour-bone microenvironment 
(Coleman 2001b, Storey and Torti 2007). Samarium-153 has also been shown to be 
preferentially taken up at sites of bone formation; emitting both β and γ particles 
whilst also having significant effects on bone pain and analgesic consumption 
(Coleman 2001b).   
The most successful strategy for targeting bone metastasis or preventing bone loss 
induced by other therapies targeting prostate cancer is the use of bisphosphonates, 
such as zoledronate, which are generally well tolerated in long term use and can be 
co-administered with chemotherapy agents (Saad et al 2004, Taichman et al 2007). 
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Bisphosphonates, as analogues of pyrophosphates, target the bone remodelling 
process directly by inhibiting osteoclast maturation and function (Taichman et al 
2007). Much debate still remains on the optimum time to administer 
bisphosphonates to prostate cancer patients (Coleman 2001c, Storey and Torti 
2007). 
 
1.2.4.3 Therapies in trial 
The unique pattern of metastases associated with prostate cancer, has resulted in 
rapid identification and exploration of potential therapeutic targets which might be 
capable of disrupting interactions between prostate cancer cells and the bone 
(Storey and Torti 2007).  New approaches being explored include targeting specific 
pathways using synthetic peptides or immunotherapy (Table 1.6). Unfortunately, 
despite the advances in prostate cancer therapy and the continued identification of 
potential new targets, prostate cancer still remains one of the major leading causes 
of death for men in developed countries. Therefore a better understanding of the 
aetiology of prostate cancer and the co-operation between the bone niche and 
prostate cancer cells may help to drive future therapeutics.  
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Table 1.6 – List of main targets being investigated to treat prostate cancer (adapted from Taichman et al 2007 and Deng et al 2014)
Cell type Target Sample agent References 
Prostate cancer cell Aberrant growth factor 
receptor activation 
EGFR: gefitinib; PDGFR: imatinib; IGF1R:A12; IL-6: 
CNT0328 
Craft et al1999, Bajaj et al 2007, Wu et al 2006, Wallner et al 
2006 
Bcl-2 AT101 Wang et al 2006 
Microtubules Ixabepilone halichondrin Tan 2006, Calabro and Stenberg 2007, Berthold et al 2005 
DNA replication Satraplatin Oh et al 2007 
Histone deacetylase  Vorinostat Marrocco et al 2007 
Proteasome Bortezomib Ikezoe et al 2004 
mTOR Rapamycin analogs Majumder and Sellers 2005 
Clusterin OGX-011 Miyake et al 2006 
Proliferative agents Calcitriol, DN-101 Beer et al 2007 
Bone Bone 
Formation 
Endothelin-1 receptor Atrasentan, Zibotentan Carducci et al 2007, Nelson et al 2012 
Bone 
resorption 
Pyrophosphate Zoledronic acid, Clondrate Prakash and Gautam 2013, Rodrigues et al 2011, Dearnaley 
et al 2009 
RANKL Denosumab, OPG-Fc, RANK-Fc Fizazi et al 2011, Smith et al 2012, Virk et al 2011, Miller et al 
2008, Whang et al 2005 
SRC Daatinib, Saracatinib, Bosutinib Yu et al 2009, Rabbani et al 2010,  
Endothelial cell VEGF Bevacizumab. VEGF-TRAP Ryan et al 2006, Baka et al 2006, Roberts et al 2013 
VEGFR Sunitinib, vatalanib, sorafenib Flaherty 2007, Pantuck et al 2007 
Αvβ3/5 integrin Cilengitide Eskens et al 2003 
Permeability  Dimethylxanthenone Seshadri et al 2007 
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1.3 Biology of prostate cancer 
The development of prostate cancer, and progression to an androgen independent 
(hormone refractory) disease, is a complex process that involves many alterations in 
multi-step signalling pathways. Molecular components of these pathways include 
cell signalling, cell cycle, cell survival/apoptotic molecules and angiogenic factors 
which can be affected by activation of oncogenes or loss-of-function of tumour 
suppressor genes. Better understanding of molecular traits and somatic alterations, 
which promote neoplastic prostate growth and drive formation to incurable prostate 
cancer, have the potential to result in more specific and sensitive screening tests 
and targeted therapies.  
 
1.3.1 Androgens, transcription factors and receptor sensitivity  
Androgens and AR signalling are vital for all prostate cellular functions and 
architectural maintenance. Androgens, usually in the form of DHT bind to receptors 
in the cytoplasm causing the receptor-ligand complex to translocate to the nucleus, 
these engage with androgen responsive elements in promoter regions of target 
genes, which directly or indirectly stimulate proliferation and inhibit apoptosis 
(Heemers and Tindall 2007). Transcription factor Forkhead box A1 (FOXA1) is a co-
activator for AR, facilitating AR accessibility to chromatin, and regulates expression 
of AR target genes (Lorente and De Bono 2014). Androgen ablation therapy 
coupled with AR antagonists is the standard therapy for disseminated prostate 
cancer; however, despite initially proving effective, recurrent hormone refractory 
prostate cancer, with disrupted AR signalling, is often detected (Balk and Knudsen 
2008). Evidence suggests that the mechanisms of androgen independence can 
either involve or bypass the AR, with potential for both mechanisms to co-exist in 
prostate cancer (Linja et al 2001, Tomlins et al 2006b). These different outcomes 
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can be achieved by AR amplification, AR hypersensitivity or through AR mutations 
(Feldman and Feldman 2001). 
Testosterone, DHT and AR signalling have also been shown to play active roles in 
prostate tumour growth and early stage cancer progression, though not 
autonomously, and thus remain a major area of research focus (Heemers and 
Tindall 2007, Balk and Knudsen 2008).    
Epidemiologic studies suggest that AR polymorphisms may contribute to the clinical 
behaviour of prostate cancer. Studies indicate that individuals with fewer than 18 
CAG repeats in exon 1 of the AR gene show a two-fold increased risk of developing 
advanced-stage prostate cancer compared to those with greater than 26 CAG 
repeats (Giovannucci et al 1997, Standford et al 1997). A point mutation in codon 
877, in the hormone binding site, of AR has been shown to alter receptor specificity 
allowing for activation by several steroid hormones (De La Taille et al 2001).  
Immunohistochemistry staining has revealed heterogeneous AR distribution, 
becoming more variable with higher grade tumours (De La Taille et al 2001).  
Approximately 30% of tumours which become androgen independent have 
amplified AR gene expression and upregulated AR expression, a response almost 
exclusively seen in recurrent hormone refractory disease (Feldman and Feldman 
2001).  AR sensitivity has also been linked to prostate cancer progression, involving 
increased stability and enhanced nuclear localisation of AR in recurrent cells in vivo. 
This was coupled with hypersensitivity to DHT for growth stimulatory effects 
compared to androgen dependent cells (~4 times lower) (Feldman and Feldman 
2001).  
Several proteins can activate AR directly or indirectly which alter the expression and 
activity of these regulatory proteins also contributing to the androgen-independent 
state associated with lethal prostate cancer progression. Epidermal growth factor 
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(EGF), insulin-like growth factor-1 (IGF-1) and keratinocyte growth factor have all 
been shown to stimulate transcription of reporter genes driven by AR-responsive 
elements in the absence of androgen, whilst Protein kinase A and HER2/neu have 
also been shown to induce the expression of AR-responsive genes such as PSA, 
independent of androgen (Feldman and Feldman 2001).  
 
1.3.2 Oncogenes 
1.3.2.1 Receptor tyrosine kinases (EGFR and HER2/neu) 
Acting as a mitogen for normal prostate epithelial cells, EGFR is also highly 
expressed in prostate cancer cells (Peehl et al 1989, Fowler et al 1988). Activation 
of EGFR signalling is linked to increased cell proliferation, malignant transformation 
and progression (Mansour et al 1994, Magi-Galluzzi et al 1997, Gioeli et al 1999). 
Increased EGFR expression also correlates with disease relapse and progression to 
the androgen-independent state (Di Lorenzo et al 2002). 
HER2/neu is a transmembrane glycoprotein containing a tyrosine kinase domain 
structurally related to the EGFR superfamily, with overexpression linked to breast 
and ovarian cancer progression (Di Lorenzo et al 2004). Results implicating HER2 
in prostate cancer have been contradictory (Scher 2000). Increased expression of 
HER2, associated with HER2 gene amplification, has been found in some prostate 
tumours, though less frequently in localised prostate cancer (Mellon et al 1992, 
Kuhn et al 1993, Ross et al 1997, Kallakury et al 1998, Mark et al 1999). Several 
studies have also linked increased HER2 overexpression with disease progression, 
including a switch from androgen dependence to androgen independence 
(Signoretti et al 2000, Osman et al 2001, Di Lorenzo et al 2004). Jorda et al (2002) 
found that HER2 over expression was present in as many as 60% of patients with 
hormone refractory prostate cancer correlating with decreased survival, whilst Di 
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Lorenzo et al (2004) also showed a potential link between relapsed patients and 
HER2 expression levels.  
 
1.3.2.2 MYC 
The MYC oncogene is a transcription factor that has pleiotropic effects on cell 
growth and differentiation and amplification or overexpression of c-MYC is found in 
many human cancers including prostate cancer (Shen and Shen 2010). The 
chromosomal region 8q24, encompasses the MYC gene, a locus which is often 
found amplified in prostate cancer, with amplification significantly higher in 
metastatic disease compared to primary disease correlating with disease 
progression, increasing Gleason score and poor prognosis (Fleming et al 1986, 
Buttyan et al 1987, Gburek et al 1997, Nupponen et al 1998, Sato et al 1999). 
Recent evidence, of upregulation of nuclear MYC protein in PIN and prostate 
cancer, suggests that MYC upregulation may also be involved in prostate cancer 
initiation though this remains controversial (Jenkins et al  1997, Gurel et al 2008, 
Schrecengost and Knudson 2013). 
 
1.3.2.3 TMPRSS2:ERG Fusion 
Several studies have identified chromosomal rearrangements which activate the 
Erythroblast transformation specific (ETS) transcription factors of which ERG, ETV1 
and ETV4 have been implicated in prostate cancer (Shen and Shen 2010). 
Approximately 50% of primary and metastatic prostate cancers contain a variation 
of this fusion which correlates with high tumour grade and poor prognosis 
(Mosquera et al 2007, Mosquera et al 2008, Demichelis et al 2007). The most 
common of these rearrangement fusions is the TMPRSS2-ERG fusion gene. 
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Fusions between the 5’ untranslated region of TMPRSS2 and 3’ exon of ERG, 
which occurs through unbalanced interchromosomal translocation, results in the N-
terminal expression of truncated ERG protein with the androgen responsive 
promoter of TMPRSS2 (Shen and Shen 2010). Though initially hypothesised to be 
involved in prostate cancer initiation due to evidence that TMPRSS2-ERG gene 
fusions first appear in late PIN lesions, subsequent in vitro and clinical data suggest 
that ETS fusions in prostate cancer may be involved in invasion and metastatic 
spread (Tomlins et al 2006a, Clark et al 2008, Mosquera et al 2008, Albadine et al 
2009).  
 
1.3.3 Tumour suppressor genes 
1.3.3.1 p53 
Somatic mutations in p53 have been identified in a diverse range of cancers, 
typically resulting in reduced cell-cycle control and increased genetic instability (De 
La Taille 2001). The prevalence of detected p53 mutations in prostate cancer varies 
between different studies, it is clear that mutations are rare events in localised 
prostate cancer (25-30% of cases), however, become more frequent in advanced, 
metastatic and hormone refractory tumours (Navone et al 1993, Bookstein et al 
1993, Viskorpi et al 1992, Barbieri et al 2013). For example, p53 mutations were 
found in as many as 75% of prostate cancer associated bone metastases, 
identifying that this subgroup of patients having a worse prognosis (Navone et al 
1999, Bauer et al 1995). 
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1.3.3.2 Phosphatase and Tensin Homologue 
The Phosphatase and Tensin Homologue (PTEN) gene located on chromosome 
10q23 is one of the most commonly mutated tumour suppressor genes in cancer 
(Barbieri et al 2013). In prostate cancer the region containing PTEN is a frequent 
target of mutations and deletion in both primary and metastatic disease.  
Approximately 70% of primary prostate cancers have PTEN mutations or alterations 
resulting in loss of function correlating with high tumour grade. Whilst allelic deletion 
of PTEN is a frequent occurrence seen in metastatic disease (Li et al 1997, Vliestra 
et al 1998, Whang et al 1998, Tomlins et al 2006b, Attard et al 2009, Choucair et al 
2012). In addition to prostate cancer, mouse models have demonstrated that PTEN 
loss also alters AR signalling and cellular response to therapy and therefore may be 
a key determinant in the formation of androgen independent advanced disease 
(Schrecengost and Knudson 2013).  
 
1.3.3.3 NKX3.1 
NKX3.1 transcription factor is a member of the NK subfamily of homeobox genes, 
which has been instrumental in prostatic bud formation. Whilst the nkx3.1 gene has 
been shown to be androgen regulated, in vivo studies suggest alternative 
mechanisms of expression exist during prostate development (Bhatia-Gaur et al 
1999, Schrecengost and Knudson 2013). Down regulation of the nkx3.1 gene, 
located on chromosome 8p12-22, is one of the most frequent chromosomal 
aberrations in prostate cancer and is believed to be critical in prostate cancer 
initiation (Bova et al 1993, Macoska et al 1995, Abate-Shen et al 2008). Frequency 
of LOH at region 8p21.2 has been detected in up to 50% of primary prostate 
cancers and 80% of metastatic cancers correlating with increased tumour grade. 
However, evidence suggests the remnant nkx3.1 allele remains unaffected 
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(Emmert-Buck et al 1995, Vocke et al 1996, Swalwell et al 2002, Bethel et al 2006, 
Schrecengost and Knudson 2013). This possibly highlights that reduction rather 
than loss of NKX3.1 expression is involved in cancer progression (Shen and Shen 
2010). 
These factors in isolation all have their merit, but when combined with other altered 
pathways their lethality becomes apparent. For example loss of both p53 and PTEN 
increases tumour progression rate, whilst over expression of HER2 confers poor 
prognosis in those patients who also have low PTEN expression (Martin et al 2011, 
Ahmad et al 2011).  
 
1.4 Metastasis  
Metastases are responsible for 90% of human cancer deaths due to the resultant 
impairment of multiple vital organs (Hanahan and Weinberg 2000, Weigelt et al 
2005). In spite of the significant advances in cancer diagnosis, surgical techniques 
and therapies, most metastases still remain resistant to conventional therapies and 
patient prognosis remains little improved from decades ago (Fidler 2003b, Sporn 
1997). The main clinical obstacle to treating cancer metastases is the biological 
heterogeneity between the primary cancer and its metastases, which is further 
hindered by the evidence of co-existence of sub-groups of cell types within a tumour 
(Fidler 2003a, Talmadge and Fidler 2010).   A better understanding into the 
pathogenesis of metastases at systemic, cellular and molecular levels and the many 
genetic and biochemical determinants that drive this process must be identified 
(Mehlen and Puisieux 2006). This approach may further promote the development 
of more targeted metastatic therapies which focus on the potential metastatic site(s) 
as well as the tumour cells themselves.  
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1.4.1 Theories 
In 1889 Stephen Paget, an English surgeon, published an article in The Lancet 
describing the susceptibility of various types of cancer to form metastases in 
specific organ patterns from autopsy studies (Paget 1889). In fatal breast cancer 
cases, Paget observed that high incidence of metastases were occurring in the 
livers, ovaries and specific bones, however not in the spleen (Paget 1889). Paget 
proposed that these non-random patterns were due to the dependence and affinity 
the cancer cell (seed) may have on the secondary organ site (soil). This 
contradicted the prevailing Virchow theory that metastasis was the result of tumour 
cell arrest and emboli formation in the vasculature (Virchow R 1858).  In the 1920’s 
Paget’s theory was challenged by James Ewing (Ewing J, 1928), who suggested 
that circulatory patterns and mechanical factors between a primary tumour and 
specific secondary organs were sufficient to account for organ-specific metastasis. 
However, more recent research suggests that these theories are not mutually 
exclusive and that there is validity for each of the proposed theories in the 
metastatic spread of cancer (Fidler and Kripke 1977, Hart and Fidler 1980).  
 
1.4.2 Metastatic Cascade  
Successful metastasis to distant organs requires a series of co-ordinated, complex 
interrelated processes, all of which must be successfully completed for 
establishment of a secondary tumour at a distant site from the disseminating 
primary cancer (Figure 1.6). 
 In principle, the core metastatic events are the same for all tumours, including the 
development of a vascular network (angiogenesis) and invasive potential, evasion 
of the immune response and ability to respond and colonise organ specific 
environments (Fidler et al 1978, Price et al 1988). This predisposition arises from 
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specific molecular signals and interactions extensively supported by disseminated 
tumour cells’ autocrine effects, host responses and organ microenvironments 
(Talmadge and Fidler 2010).  Initially, local invasion at the primary site together with 
angiogenesis must occur for the tumour to survive. During this process, sub-
populations of malignant cells down-regulate their cell-cell contacts and cell-matrix 
adhesive characteristics, become motile and acquire the ability to breakdown the 
extra-cellular matrix (ECM) by the production of various proteolytic enzymes such 
as matrix metalloproteinases (MMPs), tissue serine proteinases and adamalysin-
related membrane proteases (ADAMs). Once the malignant cell(s) has reached the 
interstitium it enters the vascular and lymph circulation through intravasation and 
undergoes distal migration (Bogenrieder and Herlyn 2003).  
For site-specific establishment of metastases following migration and survival in the 
circulation, malignant cells arrest and attach to the endothelial lining. Extravasation, 
by breaching the endothelial barriers at secondary sites, allows the cancer cells to 
transmigrate into the new interstitium. Colonisation of this environment occurs 
allowing subsequent cancer cell proliferation, or dormancy, which will ultimately 
result in secondary tumour formation when the environment is favourable.  
The metastatic process is highly inefficient with only 0.001-0.02% of cancer cells 
experimentally introduced into the circulation forming metastatic foci (Fidler 1970). 
Metastatic tumour cells also have the potential to undergo a period of dormancy, 
which may already have occurred in subgroups of patients presenting with primary 
disease, which can result in cancer recurrence after years or possibly decades of 
remission, even after primary cancer removal. Tarin et al (1984) and Kasimir-Bauer 
(2009), have demonstrated that, though there may be detectable tumour cells in 
patient circulation or bone marrow, which have potential prognostic implications, not 
all of these cells, if any, may result in metastatic foci, due to a number of factors 
including host response or tumour cell dormancy (Talmadge and Fidler 2010). 
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Figure 1.6 – Metastatic cascade 
Representation of the processes that occur in the metastatic cascade, initially the primary tumour develops and invades local tissue supporting itself 
with blood vessel growth (A and B). Tumour cells invade the vasculature and enter the circulation (C and D), after which they settle and invade into a 
secondary site (E). Tumour cells colonise the new environment and adapt to the different stimuli to present as metastases (F and G). Adapted from 
Fidler 2003 and Talmadge and Fidler 2010 
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1.4.3 Factors implicated in the metastatic cascade 
Extensive research effort continues to elucidate the factors which are involved in the 
successful formation of metastasis associated with all types of cancers and to 
develop targeted therapies which will block malignant cell growth without impairing 
healthy cells. The discovery of a variety of growth factors, chemo-attractants, 
signalling pathways and genes have made some major advances in our 
understanding of the metastatic cascade in recent years. 
 
1.4.3.1 Cell proliferation and Survival 
Tumour cells can inhibit intrinsic apoptotic pathways by upregulating apoptotic 
suppressors such as Bcl2, Bcl-XL  and simultaneously decreasing mitochondrial 
membrane disruption and cytochrome c release, or by down regulation of critical 
apoptotic inducers such as the caspases, in particular caspase-2, -3, -7 and -9 
(Swanton et al 1999, Coffey et al 2001, Fiandalo and Kyprianou 2012). In lung 
cancer several caspase 9 polymorphisms have been identified which resulted in 
impaired caspase 9 activity and ultimately blocking apoptosis induction, however the 
role caspases play in prostate cancer still remains under investigation (Park et al 
2006). Chemotherapy and radiotherapy can re-initiate this intrinsic apoptotic therapy 
by damaging mitochondria resulting in the release of apoptogenic factors including 
cytochrome c release (Johnstone et al 2002).   
The extrinsic apoptotic pathway is a pathway which remains under intense 
investigation for novel anti-cancer therapies. This pathway is triggered by the 
activation of death receptors belonging to the Tumour Necrosis Factor (TNF) 
superfamily, which include Fas/APO1, TNFR and TRAIL (Jin and El-Deiry 2005). 
TRAIL mRNA expression, unlike most other family members, is not tightly regulated 
and has been constitutively detected in a range of tissues. It has been shown to 
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induce apoptosis through interaction with DR4 and DR5 receptors, which can be 
inhibited by DcR1, DcR2 and Osteoprotegerin (OPG) (Wiley et al 1995, Wu 2009). 
Most cancer cells are resistant to TRAIL induced apoptosis and evidence suggests 
if death receptor-mediated apoptosis is impaired, TRAIL may promote cancer cell 
proliferation and survival, but how this is achieved is yet to be fully elucidated 
(Ehrhardt et al 2003  , Baader et al 2005).  
Of great relevance to prostate cancer and disease progression is the role AR can 
also play in modulating cell proliferation and apoptosis via several mechanisms. 
One of the most important contributors to the anti-apoptotic effects exerted by AR is 
p21, which has been proven to protect against p53 mediated apoptosis as 
androgens enhance the transcription of p21 (Wen et al 2014). 
 
1.4.3.2 Lymph/angiogenesis  
Tumour angiogenesis, whether it is an early pathological event or in response to 
hypoxia and nutrient deprivation, involves a complex interplay between pro- and anti 
angiogenic factors which influence tumour cells, endothelial cells and surrounding 
stroma (Mukherji et al 2013). Therefore targeting one aspect of this remodelling 
process may initially produce a response; however it does not guarantee that it will 
not promote another angiogenic response via a different pathway (Weis and 
Cheresh 2011). Several key factors have been identified in prostate cancer 
progression and metastasis, including vascular endothelial growth factor (VEGF), 
fibroblast growth factor (FGF) and hepatocyte growth factor (HGF) (Strohmeyer et al 
2000, Doll et al 2001, Humphrey et al 1995).  HGF can have direct effects on 
endothelial cell proliferation, migration and tubule formation whilst also inducing the 
expression of other pro-angiogenic factors such as VEGF, thus contributing to 
cancer progression (Ferrer et al 1997, Wojta et al 1999, Jiang et al 2005b). 
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1.4.3.3 Adhesion/De-adhesion to the ECM 
An integral part of the metastatic cascade is the changing adhesive capabilities of 
cancer cells that dictate their interactions with the ECM and each other. The 
majority of cell-adhesion molecules which have been identified fall into one of three 
categories; integrins, immunoglobulin superfamily or the cadherins, all of which 
have been implicated in cancer metastases (Bogenrieder and Herlyn 2003).   
Cell-matrix binding is largely mediated by integrins, a family of 24 heterodimeric 
binding proteins comprising α- and β-chain subunits which combine and ligate 
several ECM proteins (Hynes 2002). The integrin family have shown aberrant 
expression on a variety of tumour cells which contributes to their ability to mediate 
physical interactions with the ECM and regulate signalling pathways. Both of these 
are fundamental to cancer cell adhesion as well as pro-survival, proliferative, 
angiogenesis and control the actin cytoskeleton and cell movement essential for 
establishment of a secondary tumour at another site (Hynes et al 2002, Goel et al 
2008).  
Some of the integrin subunits implicated in prostate cancer progression are listed in 
Table 1.7. Integrin β1 associates with many α subunits, some of which are up-
regulated in prostate cancer, predominately as α2β1 or α6β1 (Fornaro et al 2001, 
Alam et al 2007). Goel et al (2005) has shown expression of β1A integrin variant is 
upregulated and necessary for cancer cells to be able to grow in an anchorage- 
independent manner, suggesting that this integrin may be important in prostate 
cancer progression.  
Some of the integrins best characterised for their role in prostate cancer progression 
have also been linked with the bone environment, and therefore may contribute to 
the osteotrophic nature of the disease progression, by aiding the settling of 
disseminating cancer cells. Zheng et al (1999) demonstrated that integrin αvβ3 was 
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up-regulated in prostate cancer cells compared to the normal prostate epithelium. 
The αvβ3 integrin has also been shown to interact with several bone derived factors 
including osteopontin (OPN), bone sialprotein (BSP), fibronectin and vitronectin and 
therefore influencing osteotrophic phenotypes in several cancer types, including 
breast and prostate (Sun et al 2007, McCabe et al 2007, Zhao et al 2007). Several 
other studies have shown that breast cancer cells expressing αvβ3 are associated 
with higher rates of bone metastasis, tumour associated osteolysis and bone 
colonization, potentially through the co-operation with MMP-2 and -9 promoting 
invasion (Sloan et al 2006, Karadag et al 2004, Rolli et al 2003, Gupta et al 2012). 
For any cancer to progress, tumour cells must intravasate and metastasise, which 
can be achieved by loss of cell polarity and cell-cell binding and a switch from an 
epithelial to a mesenchymal phenotype, a process referred to as epithelial to 
mesenchymal transition (EMT) (Micalizzi et al 2010). The cadherin-catenin complex 
is essential for both morphogenesis and subsequent structural and functional 
organisation of epithelia. Disruption of either of the interactive components produces 
significant alterations in cellular behaviour (Lynch et al 2010). This can occur within 
the tumour by down regulation of molecular binding complexes, such as the E-
cadherin/β-catenin complex, which are associated with an epithelial phenotype, 
resulting in tumour cells assuming a mesenchymal phenotype associated with 
increased N-cadherin expression (Cadherin switching), giving them the ability to 
intravasate through the basement membrane and migrate to distant sites (Micalizzi 
et al 2010).  
The locus coding E-cadherin (16q22.1) is considered to be a tumour-suppressor 
gene; loss of function enables cell detachment and induces an invasive phenotype 
and occasionally, mutations of the E-cadherin gene can lead to the absence of or 
expression of a non-functional protein. E-cadherin is the prototypic type I cadherin 
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Table 1.7 – Integrins implicated in prostate cancer (adapted from Goel et al 2008) 
 Deregulation References 
α 
Subunit 
  
α2 Downregulated in 70% of low grade (II and 
III) cancers. 
Upregulated in metastases 
Bonkhoff et al 1993, 
Nagle et al 1994 
α3, α4, α5 Downregulated in adenocarcinoma Nagle et al 1994 
α6 Polarised distribution in BPH, less polarised 
with increasing grade. Upregulated in 
metastases 
Bonkhoff et al 1993, 
Knox et al 1994, Nagle 
et al 1995, Davis et al 
2001 
α7 Downregulated and mutated in 
adenocarcinoma and recurrent 
adenocarcinoma  
Ren et al 2007 
β 
Subunit 
  
β1 Upregulated in adenocarcinoma; 
redistrubtion with progression 
Knox et al 1994, Murant 
et al 1997,  
β1C Expressed at mRNA and protein levels in 
normal prostate epithelium but 
downregulated in adenocarcinoma 
regardless of Gleason score (II to V) 
Fornaro et al 1996, 
Fornaro et al 1998, 
Fornaro et al 1999, 
Perlino et al 2000 
β3 Absent in normal prostate cancer cells. 
Expressed in adenocarcinoma and 
metastatic lesions,  
Zheng et al 1999 
β4 Downregulated in adenocarcinoma 
regardless of Gleason score (II to V) 
Nagle et al 1995, Allen 
et al 1998, Davis et al 
2001 
β6 Absent in normal prostate cells. Upregulated 
in adenocarcinoma and metastases 
Goel et al 2008 
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which mediates homophilic interactions by forming adhesive bonds between one or 
several immunoglobulin domains in the extracellular region, connecting to actin 
microfilaments, to stabilise the complex, indirectly via α- and β-catenin in the 
cytoplasm (Kemler 1993). The integrity of the cadherin-catenin complex and its 
anchorage to the actin cytoskeleton are required for E-cadherin-mediated 
intercellular adhesion. Loss of E-cadherin expression seems heavily involved in 
EMT as it has emerged as the caretaker of the epithelial phenotype (Thiery 2002). 
In vitro experiments have shown there is a direct correlation between the lack of E-
cadherin production and the loss of the epithelial phenotype.  Down regulation of E-
cadherin during cancer progression occurs by epigenetic mechanisms, including 
transcriptional repression and promoter hypermethylation (Graff et al 1995). E-
cadherin production is maintained in most differentiated tumours, including prostate 
and breast, but there does appear to be an inverse correlation between E-cadherin 
expression and increasing tumour grade, presence of bone metastases and poor 
patient survival (Umbas et al 1994). An archival study of primary prostate tissue and 
prostatic bone metastases from the same patients also showed decreased 
expression of E-cadherin messenger RNA in metastases in nine of the total cases 
(Bryden et al 1999). 
β-catenin has dual functions in prostatic and other tissues. As well as its role in the 
cadherin-catenin complexes, β-catenin also regulates signal transduction by binding 
to DNA and activating gene transcription factors such as Tcf and Lef in the nucleus, 
which may function as co-activators of AR (Semba et al 2001). Less than 4% of 
primary prostate tumours have β-catenin mutations, however aberrant β-catenin 
expression seems to affect the function of cadherin-catenin complexes (Voeller et al 
1998). In a study of paired primary or bone metastases, 13 out of the 14 primary 
tumours had high β-catenin expression, whereas 12 of the 14 metastases showed 
down regulation of β-catenin mRNA levels compared with their primary tumours 
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(Bryden et al 1999). Whilst Umbas et al (1992) and Bryden et al (2002b) showed 
reduced or absent β-catenin to be associated with high grade prostate tumours and 
prostatic bone metastasis.   
 
1.4.3.4 Degradation of the ECM  
Cancer invasion requires the degradation of the ECM. The ECM is comprised of 
basement membrane and connective tissue. In cancer this degradation of the ECM 
is achieved by families of protetases including MMPs and serine proteases such as 
urokinase-type plasminogen activator (uPA) (Overall and Lopez-Otin 2002). 
 MMPs are zinc binding pro-enzymes of which 24 different members have been 
identified to date. MMP activity is regulated by tissue inhibitor of metalloproteinases 
(TIMPs), an imbalance in the MMP:TIMP ratio due to either TIMP downregulation or 
increased MMP production by tumour cells can induce an invasive phenotype 
(Lokeshwar et al 1993). This mechanism is vital for endothelial barrier degradation 
for cancer cell escape from the primary site or to colonise and establish at a 
different site e.g. in the bone (Chambers et al 2002). MMPs require proteolytic 
cleavage, for example in prostate cancer MMP-2 and MMP-13, activated by 
membrane-type 1 MMP, once activated can activate MMP-9 (Morgia et al 2005). 
Both MMP9 and MMP2 levels and the ratios of MMP-2/9:TIMP-1 have been shown 
to be increased in primary prostate cancer tissues compared to normal prostate 
epithelium and were associated with higher Gleason score and poorer patient 
survival (Wood et al 1997, Lichtinghahen et al 2002, Trudel et al 2003).  
The degradation of the ECM is also facilitated through the action of uPA converting 
plasminogen to plasmin, as well as having the ability to activate other latent 
proteinases including MMPs, of which MMP-2 and -9 have been linked to prostate 
cancer and the development of metastases (Jin et al 2011, Hart et al 2002). 
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1.4.3.5 Cell Migration 
Cell migration, initiated by extracellular stimuli, is co-ordinated by several inter-
dependent steps involving the cytoskeleton and ECM. Cell motility and migration in 
prostate and other cancers are linked integrally to Ras and other GTP-binding 
proteins e.g. Rho and Rac which are important for cytoskeletal assembly, 
intracellular signalling and physical movement of cell membranes and whole cells 
(Clarke et al 2009).  
The Ras family, comprising h-ras, k-ras, n-ras, r-ras and m-ras, are transmembrane 
glycosylated proteins that regulate downstream cellular activities including cell 
proliferation, nuclear transcription, apoptosis and invasion (Hu et al 2003, Adjei 
2001).  Ras acts as a membrane transducer, allowing extracellular signals (e.g. 
EGF, FGF, IGF) to bind to receptor tyrosine kinases which in turn activate the sub-
family GTPases, which have major influence on cell signalling. Rho GTPases are 
similar to Ras in their structure and synthesis; their activation lies downstream of 
Ras and they are therefore Ras dependent (Clarke et al 2009). The Rho GTPase 
family, comprised of Rho A, B, C, E and G, Rac1, Rac2, cdc42-H5 and TC10, are all 
proteins involved in cell motility acting through actin dynamics, guiding 
morphological changes, including cell growth and movement (Giniger 2002, Clarke 
et al 2009). Cell movement may occur through the extension of filopodia bound to 
the cortical actin network and a fixed extracellular ligand, resulting in net movement 
of the whole cell.  
The predominant theory is that the Ras-Rho axis is activated in prostate cancer 
metastasis and this underpins the acquisition of cell motility that is fundamental for 
successful metastasis. Therefore therapeutic strategies have been developed to 
prevent Rho synthesis or activity resulting in reduced cell motility, with a 
corresponding reduction in invasion across endothelial barriers. Montague et al 
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(2004), using bisphosphonates to inhibit the mevalonate pathway (RhoA) in prostate 
cancer, showed that cell motility and transmigration of prostate cancer cells across 
human bone marrow endothelial barriers and human bone marrow stroma were 
inhibited in the presence of zoledronic acid. A further study examined the effects of 
inhibiting the farnesyl and geranyl-geranyl prenylation pathways and showed that 
migration and motility of prostate cancer cells were reduced dramatically by 
inhibition of Ras prenylation and therefore also inhibition of Rho activation (Clarke et 
al 2009).  
 
1.4.3.6 Homing/ Colonisation 
In solid tumours, malignant cells increasingly enter the circulation as the tumour 
load grows. Once cells intravasate and survive in the circulation they have the 
potential to, at their preferred metastatic site(s), extravasate through the local 
vascular endothelial lining and gain access to underlying stroma (Jin et al 2011). 
However, what drives these processes and dictates where they will occur remains 
poorly understood. Though in recent years the theory of cancer cells creating a pre-
metastatic niche, in which cells can prepare sites for metastases, has evolved 
(Weilbaecher et al 2011). The tendency for prostate cancer to predominantly 
metastasise to the bone, and the increasing incidence associated with other 
cancers, drives the need for better understanding of how bone metastases develop.  
The complex bone environment is a pre-metastatic niche which is capable of being 
affected by endocrine signals from tumour cells and the circulation thus aiding 
homing and colonisation. For example systemic factors, like parathyroid hormone 
related protein (PTHrP), are produced by a variety of tumours promoting bone 
resorption and enhancing the production of local bone factors including chemokines 
(Weilbaecher et al 2011).  Breast cancer cells have been shown to increase bone 
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resorption by producing herpanase (Kelly et al 2005), whilst prostate cancer cells 
have been shown to upregulate OPN from both tumour cells and fibroblasts, and 
MMPs from osteoclasts, promoting bone marrow cell recruitment and tumour 
formation (Pazolli et al 2009, Lynch et al 2005).  Kaplan et al (2006) showed that in 
melanoma and lung cancer models VEGFR1 positive bone marrow derived 
haematopoietic stem cells homed to sites of future metastases, forming cellular 
clusters, producing inflammatory cytokines and up-regulating fibronectin production, 
preceding tumour cell arrival (Hiratsuka et al 2002). 
Despite the introduction and accessibility of PSA testing, approximately 22% of 
newly diagnosed prostate cancers have metastatic components (Wolff et al 1998). 
Morgan et al (2009) showed that, in prostate cancer patients who had undergone a 
radical prostatectomy, up to 72% had detectable disseminated tumour cells in their 
bone marrow, demonstrating the metastatic potential of the skeleton. Metastatic 
prostate cancer cells have been shown to directly compete for occupancy in the 
haematopoietic stem cell niche during localisation to the bone, subsequently driving 
them into progenitor pools (Shiozawa et al 2011). 
Both osteoblasts and bone marrow endothelial cells express CXC chemokine 
stromal-derived factor-1 (SDF-1), which has been shown to promote prostate 
cancer cell migration and upregulate MMP-9 and αvβ3 in prostate cancer cells (Sun 
et al 2005, Sun et al 2007, Chinni et al 2006). Integrin αvβ3 interacts with OPN, 
fibronectin and vitronectin and its expression has been associated with higher rates 
of bone metastases and tumour induced osteolysis (Clezardin 2009, Schneider et al 
2011). Tumour cell expression of β1 integrin family members, including α5β1, α2β1 
and α4β1, which are receptors for fibronectin, collagen I and VCAM-1 have been 
implicated in interactions between tumour cells and bone marrow stroma (Korah et 
al 2004, Hall et al 2008, Hall et al 2006, Michigami et al 2000).  
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Once cells have undergone colonisation of the secondary environment, this does 
not always result in immediate tumour formation, dormancy can also occur. Prostate 
cancer cells have been shown to bind to osteoblast annexin II receptors, which are 
well known dormancy inducers, and were found to reduce cell cycle progression of 
prostate cancer cells, thus implicating osteoblasts as facilitators for tumour 
dormancy in bone (Shiozawa et al 2010). 
 
1.5 Biology of bone 
Bone is a specialised dynamic tissue which provides structural support and 
protective functions whilst also regulating calcium levels and providing a reservoir of 
hematopoietic cells. There are three distinct cell types within bone which account for 
90% of all cells in the adult skeleton (Sommerfeldt and Rubin 2001), all of which 
play a pivotal role in bone homeostasis, remodelling and pathophysiology (Coleman 
2001a). The skeleton, comprising this dynamic tissue, receives 5-10% of cardiac 
output, which supplies cells of the marrow, tissue and periosteum with the required 
nutrients through an elaborate structure of vasculature canals, ensuring that no cell 
lies more than 300µm from a blood vessel even within the densest parts of the 
cortical bone tissue. 
 
1.5.1 Bone structure 
All bones throughout the human body are classified by their shape, which includes 
short, long and flat bones and consist of a central reservoir of fatty or hematopoietic 
marrow which provides a constant source of stem cells. These bones are composed 
of two types of osseous tissues, cortical and trabecular, in differing concentrations 
to facilitate their versatile functional demands (Buckwalter et al 1996a). Cortical 
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bone, due to its structural role in the skeleton, is mainly found in the shafts of long 
bones whilst, in contrast, trabecular bone, with its loosely organised structure and 
porous matrix, is generally located in the interior of metabolically active bone ends 
which undergo greater remodelling than cortical bone.   
Long bones are divided into three sections:- 
The diaphysis refers to the long, narrow shaft of the bones mainly composed of 
cortical bone, made from overlapping osteons (cylindrical units), with a central canal 
of nerves and blood vessels surrounded by densely packed collagen fibrils in 
concentric lamellae providing a protective outer layer. This dense organisation 
provides maximum strength and load bearing capacity (Rauner et al 2012). 
Epiphysis are located above the growth plates at the ends of long bones and are 
characterised by the orderly proliferation and maturation of cells which provide bone 
elongation, throughout childhood and puberty, until the skeleton has reached 
maturity, generally in the mid-twenties (Buckwalter et al 1996a). During this constant 
proliferation, cartilage is continuously replaced with bone matrix, after which the 
epiphysis becomes completely ossified.   
The area called the metaphysis is located between the diaphysis and the epiphysis 
and encapsulates the growth plates at the ends of long, flat and vertebral bones 
where multidirectional force may be applied. The metaphysis contains a meshwork 
of trabecular bone surrounded by hematopoietic cells, fatty marrow and blood 
vessels, providing a large metabolically active surface area, encased in a thin shell 
of cortical bone (Clarke 2008).  
The periosteum is a fibrous connective tissue which surrounds the outer cortical 
surface of bone, though not at the sites of joints (Clarke 2008).  The periosteum 
consists of two layers: a dense fibrous outer layer which has high collagen content, 
and an inner layer, also known as the osteogenic layer, which has a looser cellular 
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structure (Buckwalter et al 1996a). During bone elongation, remodelling and repair, 
the cells of the osteogenic layer secrete the organic matrix aiding enlargement of 
the bone diameter (Buckwalter et al 1996b).  
 
1.5.2 Bone matrix 
Bone matrix is a composite material consisting of organic and inorganic mineral 
components some of which are derived exogenously and may help to regulate 
matrix mineralisation (Clarke 2008). Approximately 90% of bone matrix is organic 
and resembles the matrix of dense fibrous tissue. The majority of organic matrix 
proteins are collagenous, predominantly composed of type I collagen along with 
small amounts of types III, V and XII. Type I collagen is distinguished from other 
collagens by its unique amino-acid content and the relatively large diameter of its 
fibrils which gives bone its form and provides great strength, durability and stability 
which remains essentially unchanged, even after death (Buckwalter et al 1996b).   
The remaining 10% of the bone matrix, the inorganic matrix, serves as a reservoir 
for 99% of the body’s calcium, 85% of the phosphorous and between 40-60% of the 
sodium and magnesium (Sommerfeldt and Rubin 2001). Tight regulation of these 
ions, to and from the extracellular fluid, is vital for normal physiological conditions as 
they influence processes such as nerve conduction and muscle contraction. It also 
consists of non-collagenous glycoproteins, bone-specific proteoglycans and growth 
factors which can influence matrix organisation, bone mineralisation and the 
differentiation and function of bone cells. Examples of these proteins which help to 
initiate calcification include osteocalcin, osteonectin (ON), BSP, bone 
phosphoproteins and small proteoglycans.  Growth factors which have been 
identified as present in the bone matrix include transforming growth factor β (TGFβ) 
family, insulin like growth factor (IGF-) -1 and -2, bone morphogenic proteins 
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(BMPs), platelet derived growth factors (PDGF), interleukins (IL-) -1 and -6  and 
colony stimulating factors (CSFs).   
 
1.5.3 Bone marrow 
The bone marrow, found within axial and long bones, consists of hematopoietic 
tissue and adipose cells surrounded by vascular tissue interspersed within 
trabecular bone (Travlos 2006).  Normal bone marrow has a defined architecture 
within the bone which allows it to play an inter-dependent role in cell differentiation 
(Compston 2002). Bone marrow angiogenesis and osteogenesis, in developing and 
mature bones, have been shown to be closely linked both under normal physiology 
and pathophysiology (Compston 2002).  
 
1.5.4 Bone cells 
Due to the diverse range of processes in bone remodelling and mineral 
homeostasis, bone cells assume specialised forms distinguishable by morphology, 
function and characteristic location. There are three integral types of bone cells, 
osteoblasts, osteoclasts and osteocytes, which originate from two distinct stem cell 
lines under the influence of a variety of osteotropic hormones and cytokines 
(Nakamura 2007). The mesenchymal stem cell line, which has the potential to 
become osteoblasts, bone lining cells or osteocytes, consists of undifferentiated 
cells which reside in bone canals, the endosteum, periosteum and marrow. The 
hematopoietic stem cell line consists of circulating marrow monocytes which can 
become osteoclasts.   
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1.5.4.1 Osteoblasts 
Osteoblasts are responsible for creating and maintaining skeletal architecture by 
producing extracellular matrix proteins and regulating matrix mineralisation, initially 
during bone formation and later during bone remodelling. The life span of a human 
osteoblast is 8 weeks in which it can lay down between 0.5-1.5μm of osteoid per 
day (Sommerfeldt and Rubin 2001). Osteoblasts are highly anchorage dependent 
and rely on extensive cell-matrix and cell-cell contacts, via a variety of 
transmembrane proteins and specific receptors, to maintain cellular function and 
responsiveness to metabolic and mechanical stimuli. Osteoblasts also regulate 
osteoclast differentiation and resorption activity by the secretion of cytokines or by 
direct cell-cell contact (Buckwalter et al 1996b).  
 
1.5.4.1.1 Morphology and physiology 
Osteoblasts develop from irregular shaped cells containing a single nucleus, few 
organelles and minimal cytoplasm (pre-osteoblasts) into a rounded polyhedral form 
with an osteoid seam separating them from the mineralised matrix (immature 
osteoblasts) (Clarke 2008). Mature active osteoblasts secrete bone matrix and are 
cuboidal cells, with large Golgi apparatus and abundant rough endoplasmic 
reticulum, with regions of the plasma membrane specialised for the trafficking and 
secretion of vesicles which facilitate the deposition of new bone matrix (Anderson 
2003). Cytoplasmic components of the osteoblasts extend through the osteoid 
matrix to come into direct contact with osteocytes within the mineralised matrix, thus 
providing co-ordinated activity from both cell types. Tight junctions also form 
between all active osteoblasts allowing communications to occur between each 
other (Shin et al 2000). 
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1.5.4.1.2 Osteoblast differentiation and maturation 
Osteoblasts and osteocytes are of pluripotent mesenchymal stem cell origin (Caplan 
1991, Owen 1988, Pittenger et al 1999), which prior to committing to become 
osteoblasts, can also differentiate into other mesenchymal cells including 
fibroblasts, chondrocytes, myoblasts and bone marrow stromal cells depending on 
the activated signalling transcription pathways (Friedenstein et al 1987, Yamaguchi 
et al 2000).   Three distinct osteoblast development stages have been identified: 
osteoblast proliferation, osteoblast maturation and lastly matrix synthesis and 
mineralisation which allow progressive development of the osteoblast phenotype, 
from an immature proliferating mesenchymal cell to a mature active bone matrix 
secreting osteoblast, characterised by a definitive sequential expression of tissue-
specific genes (Buckwalter et al 1996b).    
Runx-2, a runt-related gene, plays a crucial role in the early commitment of 
mesenchymal cells to osteoblast differentiation. This has been demonstrated in 
Runx-2 deficient mice models which completely lacked bone formation, because of 
the absence of osteoblasts (Komori 2010, Otto et al 1997). Runx-2 induces the 
expression of major bone matrix protein genes or activates their promoters including 
Ibsp/BSP, Fn1/Fibronectin and TNFRSF11b/OPG, which are involved in the 
production of bone matrix proteins such as type I collagen, OPN, BSP and 
osteocalcin (Ducy et al 1997, Lee et al 2000, Thirunavukkarasu et al 2000). This, 
accompanied by Sp7 and canonical Wnt signalling, leads to an increase in 
immature non-functioning osteoblasts by blocking differentiation of mesenchymal 
cells into chrondrocytes (Hill et al 2005, Hu et al 2005). Runx-2 expression is not 
essential to maintain bone matrix protein gene expression as demonstrated by it 
being down-regulated in the late stage of osteoblast maturation, and in mature 
active osteoblasts (Komori 2010).  
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Several other specific transcription factors, including Osterix (Osx) and core binding 
factor α1 (Cbfa 1) are critical mediators in the commitment of mesenchymal cells 
into the osteoblast cell lineage and osteoblast differentiation, though both are not 
sufficient alone to support the maturation of osteoblasts (Banerjee et al 1997, Ducy 
et al 1997, Komori et al 1997, Hoshi et al 1999, Lee et al 1999, Otto et al 1997).  
The precursors that undergo proliferation and differentiate into immature osteoblasts 
are elliptical cells that are capable of proliferation but unable to deposit bone matrix.  
The accumulation of matrix proteins contributes, in part, to the cessation of cell 
proliferation. For osteoblasts to start matrix synthesis and mineralisation, BMP-2 
and BMP-5 play a significant role in increasing alkaline phosphatase activity, 
osteocalcin synthesis and parathyroid hormone (PTH) responsiveness (Yamaguchi 
et al 1991, Takuwa et al 1991). Immediately after growth arrest, a developmental 
sequence involving the selective expression of specific genes which characterise 
the differentiated osteoblast phenotype occurs (alkaline phosphatase, osteocalcin) 
and therefore initiates the process of bone formation (Stein et al 1993).  
To proliferate and differentiate into mature active osteoblasts the release of a variety 
of osteotropic hormones and growth factors are also required (PTH, Vitamin D, 
Prostaglandin-E2 and IL-11) (Rauner et al 2012). During bone matrix secretion and 
mineralisation mature osteoblasts synthesise and secrete type I collagen, which is 
oriented along lines of stress, and then deposit bone matrix and various non-
collagen proteins including osteocalcin, OPN and BSP. Once this process is 
complete mature osteoblasts can follow one of three pathways:- 
1) They can remain on the bone surface, decrease their synthesising 
activity and assume a flatter bone-lining cell form and regulate the flux of 
mineral ions but retain the ability to re-differentiate into secreting 
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osteoblasts upon exposure to various stimuli, including hormones and 
mechanical forces 
2) They can become embedded within the matrix and become osteocytes 
3) They can undergo an apoptotic process by an unknown mechanism. 
In adults, at the end of the synthesis and mineralisation of the bone matrix, cellular 
levels of alkaline phosphatase mRNA decline (Lian and Stein 1995) and 
approximately 70% of mature osteoblasts undergo apoptosis, whilst the remainder 
can differentiate into lining cells or osteocytes (Franz-Odendaal et al 2006, Lynch et 
al 1995, Clarke 2008).  
 
1.5.4.2 Osteoclasts 
Osteoclasts, since their discovery in 1873 have shaped the progression in bone 
biology, highlighting the complex intercellular environment we know it to be today 
(Martin 2013). Osteoclasts are highly active, short lived cells with the ability to 
resorb bone at specific sites called Howship’s lacunae (Edwards and Mundy 2011, 
Clarke 2008). Systemic hormones, e.g. PTH and local cytokines stimulate 
osteoblasts to release mediators which can activate osteoclasts and stimulate 
osteoclast differentiation.  
  
1.5.4.2.1 Morphology and physiology 
Osteoclasts are particularly specialised for their bone resorption role and are 
characterised as highly migratory, multinucleated, polarised cells with pockets of 
lysosomal enzymes (Sommerfeldt and Rubin 2001). They show distinctive complex 
folding of the cytoplasmic membrane (ruffled border) which comes into contact with 
the site of bone matrix resorption. Typically osteoclasts have between 3-20 nuclei 
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which, when the cells are active, fill much of the cytoplasm to supply the great 
amount of energy required to resorb bone, as well as large numbers of mitochondria 
and lysosomes (Martin 2013).  
 
1.5.4.2.2 Differentiation and maturation 
Much of what we understand about osteoclast differentiation and maturation comes 
from mouse models and pathophysiological conditions such as osteopetrosis and 
osteoporosis. Unlike other bone cells, osteoclasts originate from a hematopoietic 
stem-cell precursor within the mononuclear monocyte-macrophage family, found 
circulating in the marrow and blood stream, under the influence of hormones, 
growth factors and chemo-attractant factors such as inflammation, red blood cells 
and platelets (Boyce 2013). When stimulated, mononuclear osteoclast precursors 
proliferate and fuse to form large multinucleated osteoclasts referred to as 
polykaryons (Boyle et al 2003).  
For hematopoietic stem cells to be committed to myeloid precursors activation of 
PU.1 and MITF transcription factors must occur, however to further commit to the 
osteoclast lineage, the stimulation of CSF-1R activates other intracellular proteins, 
including c-Fos and p50/p52, resulting in alterations to cellular structures (Edwards 
and Mundy 2011, Boyle et al 2003). A feature of the mature pre-osteoclast is the up-
regulation of the Receptor Activator of Nuclear factor ᴋB (RANK) receptor, which 
under the influence of haematopoietic factors, M-CSF and RANK Ligand (RANKL), 
allows osteoclasts to form polykaryons, attach to the bone and begin bone lysis 
(Boyle et al 2003, Edward and Mundy 2011). 
Efficient osteoclast activity at the bone surface requires the interaction with the bone 
surface (Edwards and Mundy 2011). There is strong evidence to suggest that 
sphingolipid phosphate receptors are one of the major chemo-attractant factors 
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which attract osteoclast precursors to bone remodelling sites, whilst both M-CSF 
and RANKL are produced by osteoblasts and bone marrow stromal cells, therefore 
ensuring that osteoclast differentiation and fusion into polykaryons occurs near 
active bone remodelling sites (Boyce 2013).  
Initially, upon contact with the bone surface, osteoclasts form tight junctions using 
integrin complexes (αvβ3) and RANK, which stimulates Src and results in the 
formation of the ruffled membrane as secretory vesicles fuse with the membrane 
(Teitelbaum 2011).  During bone reabsorption osteoclasts characteristically create 
depressions, referred to as Howship lacunae, by secreting a range of ions and 
enzymes which de-mineralise bone and degrade the matrix. During bone 
reabsorption osteoclasts have the capacity to phagocytose and degrade some 
matrix fragments in cytoplasmic vacuoles.  
Evidence suggests that most osteoclasts undergo apoptosis during the reversal 
stage of bone remodelling, which under normal physiology is mediated by oestrogen 
and TGFβ, which increases Fas-ligand expression inhibiting gene expression 
essential for mature osteoclast activity (Nakamura et al 2007, Boyce 2013).  
   
1.5.4.3 Osteocytes 
More than 90% of bone cells in the mature human skeleton are osteocytes, 
metabolically quiescent mono-nucleated osteoblasts embedded in the bone matrix; 
they communicate with other bone cells through cell processes and function as 
strain and stress sensors (Lozupone et al 1996). Long, branching cytoplasmic 
projections from their ellipsoidal or lens-shaped bodies protrude through canaliculi, 
extend throughout the mineralised bone matrix and come into contact with 
cytoplasmic processes from other cells (Sommerfeldt and Rubin 2001).  
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This large, complex network of cells covering the internal and external surfaces of 
the bone are extremely sensitive to stresses on the bone, and control the movement 
of ions in and out of the mineralised matrix (Buckwalter et al 1996b). This 
arrangement is critical in allowing the cell-mediated exchange of minerals to take 
place between the fluid in the bone and the blood. Interconnections between 
osteocytes, osteoblasts and bone-lining cells also allow this cell network to sense 
deformation of bone, and therein co-ordinate the formation and resorption of bone.   
 
1.5.5 Bone remodelling 
Bone forms in early life mainly through endochondral ossification, in which the initial 
bone pattern outlined in mineralised cartilage is replaced by mineralised bone and is 
thereafter maintained throughout life by a tightly regulated remodelling process 
(Weitzmann 2013). The physiological bone remodelling process is homeostatic, in 
which the rate of osteoclastic bone resorption is matched by the rate of osteoblastic 
bone formation, ultimately resulting in bone repair without gain or loss of bone mass 
(Weitzmann 2013). Annually the remodelling process has the capacity to replace 
approximately 20% of adult bone tissue, with each cycle lasting up to 8 months, 
though research has shown this process becomes less effective with age (Murthy et 
al 2009, Weitzmann 2013). The bone remodelling cycle is continuous, occurring in 
small pockets of cells called basic multicellular units (BMUs) (Proff and Romer 
2009). A BMU refers to the collection of functional cells involved in the bone 
remodelling process in which osteoblasts and osteoclasts are pivotal (Kular et al 
2012).  In 1965, Epker and Frost demonstrated that the interactions between 
osteoblasts and osteoclasts are essential components of bone remodelling whilst 
also playing an integral role in its regulation, however it was not until the late 1990’s 
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that more in-depth understanding of how this was achieved emerged (Epker and 
Frost 1965). 
Bone remodelling is a prolonged, tightly regulated process influenced by factors 
such as injury and age, as well as local and systemic biological stimuli, including 
blood calcium levels, hormones, cytokines and growth factors induced by bone 
micro-damage or mechanical loading (Aubin 2001, Murthy et al 2009). The bone 
remodelling cycle consists of five distinct, highly regulated and sequential phases: 
activation, resorption, reversal, formation and quiescence (Murthy et al 2009) 
(Figure 1.7).  
The process is initialised by bone-lining cells, which lie directly against the bone 
matrix and have an elongated form with extended cytoplasms which penetrate the 
bone matrix to come into contact with cytoplasmic extensions of osteocytes (Clarke 
2008). These connections create an extensive network of intercellular 
communication, which help to direct sites of remodelling, though there is some 
evidence to imply that remodelling sites may also develop in a random manner. 
Osteocytes, when exposed to PTH, result in bone lining cells contracting and 
secreting enzymes that remove the thin osteoid layer that covers the mineralised 
matrix, thus appearing to be the first steps in attracting and permitting osteoclasts to 
attach to the bone surface and begin resorption.  
During the activation phase, osteoclastic precursors are recruited to the remodelling 
site from circulating blood and bone marrow and differentiate into fused polykaryons 
under the influence of RANKL from the quiescent osteoblasts (Clarke 2008). 
Structural changes within the osteoclasts result in the formation of a tight junction 
between the bone surface RGD (arginine, glycine and asparagine)-containing 
peptides in the bone matrix and the osteoclast basal membrane (αvβ3 integrin 
receptors), resulting in the ruffled border patterns associated with mature 
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osteoclasts (Boyle et al 2003, Clarke 2008). The sealed compartment becomes an 
acidified milieu as hydrogen and chloride ions are trafficked through the ruffled 
borders by proton pumps and chloride channels, uniting in the compartment space 
to form HCl, lowering the pH to 4, the optimal pH for protease cathepsin K (CATK), 
ultimately resulting in the de-mineralisation of bone (Clarke 2008, Boyce 2013, 
Martin TJ 2013). Lysosomal vesicles also secrete osteolytic enzymes, including 
tartrate-resistant acid phosphatase (TRAP), which degrade the bone matrix 
resulting in the formation of Howship’s lacunae in trabecular bone or Haversian 
canals in cortical bone (Clarke 2008, Boyle et al 2003). During the enzymatic 
degradation, bone products including solubilised calcium and phosphorous ions, are 
released into the blood stream or reabsorbed by the osteoclasts to be phagocytosed 
(Murthy et al 2009). This stage in the remodelling process is strictly related to the 
interaction of osteoclasts with bone matrix proteins, including OPN and BSP which 
would have been secreted by osteoblasts during the previous cycle of bone 
formation.  
 During the reversal stage, osteoclasts detach from the bone surface, undergo 
apoptosis, are replaced by osteoblast precursors which are attracted to the 
resorption site, and start to proliferate and differentiate. However the signals which 
influence and control this process still remain elusive. 
.  
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Figure 1.7 – Phases of bone remodelling
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During the formation phase, mature osteoblasts synthesise and release osteoid and 
new collagenous organic matrix. Osteoblasts regulate the mineralisation process by 
releasing membrane bound vesicles containing concentrated calcium and 
phosphorous precipitated from the blood stream, released during the absorption 
phase (Anderson 2003). At the end of this phase the majority of osteoblasts also 
undergo apoptosis.  The remaining osteoblasts become buried in the new matrix 
and, during the quiescence phase, trans-differentiate into osteocytes and bone 
lining cells forming an extensive canalicular network (Clarke 2008). It is these cells 
which regulate the flux of ions and minerals and retain the ability to re-differentiate 
into osteoblasts upon exposure to PTH or mechanical forces, which in turn can re-
induce the bone remodelling cycle (Clarke 2008). 
 
1.5.5.1 Factors influencing bone remodelling  
Through intensive research into bone resorption related pathophysiologies, a variety 
of both paracrine and endocrine factors have been identified which regulate bone 
remodelling. However, much of this process and the factors involved also remain 
poorly understood especially those that influence osteoblasts. Several in vivo 
studies have also demonstrated that bone formation can occur without the presence 
of osteoclasts and bone resorption can occur in the absence of osteoblasts, which 
suggests that these cells can function independently of each other (Butt and Coral 
1998, Kong et al 1999, Sims and Gooi 2008).  
The RANKL: OPG ratio is a major determinant of bone mass (Hofbauer and 
Schoppet 2004, Boyce and Xing 2008). Osteoblasts incorporate both pro- and anti-
resorptive signals, from hormonal and mechanical changes, balancing and 
controlling the bone remodelling response through alteration in the expression of the 
cytokine receptor RANKL and its inhibitor OPG (Yasuda et al 1998, Lacey et al 
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1998, Simonet et al 1997, Tsuda et al 1997).  RANKL binds to its receptor RANK on 
the surface of osteoclast precursors and induces a number of intracellular 
pathways. These include the NF-κB and Jun N-terminal kinase signalling pathways, 
which drive differentiation into an osteoclast phenotype, activating bone resorption 
and osteoclast survival through regulation of many genes involved in 
osteoclastogenesis, including TRAP, CATK and calcitonin (Boyle et al 2003). OPG 
as the secreted decoy receptor for RANKL from osteoblast cells binds to RANKL 
preventing its association with RANK and thus inhibiting osteoclast differentiation 
and promoting osteoclast apoptosis.  In vivo evidence suggests that PTH and 1,25 
(OH)2D3 increase RANKL mRNA expression and decrease OPG mRNA expression 
thus increasing bone resorption, whilst bone protective factors such as oestradiol 
and testosterone tend to increase the expression of OPG relative to RANKL (Table 
1.8)  (Lee and Lorenzo 1999, Rogers and Eastell 2005, Buxton et al 2004, Horwood 
et al 1998).  
Whilst the RANKL/OPG/RANK signalling is dominant in the regulation of bone 
remodelling other signalling molecules have been identified which act directly on 
osteoclasts, magnifying or diminishing the effect of RANKL.  Other factors which 
have been shown to influence osteoclast formation, activation and resorption 
include IL-6, macrophage colony stimulating factor (M-CSF), PTH, 1,25-
dihydoxvitamin D and calcitonin. The survival of the mature osteoclasts has also 
been shown to be regulated by RANKL and IL-1, due to the ability of these 
cytokines to induce NF-κB signalling.  
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Table 1.8 – Factors which regulate bone remodelling
Factor Effect/Mechanism of action Reference(s) 
Hormones PTH, 1,25 (OH)2D3 Promotes osteoclast differentiation Lee and Lorenzo 1999 
PTHrP Induces osteoblast differentiation Iwanura et al 1996 
Calcitonin Inhibits osteoclast activity Tian et al 2007 
Oestradiol, 
Androgens 
Induces apoptosis in osteoclasts, promotes osteoblast proliferation 
and differentiation 
Majeska et al 1994, Hofbauer and 
Khosla 1999 
Local Factors IGFs Promotes osteoblast differentiation and prevents osteoblast apoptosis Gazzerro and Canalis 2006 
BMPs, PDGF-BB Promotes osteoblast differentiation Gazzerro and Canalis 2006, Caplan 
and Correa 2011, Autzen et al 1998 
FGF (-1 and -2) Promotes osteoblast proliferation and differentiation Dunstan et al 1999 
Prostaglandins Either promotes osteoclast apoptosis (PGD) or osteoclast 
differentiation (PGE2) 
Durand et al 2008, Yue et al 2014, 
Liu et al 2005 
Cytokines RANKL Promotes osteoclast proliferation, differentiation and 
osteoclastogenesis  
Boyce 2013 
OPG Inhibits osteoclast differentiation, promotes osteoblasts through 
inhibition of RANKL 
Khosla 2001 
TGFβ Promotes osteoblast proliferation Dallas et al 2002 
IFNγ/IFNβ Inhibits osteoclast differentiation Hayashida et al 2014, Kim et al 
2012 
ILs Promotes osteoclast differentiation (IL-3), promotes osteocytes (IL-6) Bakker et al 2014, Hong et al 2013 
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1.6 Bone metastasis 
The variability of metastatic patterns in cancer is undoubtedly influenced by the 
molecular and cellular characteristics of both the tumour cells and the tissues to 
which they metastasise (Coleman 2001b). The skeleton is a common site of 
metastasis for a number of solid tumours but particularly for breast, prostate and 
lung cancer patients, which may be reflected in the high incidence and relatively 
long clinical course of these tumours due to improved first line therapies. Patient 
studies suggest that bone metastasis can occur in 65-80% of metastatic breast and 
prostate cases. Other bone metastasis incidence is increasing because bone 
marrow has been shown to act as a reservoir for dormant tumour cells, which resist 
chemotherapeutic treatment and re-emerge later with metastatic potential in the 
bone, or other organs (Berg et al 2007, Weilbaecher et al 2011). Half of patients 
with metastatic prostate cancer will die of the disease within 30-35 months, whilst 
subsequent autopsy series have suggested that the majority of these metastatic 
prostate cancer patients (~85%) died with evidence of bone metastases (Carlin and 
Andriole 2000, Bubendorf et al 2000).  
Bone metastases most commonly affect the axial skeleton, a distribution pattern 
which suggests that physiological properties of bone circulation within the bone 
marrow cavity, including capillary structure and the sluggish blood flow, assist in the 
establishment of metastases (Coleman 2000). The spine, pelvis and ribs are the 
earliest detection sites for bone metastases, whilst the skull, femur, humerus, 
scapula and sternum are commonly involved at later stages (Koutsiliers 1995). 
However, Leonard Weiss (1992), in a series of autopsy studies documented that 
there were larger numbers of bone metastases than would solely be based on 
blood-flow patterns for both breast and prostate cancer. More recent research has 
highlighted that tumour invasion into the bone is associated with osteoclast and 
osteoblast recruitment, resulting in the liberation of growth factors from the bone 
68 
 
matrix which provides a feedback to enhancing tumour cell survival and growth 
(Weilbaecher et al 2011). The bone microenvironment is a complicated place of 
recruitment and modulation of many other cell types, including platelets, immune 
cells and nerve cells which have the ability to induce angiogenesis. Once 
established in the bone microenvironment cancer cells, and the other cell types, 
participate in complex interplays which result in perturbations of bone metabolism 
and increased tumour growth which facilitate tumour progression (Figure 1.8).  
Clinically, bone metastases cause considerable patient morbidity resulting in poor 
quality of life. Current treatment options remain palliative, managing symptoms such 
as debilitating pain, impaired mobility, hypercalcaemia, pathological fracture and 
spinal cord or nerve compression, with little impact on long term survival (Costa and 
Major 2009, Lee et al 2011). Hypercalcaemia is probably the most common 
metabolic complication of malignant disease which, if left, becomes severe and 
causes a number of additional symptoms including dysfunction of the 
gastrointestinal tract, kidneys and central nervous system.  This problem is more 
prevalent in cancers with increased osteoclastic bone resorption, either multi-focally 
as in the case of metastatic breast cancer, or as a generalised process, stimulated 
by PTHrP or other systemic tumour products. Current therapies include 
bisphosphonates or neutralising receptor activator of NF-kB ligand (RANKL) 
antibodies, both of which target osteoclastogenesis (Weilbaecher et al 2011). 
However, 30-50% of these patients with such treatment plans will still develop new 
bone metastasis, skeletal complications and disease progression (Roodman 2004).   
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Figure 1.8 – Vicious cycle in bone metastases
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1.6.1 Types of bone metastasis 
With strong evidence that approximately half of the most common primary solid 
tumours will eventually metastasise to the bone an understanding of how the 
different phenotypes arise is needed (Koutsillieris 1995). Bone metastases are 
typically classified according to their radiographic lesion appearance, generally one 
of two distinct phenotypes (Figure 1.9). The two distinct bone metastatic phenotypes 
are a reflection of either dysregulated bone destruction (osteolytic) or bone 
formation (osteoblastic). In truth this classification is probably overly simplistic, and 
two extremes of a spectrum, perhaps a better reflection would be that patients 
exhibit both processes, which are accelerated, in the affected bones (Guise et al 
2006).  
 
 
1.6.1.1 Osteolytic metastasis 
Cancers commonly associated with profound osteolysis include breast, lung and 
renal which result in the destruction of bone, by increased numbers of osteoclasts, 
causing intractable pain and fractures (Roodman 2001). This increase in osteoclasts 
is as a result of factors secreted by the tumour cells themselves which drive the 
differentiation of osteoclasts and promote osteoclast survival. This can be done as a 
consequence of tumour-induced activation of bone-matrix resorption due to tumour 
cells expressing RANKL, or through the up regulation of RANKL expression in 
surrounding areas. The exacerbation of bone reabsorption, can induce the vicious 
cycle, resulting in the release of other factors which can promote tumour cell growth 
and progression of bone metastases. This, to some degree, has been replicated in 
in vivo models where vitamin D deficiency, oestrogen or androgen deprivation or 
administration of G-CSF, GM-CSF and PTH can increase osteoclast numbers and  
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Figure 1.9 – Bone metastasis phenotype 
(A) X-ray image of an osteolytic bone metastasis often associated with breast and renal cancer 
(B) Osteolytic bone metastasis from renal cancer invading the bone marrow.  
(C) X-ray image of an osteoblastic bone metastasis often associated with prostate cancer  
(D) Osteoblastic bone metastasis, showing thickened trabeculae with large numbers of 
osteoblasts surrounding the cancer cells 
(Adapted from www.clinicaloptions.com/Urology/ and Chirgwin and Roodman et al 2014) 
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thus develop and increase osteolytic tumour burden (Scneider et al 2005, Ooi et al 
2010, Hirbe et al 2007, Park et al 2007a). 
 
1.6.1.2 Osteoblastic metastasis  
This type of bone metastases is most commonly associated with prostate cancer. 
The osteoblastic nature of bone metastases results in the formation of bone, with an 
immature and woven structure, which is of poor quality, (Clarke et al 1991). Reports 
have shown that in prostate cancer the osteoblastic phenotype accounted for 85% 
of bone lesions, whilst a mix of lesions was reported in 12% of cases with only 4% 
of bone lesions being osteolytic (Charhon et al 1983, Roudier et al 2004).   
Clinical and experimental evidence indicates that bone resorption still occurs and is 
also increased in osteoblastic metastases. The concentration of bone resorption 
markers, including N-telopeptide (NTX) and C-telopeptide type I collagen (CTx), are 
elevated in prostate cancer patients with osteoblastic disease and is a strong 
predictor of morbidity and mortality (Coleman et al 2005). New bone formation in 
osteoblastic metastases is always produced via an osteoblast-dependent 
mechanism, however osteolysis is also present, produced by osteoclast mediated 
and tumour cell mediated bone resorption, thus generating a feedback cycle and 
driving tumour progression in the bone (Galasko 1975).  
 
1.6.2 Prostate cancer osteotropism and osteomimicry 
Skeletal metastases in prostate cancer patients are frequently the only sites of 
disease progression, after long lasting remission achieved by androgen depletion 
therapies (Kousiliers et al 1995). Prostate cancer metastases to the bone follow the 
natural progression of the disease, typically targeting the lumbar spine, vertebrae 
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and pelvis. Disseminating prostate cancer cells have been shown to circulate 
through the blood stream and ultimately colonise the long bones and become 
metastatic lesions, localised to the red marrow within the metaphysis (Thobe et al 
2011). There are many factors which are believed to facilitate this high incidence of 
bone metastases including anatomical, physical, physiological and molecular 
interactions between tumour cells, bone cells and the bone microenvironment (Saad 
et al 2006, Chirgwin and Guise 2007).  
Tumour cells have been demonstrated to preferentially adhere to the bone marrow 
endothelium, immobilising in capillary beds, using the same physiological 
mechanism as haemotopoietic stem cells (HSC) homing to the bone (Saad et al 
2006, Lehr and Pienta 1998, Brenner et al 2004, Kang et al 2003). Metastatic 
prostate cancer cells directly compete for the occupancy of the HSC niche during 
localisation to the bone marrow, which may be accelerated in prostate cancer 
because of the Baston’s plexus of veins and the sluggish nature of blood flow 
through the bone marrow sinusoids, which may aid bone colonisation. Upon entry 
into the bone, Goltzman et al (1992) reported that prostate cancer cells could 
preferentially adhere to bone marrow stromal cells. Others have demonstrated that 
prostate cancer bone colonisation is facilitated by a number of tethering proteins 
which are expressed in the sinusoid epithelium including VCAM-1, which when 
combined with the decreased blood flow rates allowed prostate cancer cells to 
adhere to the epithelium (Scott et al 2001, Jacobsen et al 1996). This process has 
also been reported to be mediated by α2β1 integrin, which aids the attachment of 
prostate cancer cells to extracellular matrix proteins (BSP and type I collagen) 
possibly in concert with CXCR4 (Hall et al 2006, Clezardin and Teti 2007). 
Evidence also suggests that growth factors from the bone matrix and prostate 
cancer cells, when in close proximity, bi-directionally interact as chemo-attractants.  
Several investigations have reported that type I collagen peptides, components of 
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bone marrow fibroblast conditioned media, TGF-β, IGF- I and II and ON all act as 
bone-derived chemo-attractants for prostate cancer cells in vitro. This has been 
supported by evidence that human prostate cancer tissues contain mitogens for 
osteoblasts and mesenchymal cells (Koutsiliers et al 1987, Jacobs and Lawson 
1980). Metastatic prostate cancer cells have also been shown to secrete a variety of 
other factors which also affect osteoblast differentiation and proliferation and thus 
bone formation facilitating tumour cell growth (Table 1.9).   
Prostate cancer cells express the calcium-sensing receptor (CASR) and respond to 
ionised calcium resulting in inhibition of apoptosis and stimulation of proliferation. 
The importance of this receptor in prostate cancer progression was demonstrated 
by short hairpin RNA knockdown of this receptor, reduced expression of CASR 
reduced tumour localisation to the bone (Liao et al 2006).  Ionised calcium also 
leads to an increased PTHRP secretion by tumour cells and hence induces further 
resorption and calcium release.   
uPA is synthesised as a single chain precursor which is converted, by a serine 
protease, to a two chain entity, linked with a disulphide bridge. Some evidence 
suggests that high molecular weight uPA can produce a dose-dependent mitogenic 
effect in osteoblasts (Rabbini et al 1992). There is some evidence to suggest that 
the amino-terminal fragment of the uPA may also have a pro-tumourigenic effect 
possibly by contributing to the activation of latent growth factors such as TGFβ or 
IGF-1, which can also independently stimulate osteoblast activity (Koutsilieris et al 
1993).   In a clinical setting, metastatic prostate cancer patients’ also present with 
elevated ET-1 plasma levels (Nelson et al 1995).  
75 
 
 
 
 
 
 
Table 1.9 - Secreted Prostate Factors which influence osteoblasts (adapted from Logothetis and Lin 2005)
Factor Target Effect on osteoblasts Reference(s) 
BMP-2 Osteoblasts Increases differentiation, osteoblast mitogen Harris et al 1994, Autzen et al 1998  
TGF-β Osteoblasts Increases proliferation Marquardt et al 1987,Shariat et al 2001 
IGF-1 Osteoblasts Increased proliferation and differentiation, 
osteoblast mitogen 
Chan et al 1998 
IGFBP-3 IGF-1 Inhibits proliferation Li et al 2003 
PDGF Osteoblasts Increased proliferation Funa et al 1991, Fudge et al 1994 
FGF Osteoblasts Increased proliferation and differentiation Matuo et al 1987 
VEGF Osteoblasts, 
Endothelial 
cells 
Increased proliferation Ferrer et al 1997/ Dai et al 2004 
WNT Osteoblasts Increased proliferation and differentiation Chen et al 2004 
ET-1 Osteoblasts Increased proliferation and differentiation, 
osteoblast mitogen 
Nelson et al 1995 
PSA IGFBP-3 
and PTHRP 
Increased proliferation, osteoblast mitogen Cramer et al 1996, Iwamura et al 1996, Cohen et al 1992 
uPA IGFBP-3 Increased proliferation, osteoblast mitogen Rabbani et al 1990, Koutsilliers 1993 
MDA-BF-1 Osteoblasts Increased proliferation and differentiation Vakar-Lopez et al 2004 
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Though the predominant phenotype of bone metastases associated with prostate 
cancer is osteoblastic, studies have shown that osteolytic factors can also play a 
role in disease progression. Lynch et al (2005) showed that MMP-7 cleavage of 
RANKL, in prostate cancer, can promote osteoclastic activity. Lu et al (2009) also 
showed that in prostate cancer, osteoclastogenesis could also be indirectly 
stimulated by MMP-1 and A Disintegrin-like and Metalloproteinase with 
Thrombospondin Motifs 1 (ADAMTS1) proteolytically cleaving EGF-like ligands to 
decrease osteoblast-derived OPG.  
Other factors which affect prostate cancer progression in the bone include Dickkopf-
1 (DKK-1), sclerostin and Wnt-signalling. Upregulation of DKK-1 and sclerostin have 
been shown to favour osteoclastogenesis and thus inhibit the progression of bone 
metastases (Yavropoulou et al 20102, Diarra et al 2007). However, evidence 
suggests that DKK-1 levels decrease in patients with bone metastases, and is 
associated with an increase in Wnt promoting osteoblasts and inhibiting osteoclast 
differentiation, therefore leading to an osteoblastic phenotype (Sottnik et al 2012, Tu 
et al 2012).  
A prevailing theory about prostate cancer associated bone metastases is that 
proposed by Koeneman et al (1999) in which disseminated prostate cancer cells 
acquire a ‘bone-like phenotype’ (osteomimetic) to exploit the bone metastatic niche 
facilitating both bone localisation and cancer cell proliferation. Koeneman et al 
(1999) showed that prostate cancer cells in culture and in vivo can acquire 
characteristics associated with osteoclastic development and metastasis, relying on 
expression of osteoblastic genes including RUNX2 (Blyth et al 2005, Clezardin and 
Teti 2007, Pratap et al 2005, Galindo et al 2005).  
Despite these findings, much of the interplay which occurs between cancer cells, 
bone cells and the bone environment still needs to be elucidated.  
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1.7 RANK/ RANKL/OPG proteins and their signalling pathway 
The discovery of the OPG/RANK/RANKL system revolutionised our understanding 
of the molecular mechanisms responsible for the regulation of bone turnover. The 
interactions between tumour cells, tumour-derived factors and the bone 
microenvironment are crucial for the initiation and promotion of skeletal 
malignancies. A better understanding of the processes involved in this complex 
system is essential for the development of more targeted therapies and specific 
biomarkers for diagnostic and prognostic uses.  
 
1.7.1 Tumour Necrosis Factor Receptor Superfamily 
The tumour necrosis factor receptor superfamily (TNFRSF) is highly conserved and 
found in all mammals (Croft et al 2012). The TNFRSF are comprised of 18 genes 
encoding 19 type II transmembrane proteins with unique structural attributes that 
couple them directly to signalling cascades resulting in varied and pleiotropic 
actions involving cell proliferation, differentiation and survival (Bodmer et al 2002, 
Locksley et al 2001). The normal and pathophysiological function of each TNFRSF 
depends on the 3-fold symmetry that defines their essential signalling stoichiometry 
and structure (Locksley et al 2001). Due to this, the TNFRSF continues to be a 
major focus for targeted therapies against a wide range of human conditions 
including atherosclerosis, autoimmune disorders and cancer (Locksley et al 2001).   
The TNFRSF type II transmembrane proteins contain several cysteine-rich 
domains; and exist both as membrane-embedded and soluble factors after 
extracellular cleavage (Idriss and Naismith 2000, Croft et al 2012).  For most family 
members, both of these active forms are self-assembling, non-covalent homo-
trimers, whose individual chains fold as compact β sandwiches and interact at 
hydrophobic interfaces (Fesik, 2000, Tansey and Szymkowski 2009).  The 25-30% 
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amino acid similarity between this family of ligands is largely confined within the 
internal aromatic residues responsible for trimer assembly. There appears to be little 
sequence similarity elsewhere which could account for the receptor selectivity 
(Locksley et al 2001).  
 
1.7.2 Osteoprotegerin 
Osteoprotegerin (OPG), also named osteoclastogenesis inhibitory factor (OCIF), 
was discovered simultaneously by Simonet et al 1997 and Tsuda et al in 1997, and 
has since been characterised as a novel protein integral to the regulation of bone 
turnover. As a decoy receptor for RANKL, OPG was found to be the paracrine 
regulator of osteoclast formation produced by osteoblasts constitutively to moderate 
osteoclast formation from RANKL stimulation (Martin TJ 2013). In vivo experiments 
showed that transgenic mice expressing this secreted protein exhibited a general 
increase in bone density, associated with a lack of osteoclasts (Boyle et al 2003). 
OPG is classed as a member of the TNFRSF however, unlike other family 
members, lacks the transmembrane proteins that can elicit signal transduction in a 
variety of cells resulting in a lack of apparent cell-associated signals (Baud’huin et al 
2013).  
TNFRSF11B is a highly conserved gene, originally isolated in rats, which has been 
shown to have 94% homology to the human gene. OPG mRNA has been detected 
in a variety of tissues including vascular tissues, bone, prostate, testis, kidney, liver, 
lung and heart, however, most extensive work and knowledge is available regarding 
its role in bone biology (Lacey et al 1998).  Synthesised by osteoblasts, stromal 
cells, vascular smooth muscle cells, B lymphocytes and articular chondrocytes, 
OPG is characterised as a soluble glycoprotein that can exist as both a 60kDa 
monomer and a 120kDa disulphide-linked dimer. 
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1.7.2.1 Structure 
The human OPG gene, TNFRSF11B, is located on chromosome 8q23-24 and 
contains 5 different exons spread over 29kb. When transcribed, OPG cDNA 
encodes a 401 amino acid polypeptide chain, which after cleavage of the 21 amino 
acid signal peptide, at position 22, results in a mature form of 380 amino acids 
(Figure 1.10 A) (Simonet et al 1997).  
OPG has features of a secreted glycoprotein including a hydrophobic leader peptide 
and 4 potential sites of N-linked glycosylation. The N-terminus structure has a 
strong similarity to all other members of the TNFR superfamily, most notably to 
TNFR-2 and CD40. However, unlike the transmembrane members of the TNFRSF, 
OPG is unique because it contains no hydrophobic transmembrane-spanning 
sequence which is required for intracellular signalling. The N-terminus, contains 4 
canonical cysteine rich N-terminal domains involved in the formation of ‘tethered 
loops’, conferring ligand binding, which are required for biological activity, including 
the inhibition of osteoclastogenesis (residues 22-194) (Figure 1.10 B) (Smith et al 
1994).  
At the C-terminus, OPG contains 2 death domain homologous regions (D5 and D6) 
which mediate cytotoxic signals when they form a chimeric protein with Fas. This is 
a pattern which shows no known homologies to any other recognisable protein 
motifs (Yamaguchi et al 1998). Domain 7 possesses a heparin-binding site 
important for the interaction of OPG with proteoglycans. The presence of Cys-400 
within domain 7 has been shown to be central to OPG dimer formation (Yamaguchi 
et al 1998).   
Initially OPG is synthesised as a 60kDa monomer within the cell which is converted 
to a secreted disulphide-linked homodimer glycoprotein, approximately 120kDa. It is 
the dimeric form of this protein which has the highest hypocalcaemic bio-acitivity. 
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Figure 1.10 – OPG structures 
Schematics of DNA and protein structures for OPG 
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1.7.2.2 Role in bone turnover 
Since the identification of OPG in 1997 its role in the regulation of bone turnover 
through inhibition of RANKL has been best characterised. Binding of RANKL to 
RANK on pre-osteoclasts and osteoclasts is essential for their maturation and 
degradation of the bone matrix. OPG represents an endogenous receptor 
antagonist, produced by osteoblasts, that neutralises the biologic effects of all three 
forms of RANKL. OPG binding as a homodimer to the homotrimeric RANKL 
prevents it binding to RANK and subsequent osteoclast activation. In vitro studies 
have confirmed the requirement for OPG dimerization in this process, with the 
monomeric form having reduced RANKL-binding affinity (Schneeweis et al 2005).  
OPG has been shown, in the skeleton, to systemically inhibit RANKL independent of 
local bone turnover rates or access to remodelling surfaces. OPG has also been 
demonstrated to rapidly reduce osteoclast numbers whilst having no direct effect on 
osteoblasts (Kostenuik 2005). 
 
1.7.2.3 Role in cell survival 
In addition to its role in regulating bone turnover, OPG can stimulate cell survival by 
acting as a receptor for TNF-related apoptosis-inducing ligand (TRAIL) (Emery et al 
1998). TRAIL is a member of the tumour necrosis factor superfamily produced by 
immune cells within the tumour microenvironment, such as monocytes, in response 
to IFN-α and IFN-β. Activation of DR4/DR5 by TRAIL triggers the death signalling 
cascade common to the TNF family, however OPG is capable of blocking this, and 
therefore cancer cells which produce OPG have the ability to evade this form of 
apoptosis (Holen et al 2002, Neville-Webbe et al 2004, Shipman and Croucher 
2003).  
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1.7.2.4 Role in immunity 
OPG expression in a variety of tissues, including those of the vascular and immune 
system, suggests other roles, both physiologically and pathophysiologically, may 
exist for OPG. In dendritic cells, TNFα, RANKL, IL-1β and ligation of CD40 have all 
been demonstrated to up regulate OPG expression (Schoppet et al 2007, Yun et al 
1998).  
OPG expression has been shown, both in vitro and in vivo, to increase with dendritic 
cell maturity, in human lymphoid tissue possibly involving the NF-κB pathway 
(Schoppet et al 2007). It is believed that OPG may act to down regulate the immune 
response by decreasing dendritic cell survival through inhibition of RANK-RANKL 
interactions similar to its role in bone turnover (Reid and Holen 2009). This has 
been supported by an in vivo autoimmunity model, IL-2 deficient mice treated with 
OPG, prevented T-cell mediated inflammation through a reduction in dendritic cell 
survival (Ashcroft et al 2003). 
 
  1.7.2.5 Role in the vascular system 
Evidence has emerged of the possible effects OPG exerts on vasculature cells and 
tissues including the heart, arteries and veins (Collins-Osdoby 2004). Both smooth 
muscle cells and the endothelium have been shown to produce OPG (Schoppet et 
al 2002, Malyankar et al 2000). Several epidemiological studies have shown that 
increased OPG levels were detected in patients who had died from stroke or 
cardiovascular event (Browner et al 2001, Jono et al 2002 and Schoppet et al 2003, 
Kiechl et al 2004). Studies have also demonstrated that OPG may act in a paracrine 
manner on endothelial cells promoting their survival, though the mechanism by 
which this is achieved remains under debate (McGonigle et al 2009, Cross et al 
2006b, Pritzker et al 2004).  
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1.7.2.6 Role in tumourigenesis  
The role OPG may play in tumourigenesis has largely focused on those cancer 
types which preferentially metastasise to the bone and how it affects tumour cell 
survival (Zauli et al 2009). In vitro expression studies have demonstrated that both 
poorly differentiated hormone independent breast and prostate cancer cell lines 
produce sufficient OPG to protect themselves against TRAIL-induced apoptosis 
(Thomas et al 1999, Holen et al 2002, Holen et al 2005). Pettersen et al (2005) also 
reported similar observations in the colorectal cell lines. Whilst subsequent data has 
suggested that bone marrow stromal cells, which also produce OPG, produce 
sufficient levels of OPG to protect tumour cells from TRAIL-induced apoptosis 
(Neville-Webbe et al 2004, Nyambo et al 2004). Paradoxically, multiple myeloma 
cells, which do not produce OPG, result in a decrease in OPG production from bone 
stromal cells, but the bone stromal cells still produce sufficient levels of OPG to 
prevent myeloma cell apoptosis (Croucher et al 2001, Shipman and Croucher 2003, 
Giuliani et al 2001, Pearse et al 2001). This suggests there is a fine balance 
between the beneficial effects of OPG in cancer induced SREs and detrimental 
inhibition of TRAIL induced apoptosis (Reid and Holen 2009).     
One recent study provided a molecular link between prostate cancer cell lines and 
their metastatic potential. Constitutive OPG mRNA levels were found to be threefold 
to fourfold higher in prostate cancer cells compared to healthy prostate tissue 
(Brown et al 2001a). These findings are similar to those obtained in osteosarcoma 
cells, which like prostate cancer forms osteoblastic tumours in bone.  
A potential role of OPG in tumour growth angiogenesis is also emerging. Cross et al 
(2006a) demonstrated that, in vitro, as well as promoting endothelial cell survival, 
OPG promotes endothelial cell tubule formation. OPG was also observed to protect 
endothelial cells from apoptotic cell death under trophic withdrawal though this did 
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not occur through inhibition of TRAIL, suggesting other unidentified inhibitory 
mechanisms may also be induced by OPG (Cross et al 2006). Secchiero et al 
(2008) also suggested a potential pro-angiogenic role, in which p53 deficient 
endothelial cells exhibited increased OPG levels. 
The majority of in vivo models indicate that the presence of OPG can decrease 
bone lysis associated with cancer-induced SREs, indirectly resulting in a reduction 
in tumour growth possibly due to space limitations and inhibition in the release of 
bone-derived growth factors (Reid and Holen 2009). However, the impact on the 
tumour cells themselves is less well defined, with results not reproducible in 
subcutaneous xenograft models (Morony et al 2001, Zhang et al 2001).  There is 
also some evidence to suggest that OPG may play differing roles depending on the 
source and the cancer type. Fisher et al (2006) demonstrated, in a MCF-7 breast 
cancer model, that OPG overexpression resulted in increased cell proliferation in 
both the bone and soft tissue. However this was not replicated in a prostate model 
in which little effect was seen in soft tissue growth, but the tumour burden in the 
bone and osteolysis were decreased (Corey et al 2005). 
 
1.7.2.7 Clinical evidence for role in tumourigenesis 
Clinical studies have assessed OPG both in serum and using 
immunohistochemistry across various cancer types. Lipton et al (2002) and Valero 
et al (2006) reported that elevated OPG serum levels were detected in colorectal, 
pancreatic and squamous cell head and neck cancer. There also appears to be an 
association with increased OPG serum levels and the presence of bone metastases 
in breast, lung and prostate cancer (Mountzios et al 2007, Brown et al 2001b).  
In prostate cancer, immunohistochemical staining has shown increased OPG 
expression in metastatic prostate cancer sections, both osseous and non-osseous, 
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compared with normal and primary carcinoma tissue (Brown et al 2001a). Whilst 
increased OPG levels correlate with tumour burden, AR-status, metastatic bone 
disease and relapse following androgen ablation therapy (Brown et al 2001a, Jung 
et al 2004, Eaton et al 2004, Chen et al 2006). These findings suggest OPG could 
be a suitable candidate for a prognostic biomarker in prostate cancer. Similar 
patterns of immunohistochemical staining have also been reported in breast cancer. 
Oestrogen receptor (ER) positive samples were positive for OPG staining, whilst 
little staining was noted in the ER negative samples (Van Poznak et al 2006).  
Clinical data also strongly supports a potential role for OPG in tumour angiogenesis. 
Strong immunohistochemical staining was seen in endothelial cells of malignant 
tissue across a variety of cancers, including breast and colorectal (Reid and Holen 
2009). In the breast cancer study, this endothelial staining was shown to correlate 
with tumour grade and inversely correlate with ER status (Cross et al 2006a, Cross 
et al 2006b).  These findings suggest that increased angiogenesis may be an 
additional mechanism by which OPG can affect tumour progression.  
 
1.7.2.8 Signalling 
In vitro and in vivo studies have suggested that TNFRSF11B gene expression is 
regulated by the Wnt/β-catenin signalling pathway in osteoblasts (Glass et al 2005).  
Known as a canonical pathway; it promotes osteoblast commitment, proliferation 
and differentiation and enhances osteoblast and osteocyte survival (Bonewald and 
Johnson 2008). The Wnt/β-catenin pathway is activated by Wnt binding with a co-
receptor complex involving low-density lipoprotein-related protein (LRP5 and LRP6) 
and one of the frizzled family members (Fz). The complex Wnt/LRP/Fz leads to the 
release of non-phosphorylated β-catenin into the cytoplasm from where it 
translocates to the nucleus to modulate gene transcription.  
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The involvement of the canonical Wnt pathway in bone cells has been revealed in 
various studies showing that loss-of-function mutations in LRP5 (Gong et al 2001) 
resulted in decreased bone mass, whereas gain of function mutations increased 
bone mass in humans and mice (Boyden et al 2002,). OPG expression is enhanced 
in osteoblasts derived from mice with loss-of-function mutations in LRP5, whereas it 
is reduced in osteoblasts from gain-of-function mutations, suggesting that the Wnt 
signalling pathway regulates osteoclasts by increasing the OPG:RANKL ratio 
(Kubota et al 2009). 
Wnt signalling is tightly regulated by secreted antagonists, such as the secreted 
frizzled-related protein family (sFRP) and Wnt inhibitory factor (WIF-1) which 
antagonise the interaction of Wnt with its receptor Fz (Aberle et al 1997). 
 
1.7.3 RANKL 
RANKL, also known as OPG-ligand (OPGL), osteoclast differentiation factor (ODF) 
or TNF-related activation-induced cytokine (TRANCE), is a type II transmembrane 
protein (317 amino acid) containing a small N-terminal intracellular domain, a 
transmembrane region and an extracellular C-terminal consisting of a stalk and a 
receptor binding regions that forms trimers, typical of the TNFRSF.  
 
1.7.3.1 Structure 
Anderson et al (1997) mapped the RANKL gene, TNFSF11, to chromosome 13q14 
whilst the protein was discovered and isolated independently by 3 groups (Anderson 
et al 1997, Wong et al 1997 and Yasuda et al 1998b).  
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RANKL can exist in three forms, membrane bound, soluble ectodomain form 
generated by post-translation modification by TNF-α converting enzyme-like 
protease or soluble secreted form, which is predominately seen in activated T- 
lymphocytes or cancer cells generated through proteolytic cleavage of the 
extracellular stalk by MMP14 and ADAM10 (Burgess et al 1999, Lacey et al 2012). 
RANKL gene expression is mainly expressed in lymph nodes and bone marrow 
stromal cells. In the skeleton, RANKL is expressed in the primitive mesenchymal 
cells, hypertrophying chondrocytes and in areas of primary ossification and re-
modelling.   
 
1.7.3.2 Role in bone remodelling 
RANKL is an essential factor in the recruitment, differentiation, activation and 
survival of osteoclasts through binding to its specific receptor RANK, which is 
present on the surface of osteoclast precursors driving them towards mature 
osteoclasts and inhibition of apoptosis of mature osteoclasts.  RANKL is essential 
and sufficient for all other steps of the osteoclast life cycle (Dougall et al 2014).  
Exogenous administration of RANKL to normal mice increased the number and 
activity of osteoclasts, causing rapid bone loss and promoting the development of 
severe osteoporosis and lethal hypercalcaemia. Lacey et al (1998) also 
demonstrated that in vitro RANKL can directly activate isolated mature osteoclasts. 
The effects of RANKL are blocked in vitro and in vivo by the soluble inhibitor OPG, 
suggesting that these remain integral regulators of osteoclast development. Luan et 
al (2012) revealed that OPG exerts its decoy receptor function by directly blocking 
the accessibility of interacting residues on RANKL, including arg223, tyr241 and 
lys257, vital for RANK recognition. 
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RANKL expression is regulated by various osteotropic cytokines, peptides and 
steroid hormones that are known modulators of bone resorption and determinants of 
bone mass. Wong et al (1999) demonstrated that RANKL activates the 
serine/theorine kinase PKB through a signalling complex involving SRC and TRAF6. 
Upon RANK receptor engagement, SRC and TRAF6 interacted with each other. 
TRAF6 enhances the kinase activity of SRC, leading to tyrosine phosphorylation of 
downstream signalling molecules such as CBL.  A deficiency in SRC or addition of 
SRC family kinase inhibitors blocked RANKL mediated PKB activation in 
osteoclasts.  
Ikeda et al (2004) generated transgenic mice expressing dominant-negative c-Jun, 
specifically in the osteoclast lineage, and found that they developed severe 
osteopetrosis due to impaired osteoclastogenesis. This was also mimicked in vitro 
by the blockade of c-Jun signalling which markedly inhibited soluble RANKL-
induced osteoclast differentiation. Overexpression of nuclear factor of activated T 
cells 1 (NFATC1) promoted differentiation of osteoclast precursor cells into TRAP-
positive multinucleated osteoclast-like cells, even in the absence of RANKL. The 
osteoclastogenic properties of NFATC1 were abrogated by over-expression of 
dominant-negative c-Jun leading Ikeda et al (2004) to conclude that c-Jun 
signalling, in co-operation with NFAT, is crucial for RANKL-regulated osteoclast 
differentiation.  
Takayanagi et al (2002) demonstrated that RANKL induces the IFN-β gene in 
osteoclast progenitor cells. Interestingly, IFN-β inhibits the differentiation of 
osteoclasts by interfering with the RANKL-induced expression of c-Fos, an essential 
transcription factor for the formation of osteoclasts. This therefore highlights the 
potential for an auto-regulatory mechanism in which RANKL induces its own 
inhibitor. 
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1.7.3.3 Role in immunity 
RANKL has been described as a T-cell-derived cytokine (TRANCE) and appears to 
be an important regulator for T-cell-dendritic cell interactions in the immune system. 
RANKL augmented the ability of dendritic cells to stimulate naïve T-cell proliferation 
in a mixed lymphocyte reaction and increase the survival of RANK+ T cells 
generated with IL-4 and TGF-β (Anderson et al 1997). RANKL also up-regulated 
Bcl-xL expression, and thus promoted dendritic cell survival through an inhibition of 
apoptosis (Chino et al 2009).  
Kong et al (1999) reported that systemic activation of T-cells could directly trigger 
osteoclastogenesis and bone loss through RANKL in vivo. This was supported by a 
T-cell dependent model of rat adjuvant arthritis characterised by severe joint 
inflammation and bone and cartilage destruction. Blocking of RANKL with OPG 
treatment at the onset of disease prevented bone loss and cartilage destruction but 
not inflammation. These results show that both a systemic and local T-cell activation 
can lead to RANKL production and subsequent bone loss, providing a potential role 
for T-cells as regulators in bone physiology. RANKL produced by bone and immune 
cells (osteoblastic cells, activated T-cells) through the modulation of the 
differentiation, activation and survival of bone and immune cells (osteoclasts, 
dendritic cells), indicates that RANKL may represent a crucial paracrine link 
between bone metabolism and the immune system. 
Wong et al (1997) reported that a soluble form of RANKL, consisting of the 
extracellular domain, can activate JNK in T-cells but not in B-cells or bone marrow 
derived dendritic cells. They suggested that this isoform may also play a specific 
role in the regulation of T-cell function though further elucidation into how this 
occurs is needed.  
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1.7.3.4 Role in tumourigenesis 
Bone destruction, caused by aberrant production and activation of osteoclasts, is a 
prominent feature of multiple myeloma. It has been demonstrated that myeloma 
cells stimulate osteoclastogenesis by triggering a co-ordinated increase in RANKL 
and a decrease in its decoy receptor OPG (Pearse et al 2001). In co-culture, 
myeloma cell lines stimulated expression of RANKL and inhibited expression of 
OPG by stromal cells.  This data identified that RANKL and OPG are key cytokines, 
in which their dysregulation promotes bone destruction and supports myeloma 
growth. In an in vivo mouse model of melanoma metastasis, neutralisation of 
RANKL by OPG resulted in complete protection from paralysis and a marked 
reduction in tumour burden in bones but not in other organs (Croucher et al 2001). 
RANKL mRNA expression was also found to be high in tumour xenografts 
established using the PC-3 prostate cancer cell line, which has the capacity to 
induce osteolytic metastases, and low in xenografts of the LNCaP prostate cancer 
cell line, which lacks this capacity and grows as a mixed osteoblastic-osteolytic 
tumour (Corey et al 2002). 
RANKL and RANK have been shown to be involved in mammary gland 
development and therefore the roles they play in breast cancer are best 
characterised. Gonzalez-Suarez et al (2010) showed that RANK and RANKL are 
expressed within normal, premalignant and neoplastic mammary epithelium. Using 
complementary gain-of-function and loss-of-function approaches, a direct 
contribution of this pathway has been linked to breast tumourigenesis. Accelerated 
pre-neoplasias and increased mammary tumour formation were observed in MMTV-
RANK transgenic mice after treatment with carcinogen inducing hormone, 
progesterone. Reciprocally, selective pharmacologic inhibition of RANKL attenuated 
mammary tumour development not only in hormone- and carcinogen treated 
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MMTV-RANK and wild type mice but also in the MMTV-new transgenic 
spontaneous tumour model (Gonzalez-Suarez et al 2007). The reduction in 
tumourigenesis after RANKL inhibition was preceded by a reduction in pre-
neoplasias as well as rapid and sustained reductions in hormone- and carcinogen- 
induced mammary epithelial proliferation and cyclin D1 levels. Gonzalez-Suarez et 
al (2010) concluded that RANKL inhibition is acting directly on hormone-induced 
mammary epithelium, at early stages in tumourigenesis and the permissive 
contribution of progesterone to increased mammary cancer incidence is due to 
RANKL-dependent proliferative changes in the mammary epithelium.  
Jones et al (2006) demonstrated that the cytokine RANKL, in a local environment, 
can trigger a pro-migratory response in RANK expressing human epithelial cancer 
cells and melanoma cells. Most RANKL-producing T-cells expressed FOXP3, a 
transcription factor produced by regulatory T-cells.  Tan et al (2011) examined 
whether RANKL, RANK and IKK-α were involved in mammary/breast cancer 
metastasis. RANK signalling in mammary carcinoma cells which overexpress the 
proto-oncogene Erbb2 (Neu), which is frequently amplified in human breast 
cancers, was important in pulmonary metastasis. Metastatic spread of Erbb2-
transformed cancer cells also required CD4+CD25+ T cells, whose major pro-
metastatic function was RANKL induced, especially when located next to smooth 
muscle actin-positive stromal cells in mouse and human breast cancers. The 
dependence of pulmonary metastasis on T-cells was replaceable by exogenous 
RANKL, which also stimulated pulmonary metastasis of RANK-positive human 
breast cancer cells. Tan et al (2011) concluded that these results were consistent 
with the adverse impact of tumour-infiltrating CD4+ or FOXP3+ T cells on human 
breast cancer prognosis and suggested that the targeting of RANKL-RANK can be 
used in conjunction with the therapeutic elimination of primary breast tumours to 
prevent recurrent metastatic disease.    
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1.7.4 RANK 
Anderson et al (1997) identified dendritic cell cDNA which encoded a protein with 
homology to an extracellular domain of the TNFRSF. This 616 amino acid protein 
was subsequently named RANK.  
 
1.7.4.1 Structure 
The RANK gene, TNFRSF11A, is located on chromosome 18q21.33, in some 
human cell lines encoding a type I homotrimeric transmembrane protein, containing 
4 extracellular cysteine-rich pseudo-repeats as seen in the rest of the TNFRSF. 
Northern blot analysis indicated that the 4.5-kb human RANK mRNA is expressed 
ubiquitously but particularly apparent on mature osteoclasts, dendritic cells and 
some cancer cells, including breast and prostate cancers. Anderson et al (1997) 
also detected additional transcripts that were derived from the use of alternative 
polyadenylation signals in the RANK gene. 
 
1.7.4.2 Role in bone remodelling  
Nakagawa et al (1998) identified RANK as an osteoclast differentiation factor on 
osteoclast progenitor cells, essential for osteoclast differentiation which mediated 
osteoclastogenesis. Much work has gone into elucidating the role RANK and 
RANKL interaction plays in osteoporosis and the genetic condition Pagets disease. 
Dougall et al (1999) generated RANK -/- mice and found that they had profound 
osteopetrosis resulting from a block in myeloid osteoclast differentiation. However, 
RANK was not required for myeloid commitment to macrophage, granulocyte or 
dendritic cell pathways. RANK -/- mice also exhibited splenic B-cell deficiency and 
peripheral lymph nodes, except for mucosal associated lymphoid tissues. This 
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demonstrated that RANK is critical for lymph node organogenesis and osteoclast 
differentiation.  
Li et al (2000) generated RANK-null mice to determine the molecular genetic 
interactions between OPG, RANKL and RANK during bone resorption and the 
remodelling processes. RANK -/- mice lacked osteoclasts and had a profound 
defect in bone resorption and remodelling as well as in the development of the 
cartilaginous growth plates of endochondral bone. The osteopetrosis observed in 
these mice could be reversed by transplantation of bone marrow from mice 
nullizygous for the recombinase activating gene (RAG1), indicating that RANK -/- 
mice have an intrinsic defect in osteoclast function. Calciotropic hormones and pro-
resorptive cytokines are capable of inducing bone resorption, in both RANK -/- mice 
and humans without inducing hypercalcaemia, although TNF-α treatment lead to the 
rare appearance of osteoclast-like cells near the site of injection (Li et al 2000). 
Osteoclastogenesis could be initiated in RANK -/- mice by transfer of the RANK 
cDNA back into hematopoietic precursors, suggesting a means to critically evaluate 
RANK structural features required for bone resorption. Together this data has 
indicated that RANK is the intrinsic cell surface determinant that mediates RANKL 
driven effects on bone resorption and remodelling as well as the physiological 
effects of calciotropic hormones and pro-resorptive cytokines (Li et al 2000). 
Functional expression and biologic effects of RANK have mainly been characterised 
in osteoclasts and dendritic cells. After stimulation by RANKL, the activated RANK 
interacts with TNFR-associated factors (TRAF) 1-6, of which TRAF 6 appears to be 
essential for signal transduction (Wei et al 2013, Yen et al 2012). RANK signal 
transduction then diverges into three separate pathways that regulate distinct 
aspects of osteoclast functions: 
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- Protein kinase c-Jun N terminal kinase (JNK) pathway, which modulates c-fos and 
c-jun, which are expressed sequentially by late stage osteoclastic precursor cells. 
- Nuclear factor (NF)-κB pathway, which regulates osteoclastogenesis and 
proteasome formation. 
- Serine/threonine kinase Akt/PKB, which inhibits apoptosis, modulates cytoskeleton 
reorganisation and may cross-talk to the NF-κB pathway.  
 
1.7.4.3 Role in tumourigenesis 
Schramek et al (2010) demonstrated that in vivo administration of 
medroxyprogesterone acetate (MPA), used in women for hormone replacement 
therapy and contraceptives, triggers massive induction of the key osteoclast 
differentiation factors including RANKL in mammary gland epithelial cells. Genetic 
inactivation of RANK in mammary gland epithelial cells prevented MPA-induced 
epithelial proliferation, impaired expansion of CD49f(hi) stem cell-enriched 
population, and sensitised these cells to DNA damage-induced cell death. Deletion 
of RANK from the mammary epithelium also resulted in a markedly decreased 
incidence and delayed onset of MPA-driven mammary cancer. Schramek et al 
(2010) concluded that the RANKL/RANK system controls the incidence and onset of 
progestin-driven breast cancer.  
The establishment and progression of tumour cell growth in bone is a complex and 
dynamic process that depends on biological characteristics of the tumour cells, the 
properties of the bone and bone marrow microenvironment, and a network of growth 
factors, cytokines and chemokines and their antagonists as well as receptors, 
adhesion molecules and MMPs. With the identification and characterisation of the 
RANKL/RANK/OPG cytokine system, several studies have implicated RANKL, 
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RANK and OPG as an essential cytokine system that regulates tumour-bone 
interactions, though further understanding on how these pathways converge is 
needed.  
 
1.8 Hepatocyte Growth Factor and its receptor cMET 
Hepatocyte growth factor (HGF), also known as scatter factor, was discovered 30 
years ago (Nakamura et al 1984, Michalopoulos et al et al 1984, Russell et al 1984). 
In 1985, Stoker and Perryman discovered a factor which had the ability to scatter 
tightly packed colonies of epithelial cells; subsequent partial amino acid sequencing 
has revealed this factor to have over 90% homology to human HGF. HGF has been 
under intense investigation for potential roles it may play in cancer initiation and 
progression as it elicits diverse cellular responses in a range of cell types and 
tissues (Jiang et al 1999).  
 
1.8.1 HGF 
The human HGF encoding gene is located on chromosome 7q11.1-21 and is 
composed of 18 exons and 17 introns spanning approximately 70Kb (Weidner et al 
1991, Fukuyama et al 1991, Seki et al 1991).  Cloning and sequencing of HGF has 
revealed it to be a single 728 amino acid chain polypeptide, including a 29 amino 
acid signal sequence and a 25 amino acid pro-peptide sequence (Nakamura 1989).   
HGF is synthesised and secreted in a single pro-form which is converted to a 
mature heterodimeric protein, by extracellular cleavage through enzymatic 
hydrolysis of the Arg-Val bond within the pro-sequence by a serine protease 
including hepatocyte growth factor converting enzyme, thrombin, uPA and tissue 
plasminogen activator (tPA) (Naldini et al 1995, Mizuno et al 1994, Shimomura et al 
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1993, Mars et al 1993). The mature HGF protein consists of a 69kDa α-chain and a 
34kDa β-chain.  
HGF is a unique growth factor because it has 4 kringle domains each located on the 
α-subunit. Artificially induced HGF deletions in the N-terminal hairpin structure, or 
any of the kringle domains, though particularly the first or second kringle domain, 
results in the loss of biological function possibly due to a lack of protein-protein 
binding (Matasumoto et al 1991, Lerch et al 1980, van Zonneveld et al 1986). 
HGF has since been established as a mitogen that regulates cell growth and death, 
a motogen that stimulates cell motility, a morphogen that modulates cell morphology 
and tissue/organ regeneration and a pro-angiogenic and lymphangiogenic factor 
(Gherardi and Stoker 1990).  Osteoblasts have been shown to secrete HGF (Grano 
et al 1996), a process which has been shown to act as a cooperative secretion to 
stimulate the survival of haematopoietic progenitors (Taichman et al 2001). HGF is 
believed to be a coupling factor between osteoblasts and osteoclasts. HGF is 
known to play a role in osteoclast formation. HGF receptor, c-MET is expressed by 
the CD14+ monocyte fraction of human peripheral blood mononuclear cells 
(PBMC). Adamopoulos et al (2006) demonstrated that HGF was able to support 
monocyte-osteoblast differentiation in the presence of RANKL. Osteoclast formation 
is stimulated by HGF in the presence of osteoblastic cells but the mechanism(s) 
behind this remain elusive. 
HGF is a heparin binding glycoprotein which initiates intracellular signalling through 
its receptor, cMET, encoded by the c-Met proto-oncogene (Bottaro et al 1991). HGF 
signals through the tyrosine kinase receptors and phosphorylates common 
transducers and effectors such as Src, Grb2 and PI3-kinase.  
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1.8.2 c-MET 
The HGF receptor, c-MET, was first identified as an activated oncogene which has 
been mapped to chromosome 7 at q21-31 and encodes a 1408 amino acid 
glycoprotein (Park et al 1987). c-MET is considered a member of the tyrosine kinase 
(RTK) family of cell surface molecules, a family which shares common structural 
organisation: an N-terminal extracellular ligand binding domain, a single 
transmembrane α-helix and  a cytosolic C-terminal domain with intrinsic tyrosine 
kinase activity. The receptor, encoded by the c-MET proto-oncogene, is a two chain 
protein composed of a 50k-Da α-chain disulphide linked to a 145kDa β chain 
(Naldini et al 1991, Bottaro et al 1991). The α chain is exposed at the cell surface 
whilst the β chain spans the cell membrane and possesses an intracellular tyrosine 
kinase domain (Giordano et al 1993,Park et al 1987).  
HGF binds to and induces tyrosine phosphorylation of the mature c-MET receptor β 
chain. Such events are thought to promote binding of intracellular signalling proteins 
containing src homology (SH) regions such as phospholipase Cγ (PLCγ), Ras-GAP, 
phosphatidylinositol 3-kinase (PI-3K), pp60c-src and the GRB-2-Sos complex to the 
activated receptor (Ponzetto et al 1994, Jiang et al 1999, Ponzetto et al 1993). 
Several studies have shown that the two closely spaced tyrosines in the cytoplasmic 
domain of c-MET (Y1349 and Y1356) are essential for scattering and is the principal 
determinant of which SH-2 containing protein will bind to the phosphotyrosine (Koch 
et al 1991, Pawson and Gish 1992) . Y14 and Y15 recruit several SH-2 domain 
containing proteins including adaptor proteins such as Grb2, Shc, Gab1 and Cb1 
and effector proteins such as PI-3K, Src, PLCγ, Shp2 as well as transcription factor 
signal transducer and activator of transcription 3 (Stat3) (Okano et al 1993). 
 Each SH-2 containing protein may activate a different subset of signalling 
phosphopeptides thus eliciting different responses within the cell. For example, 
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Gab1 which amplifies the c-MET response, stimulates branching in morphogenesis 
in vitro by activating Shp2 and PLCγ in a sustained manner. Whilst CB1 the other 
docking protein is involved in signal transduction as well as acting as a E3 ubiquitin 
ligase that down regulates c-MET. EMT is promoted in a CB1 variant that lacks the 
part of the ring finger domain required for CB1 ubiquitin ligase activity and by a 
mutant which lacks the c-MET binding site (Fan et al 2001). 
 
1.8.3 The role of HGF and cMET in cancer 
Since its discovery, HGF has been strongly implicated in the regulation of tumour 
cell behaviour, although the degree of response varies between tumour types. The 
independent discoveries of HGF as a mitogenic agent and a motogenic stimulus, as 
well as a morphogenic regulator, demonstrate that it is a factor which can elicit 
different responses in target cells, although these activities are not mutually 
exclusive. HGF and c-MET have been found to be overexpressed at both mRNA 
and protein levels in virtually all human solid tumours as well as in haematopoietic-
derived malignancies (Jiang et al 2005b).  
HGF was initially regarded as a protein product from host stromal cells in the 
context of cancer. However the discovery that epithelial cancer cells showed 
aberrant HGF transcript and protein expression indicates that the sources and roles 
of HGF in cancer progression may be from multiple sources rather than from a 
purely stromal origin. Though additionally, stromal cells in tumour tissues over 
express the HGF transcript and HGF protein (Boccaccio et al 1998). Transcriptional 
activation of HGF in epithelial cancer cells is thought to be via the c-src and Stat3 
pathways. Together with over-expression of c-MET on cancer cells, this creates a 
mechanism for bi-stimulation of cancer cells: paracrine stimulation (HGF generated 
by stromal cells) and autocrine stimulation (HGF generated by cancer cells 
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themselves). In general, paracrine stimulation is probably the stronger of the two, as 
some tumour cell types are known to be completely free from expressing HGF. 
In a variety of cancers, including prostate and pancreatic, HGF has been shown to 
increase cancer cell proliferation and motility (Humphrey et al 1995, Hasegawa et al 
1995, Pisters et al 1995). In breast cancer, HGF has been shown to increase cell 
motility and cell invasiveness, through increased expression and secretion of 
proteolytic enzymes from cancer cells including MMP2, MMP7, MMP9 and uPA, 
and cell-matrix adhesion (Giordano et al 1993, Jiang et al 1996, Davies et al 2001).   
 
1.9 Aims 
The current study aimed to assess the importance of the endogenously produced 
OPG/RANK/RANKL family of proteins in prostate and breast cancer in differing 
osteotrophic phenotypes and their potential for involvement in dissemination to and 
colonisation of bone.  In addition, the study aimed to explore the therapeutic 
implications of targeting members of this family in relation to these cancer types.  
Specific aims were: 
1) To generate OPG knockdown models in osteotropic osteolytic PC-3 prostate 
and MDA-MB-231 breast cancer cell types and explore the impact 
suppression of OPG has in these lines. 
2) To explore the impact of alterations in OPG and RANKL levels through 
addition of recombinant protein or neutralising antibodies in the mixed 
osseous LNCaP prostate cell line.  
3) To assess the impact of extracellular environmental stimuli (HGF and 
isolated bone proteins)  on these model systems in vitro and the potential for 
these molecules in mediating the signal transduction induced by these 
growth factors or isolated bone proteins. 
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4) To assess members of this family in more complex clinical and in vivo 
settings.   
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Chapter 2 
General Materials and Methods 
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2.1 Cell lines 
Six prostate and three breast cancer cell lines were used in this study. Full details of 
cell origins and characteristics are outlined in Table 2.1. PC-3, MDA-MB-231 and 
MCF-7 were purchased from the European Collection of Animal Cell Culture 
(ECACC, Salisbury, UK). All other cells were purchased from the American Type 
Culture Collection (ATCC, Rockville, Maryland, USA).  
 
2.2 Breast cancer tissue collection 
All research involving human tissues was conducted under the ethical approval of 
the local ethics committee (Bro Taf Local Research Ethics Committee (Panel B) for 
the Bro Taf Health Board, Cardiff, UK issued 10/12/2001, reference 01/4303). All 
data was analysed anonymously and informed verbal consent given. As the tissues 
were collected before the introduction of the Human Tissue Act, UK 2004, no written 
consent was necessary and documentary measures not required. Primary breast 
cancer tissue and matching non-neoplastic mammary tissue were collected from the 
same mastectomy specimens’ immediately after surgery and stored at -80oC until 
use. All the specimens were verified and graded by a consultant pathologist. 
Medical notes and histology reports were used for the collation of clinical and 
pathological data at point of surgical intervention and during the postoperative 
follow-up (Median – 120 months).  All tissues were randomly labelled and details of 
histology, tumour grade, Nottingham prognostic index (NPI) and clinical outcomes 
were only made known during experimental data analysis.  
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Table 2.1(A): Prostate Cancer Cell lines 
 
 
 
 
 
 
 
Prostate 
cancer 
Cell line Species Morphology Origin Sources and features 
PZHPV-7 Homo 
sapiens 
Epithelial Caucasian male 
aged 70 
Derived from prostate epithelial cells cultured from normal tissue within 
the prostate peripheral zone. 
Transformed using HPV18 DNA 
CAHPV-10 Homo 
sapiens 
Epithelial Caucasian male 
aged 63 
Derived from prostate adenocarcinoma of Gleason grade 4/4. Cells 
transformed with HPV18 DNA 
Non-tumourigenic 
PC-3 Homo 
sapiens 
Epithelial Caucasian male 
aged 62 
Derived from a metastatic bone site of a grade IV prostate 
adenocarcinoma. 
Tumourigenic 
Bone metastasis phenotype - Osteolytic  
DU-145 Homo 
sapiens 
Epithelial Caucasian male 
aged 69 
Derived from brain metastasis of a prostate cancer patient. 
Not androgen sensitive, only weakly positive for acid phosphatase. 
Cells do not express PSA 
LNCaP FGC clone 
 
Homo 
sapiens 
Epithelial Caucasian male 
aged 50 
Prostate carcinoma derived from left supraclavicular lymph node 
Tumourigenic 
Androgen sensitive and androgen receptor positive 
Bone metastasis phenotype - Mixed osteolytic and osteoblastic 
MDA PCa 2b Homo 
sapiens 
Epithelial African American 
male aged 63 
Prostate androgen independent  adenocarcinoma 
Expresses PSA and androgen receptor  
Bone metastasis phenotype - Osteoblastic  
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Table 2.1(B): Breast Cancer Cell lines 
 
 
 Cell line Species Morphology Origin Sources and features 
 
 
 
Breast 
cancer 
ZR-75-1 Homo 
sapiens 
 
Epithelial Caucasian 
female aged 63 
Derived from ductal breast carcinoma. Oestrogen receptor expressed, 
mucin expressed 
MCF-7 Homo 
sapiens 
 
Epithelial Caucasian 
female aged 69 
Derived from pleural effusion of breast cancer. Oestrogen receptor and 
androgen receptor positive, also expresses IGFP, BP-2, BP-4, BP-5 
MDA MB 231 Homo 
sapiens 
 
Epithelial Caucasian 
female aged 51 
Derived from metastatic site pleural effusion of breast adenocarcinoma 
Tumourigenic 
Express WNT7B oncogene, EGFR and TNF-α receptor 
Bone metastasis phenotype – Osteolytic 
 
105 
 
2.3 Primers 
Three different categories of primers were used in this study, all of which were 
designed using the Beacon Design programme (Biosoft International, Palo Alto, 
California, USA) and synthesised by Sigma Aldrich (Poole, Dorset, UK). This 
software incorporates features including an automated search for reaction 
conditions and possible homology amplification of other genes. The conventional 
reverse transcription polymerase chain reaction (RT-PCR) and quantitative PCR 
(qPCR) forward and reverse primers used in this study are detailed in Table 2.2. 
The paired forward and reverse primers for each gene reside in one of two adjacent 
exons, whilst the amplified genome sequence includes at least one intron boundary.  
 
2.4 Antibodies 
Full details of the primary and secondary antibodies used in this study are provided 
in Table 2.3 
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Table 2.2:  Primers for conventional RT-PCR and qPCR 
ACTGAACCTGACCGTACA represents the Z sequence 
Gene Primer 
name 
Primer Sequence (5’-3’) Optimal annealing 
temperature ºC ) 
Product 
size (bps) 
 
 
 
 
 
OPG 
 
 
OPGF8 
 
 
GAACCCCAGAGCGAAATACA 
 
 
 
55 
 
 
 
509 
  
OPGR8 
 
CGGTAAGCTTTCCATCAAGC 
 
 
OPGF1 
 
GTTCTGCTTGAAACATAGGAG 
 
 
 
55 
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OPGZR1 
 
ACTGAACCTGACCGTACACGTCT
CATTTGAGAAGAACC 
 
 
  
 
RANK 
 
RANKF9 
 
CAGAGCACAGTGGGTTCAGA 
 
 
 
55 
 
 
 
462 
  
RANKR9 
 
GATGATGTCGCCCTTGAAGT 
 
 
RANKF2 
 
TCTGATGCCTTTTCCTCCAC 
 
 
 
55 
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RANKZR2 
 
ACTGAACCTGACCGTACATGGCA
GAGAAGAACTGCAAA 
 
 
 
RANKL 
 
RANKLF9 
 
GACTCCATGAAAATGCAGAT 
 
 
 
55 
 
 
 
 
500 
 
RANKLR9 
 
TCCTTTCATCAGGGTATGAG 
 
 
RANKLF1 
 
AAGGAGCTGTGCAAAAGGAA 
 
 
 
55 
 
 
74 
 
RANKLZR1 
 
ACTGAACCTGACCGTACAATCCA
CCATCGCTTTCTCTG 
 
 
 
GAPDH 
 
GAPDHF10 
 
AGCTTGTCATCAATGGAAAT 
 
 
55 
 
 
 
 
593  
GAPDHR10 
 
CTTCACCACCTTCTTGATGT 
 
GAPDHF 
 
CTGAGTACGTCGTGGAGTC 
 
 
55 
 
 
 
93  
GAPDHZR 
 
ACTGAACCTGACCGTACACAGAG
ATGATGATGACCCTTTTG 
 
PDPL 
 
PDPLF 
 
GAATCATCGTTGTGGTTATG 
 
55 
 
 
PDPLZR 
 
ACTGAACCTGACCGTACACTTTC
ATTTGCCTATCACAT 
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Table 2.3: Antibodies  
 
Primary antibodies 
 
Name Species 
Molecular 
Weight (kDa) 
Supplier 
Product 
Code 
 
Anti-OPG 
Antigen affinity 
purified 
polyclonal IgG 
 
Goat 60 R&D Systems BAF805 
 
Anti-RANK 
polyclonal 
antibody 
 
Rabbit 90 
Santa Cruz 
Biotechnology, Inc 
sc-9072 
 
Anti-GAPDH  
polyclonal 
antibody 
 
Mouse 37 
Santa Cruz 
Biotechnology Inc 
sc-32233 
 
Secondary antibodies 
 
 
Name 
 
Species 
 
Supplier 
Product 
Code 
 
Anti-mouse 
IgG 
peroxidase 
conjugate 
 
Rabbit Sigma-Aldrich A-9044 
 
Anti-rabbit IgG 
peroxidase 
conjugate 
 
Goat Sigma-Aldrich A-9169 
 
Anti-goat IgG 
peroxidase 
conjugate 
 
Rabbit Sigma-Aldrich A-5420 
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2.5 General reagents and solutions 
The following solutions were used throughout this study. All products were sourced 
from Sigma Aldrich (Poole, Dorset, UK), unless otherwise stated.  
 
2.5.1 Solutions for use in DNA cloning 
Ampicillin 
A stock solution of 100mg/ml was prepared by dissolving the ampicillin sodium salt 
(Melford Laboratories Ltd, Suffolk, UK) in sterile BSS and stored at 4ºC until use. 
 
Liquid Broth (LB) 
Ten grams of tryptone (Duchefa Biochemie, Haarlem, Netherlands), 10g of NaCl 
and 5g of yeast extract (Duchefa Biochemie, Haarlem, Netherlands) were dissolved 
in 1L of distilled water. The pH of the solution was then adjusted to 7.0, autoclaved 
and stored at room temperature until needed. Selective antibiotics were later added 
as required. 
 
LB agar 
LB agar was prepared by dissolving 10g of tryptone, 5g of yeast extract, 15g of agar 
and 10g of NaCl in 1L of distilled water before the pH was adjusted to 7.0 and the 
solution autoclaved. For use, the solution was melted in a microwave, left to cool 
before ampicillin (100μg/ml) was added, and the solution poured into single vented 
10cm2 petri dishes (Bibby Sterilin Ltd, Staffs, UK). These were left to cool and set 
before being inverted and stored at 4ºC until use. 
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2.5.2 Solutions for use in molecular biology 
Diethyl pyrocarbonate (DEPC) water 
Prior to being autoclaved, 4.75ml of distilled water was supplemented with 250ml of 
DEPC. 
 
Loading buffer (used for DNA electrophoresis) 
Twenty five milligrams of bromophenol blue and 4g of sucrose (Fisons Scientific 
Equipment, Loughborough, UK) were dissolved in 10ml of distilled water and stored 
at 4ºC until needed. 
 
Tris-Boric Acid EDTA (TBE) (5x) 
A five times stock solution containing 1.1M of TRIS, 900mM of borate, 25mM of 
EDTA at pH8.3, was made by dissolving 540g of Tris-HCl (Melford Laboratories Ltd, 
Suffolk, UK), 275g of boric acid (Melford Laboratories Ltd, Suffolk, UK) and 46.5g of 
EDTA in 10L of distilled water. The pH was adjusted to 8.3 using NaOH, and then 
stored at room temperature until further use. For preparing agarose gels and DNA 
electrophoresis the TBE was diluted to 1x concentrate using distilled water.  
 
2.5.3 Solutions for protein use 
Amido black stain 
To stain protein after electrophoresis 2.5g of amido black was dissolved in 50ml of 
acetic acid and 125ml of ethanol, after which 325μl of distilled water was added and 
the solution well mixed. 
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Amido black destain 
One hundred millilitres of acetic acid and 250ml ethanol were added to 650ml 
distilled water. 
 
10% Ammonium Persulfate (APS) 
One gram of APS was dissolved in 10ml of distilled water, separated into 2.5ml 
aliquots and stored at 4ºC until required. 
 
Coomassie blue stain 
One hundred grams of Coomassie blue was dissolved in 100ml of acetic acid and 
250ml of ethanol, which was then added to 650ml of distilled water. 
 
Coomassie blue destain 
Five hundred millilitres of methanol was mixed with 100ml of acetic acid and then 
made up to a final volume of 1L using distilled water. 
 
Lysis Buffer 
This was made by dissolving  50mM TRIS base (0.61g), 5mM EGTA (0.19g), 
150mM NaCl (0.87g) and 1ml Triton x100 in 100ml of distilled water. Protease 
inhibitors were added just before use. Protease inhibitors added were PMSF 
(100μg/ml in isopropanol), aprotinin (10μg/ml), leupeptin (10μg/ml), sodium 
vanadate (5mM) and sodium fluoride (50mM).  
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Ponceau S stain  
Supplied directly by Sigma for reversible staining of protein bands after blotting.  
 
Running buffer (10x) (for SDS-PAGE) 
Ten times running buffer stock solution containing 0.25M Tris, 1.92M glycine and 
1% SDS at pH8.3 was prepared by dissolving 303g of Tris, 1.44kg of glycine 
(Melford Laboratories Ltd, Suffolk, UK) and 100g of SDS (Melford Laboratories Ltd, 
Suffolk, UK) in 10L of distilled water. Prior to use this solution was further diluted to 
a 1x concentrate using distilled water. 
 
Transfer buffer 
Fifteen point five grams of Tris and 72g of glycine were dissolved in 4L distilled 
water before the addition of 1L of methanol (Fisher Scientific, Leicestershire, UK) to 
make a final volume of 5L in distilled water. 
 
Tris Buffered Saline (TBS) (10x) 
A 10x TBS stock solution containing 0.5M Tris and 1.38M NaCl, at pH 7.4 was 
prepared by dissolving 24.228g of Tris and 80.06g of NaCl (Melford Laboratories 
Ltd, Suffolk, UK) in 1L of distilled water. The pH was then adjusted to 7.4 using HCl 
and stored at room temperature until use. 
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2.5.4 Solutions for use in tissue culture 
Antibiotics (ABS) (100x) 
Five grams of streptomycin, 3.3g of penicillin and 12.5mg of amphotericin B in 
DMSO were dissolved in 0.5L of BSS, filtered and split into 5ml aliquots which were 
then added directly to 500ml bottles of media. 
 
Balanced Saline Solution (BSS) 
Seventy nine point five grams of NaCl, 2.1g of KH2PO4, 2g of KCl and 11.g of 
Na2HPO4 were dissolved in 10L of distilled water. The pH was subsequently 
adjusted to 7.4 using 1M of NaOH.  
 
Ethylenediaminetetraacetic Acid (EDTA) (0.02%) 
One gram of KCl (Fisons Scientific equipment, Loughborough, UK), 5.72g of 
Na2HPO4 (BDH Chemical Ltd, Poole, England, UK), 1g of KH2PO4 (BDH Chemical 
Ltd, Poole, England, UK), 40g of NaCl and 1.4g of EDTA (Duchefa Biochemie, 
Haarlem, The Netherlands) were dissolved in 5L of distilled water, the pH was 
adjusted to 7.4, autoclaved and stored until use. 
 
Trypsin (25mg/ml) 
Five hundred milligrams of trypsin were dissolved in 20ml 0.02% EDTA, mixed and 
filtered through a 0.2µm ministart filter (Sartorius, Epsom, UK). The solution was 
then aliquoted into 250µl samples and stored at -20ºC until use. For use in cell 
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culture work, an aliquot was further diluted in 10ml of 0.05M EDTA and 
subsequently used to detach cells.  
 
2.5.5 Specialised reagents 
Bone matrix extract (BME) 
Ethical approval was granted by the Bro Taf Local Research Ethics Committee 
(Panel B) for the Bro Taf Health Board, Cardiff, UK. All patients gave informed and 
written consent. Femoral heads were collected from patients undergoing total hip 
replacements, placed in sterile containers and stored at -20ºC until the end of the 
surgery, after which they were transferred to -80ºC. The bone samples were then 
crushed into smaller frozen sections using a bone mill (Spierings Orthopaedics BV, 
Njmegen, The Netherlands), which were then further crushed using a pestle and 
mortar (5ml of bone fragments: 20ml BSS) whilst liquid nitrogen was applied to 
maintain sample temperatures. This mixture was resuspended in sterile BSS buffer 
and placed in a Bioruptor unit (Diagenode, Seraing, Belgium) and subjected to 5 
minutes of interrupted pulses, 30 seconds on followed by 30 seconds off.  Debris 
was removed by centrifugation at 3000rpm for 5 minutes at 4ºC. The supernatant 
was then transferred to a fresh tube for quantification. The protein extract was 
quantified using a Bio-Rad DC protein assay kit (Bio-Rad Laboratories, Hemel 
Hempstead, UK) and then diluted to a stock solution of 2mg/ml and stored at -80ºC 
until use.  
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Denosumab 
Purchased from Amgen Limited (Cambridge, UK), a 60mg solution in a pre-filled 
syringe was dissolved in BSS containing 0.1%BSA to 10mg/ml and stored in 500μl 
aliquots at -20ºC until use. 
 
Hepatocyte growth factor (HGF) 
HGF was a kind gift from Professor Kunio Matsumoto (Kanazawa University), 
aliquoted into 10μg/ml with sterile BSS containing 0.1% BSA and stored at -20ºC 
until use. 
 
Recombinant human OPG 
Was purchased from PeproTech (Rocky Hill, New Jersey, USA), and diluted to 
10μg/ml using sterile BSS: 0.1% BSA stored at -20ºC until use. 
 
 
 
 
 
 
115 
 
2.6 Cell maintenance, culture and storage 
2.6.1 Preparation of growth medium for maintenance of cells 
All cell lines unless listed below, were cultured in DMEM/Ham's F12 with L-
glutamine medium (Sigma, Dorset, UK) supplemented with ABS (as described in 
section 2.5.4) and 10% Foetal Calf serum (FCS).  
LNCaP cells were cultured in RPMI 1640 medium (Sigma, Dorset, UK) 
supplemented with ABS and 10% FCS. 
MDA-PCa-2b cells were maintained in ATCC formulated F-12K medium 
supplemented with ABS, 20% FCS, 25ng/ml cholera toxin, 10ng/ml mouse EGF 
(Santa-Cruz, sc-4552), 0.005mM phosphoethanolamine, 45nM selenious acid, 
100pg/ml hydrocortisone and 0.005mg/ml bovine insulin.  
Transfected cells, containing the pEF6 plasmid, were cultured initially in appropriate 
“selection” medium containing 5μg/ml Blasticidin S (Melford Laboratories Ltd, 
Suffolk, UK), for up to 2 weeks. Resulting transfectants were then routinely cultured 
in an appropriate “maintenance” medium supplemented with 0.5μg/ml Blasticidin S 
so mammalian cells would continue to retain the plasmid vector for verification and 
use in subsequent in vitro studies. 
 
2.6.2 Cell Maintenance 
Cells were maintained and grown in 25cm2 or 75cm2 tissue culture flasks (Greiner 
Bio-One Ltd, Gloucestershire, UK), in an incubator at 37ºC, 5% CO2 and 95% 
humidity. hFOB 1.19 cells were cultured in an incubator at 34ºC, 5% CO2 and 95% 
humidity. All tissue culture techniques were carried out using aseptic techniques 
with autoclaved and sterile equipment inside a class II laminar flow cabinet. Cells 
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were maintained in the supplemented media as described in section 2.6.1 and 
routinely sub-cultured upon reaching 80-90% confluence. Confluence was gauged 
visually by assessing the appropriate coverage of cells over the surface of the tissue 
culture flask under a light microscope.  
 
2.6.3 Detachment of adherent cells 
Upon reaching confluence, medium was aspirated; cells were briefly washed in 
sterile EDTA-BSS buffer to remove any remaining serum which would have an 
inhibitory effect on the action of trypsin. Adherent cells were detached from the 
tissue culture flask by incubating with 2 - 5ml of trypsin: EDTA (0.01% trypsin: 
0.02% EDTA in BSS buffer) for several minutes at 37ºC. Once detached the cell 
suspension was placed in a 30ml universal container (Greiner Bio-One Ltd, 
Gloucestershire, UK) and centrifuged at 1600rpm for 5 minutes to pellet cells. The 
supernatant was removed and the cell pellet was resuspended in an appropriate 
amount of pre-warmed medium. Cells were either counted for immediate use in 
experiments or transferred into a fresh tissue culture flask for sub-culturing. 
 
2.6.4 Cell counting 
Throughout this study a Neubauer haemocytometer counting chamber (Mod-Fuchs 
Rosenthal, Hawksley, UK) was used. A haemocytometer counting chamber allows 
for the number of cells in a previously determined volume to be calculated, to obtain 
the quantity of cells per millilitre. Cells were counted using an inverted light 
microscope under 10 x 10 magnification (Reichert, Austria). The chamber contains 
9 large squares (1mm x 1mm x 0.2mm) each subdivided into 16 square areas, of 
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which three of the large squares were counted as a representation of the chamber 
on each occasion to determine cell numbers using the following equation:- 
Cell number/ml = (number of cells counted in each 16 squares/2) x (1x104)  
This allowed the accurate estimation of cell densities to be seeded during in vitro 
and in vivo cellular functional assays. 
 
2.6.5 Storage of cell stocks in liquid nitrogen 
Stocks of low passage cells and transfected cells were stored in liquid nitrogen. 
Cells were first detached from a large 75cm2 flask using trypsin:EDTA as described 
in section 2.6.3. These cells were resuspended in the required volume (dependent 
on the number of samples to be frozen and recommended density) of a cyro-
protective solution consisting of the suppliers’ recommended percentage of dimethyl 
sulphoxide (DMSO) in growth medium (typically 5-10%). Following resuspension 
cells were aliquoted into 1ml volumes in pre-labelled 1.8ml cryotubes (Greiner Bio-
One, Germany), wrapped loosely in tissue paper and stored overnight in a -80ºC 
freezer. Cells were transferred the following day to liquid nitrogen tanks for long 
term storage. 
 
2.6.6 Cell revival from liquid nitrogen 
When required, cells were removed from liquid nitrogen and revived. Following their 
removal from liquid nitrogen, cells were thawed rapidly by placing them in a water 
bath at 37ºC. Once thawed, the content of the cryotube was placed in a universal 
container containing 10ml of pre-warmed medium to immediately dilute the DMSO 
present. To pellet the cells the universal containers were centrifuged at 1600rpm for 
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5 minutes. The supernatant was aspirated, the cell pellet was resuspended in 5ml of 
pre-warmed medium and placed into a fresh 25cm2 tissue culture flask and then 
incubated at 37ºC.   
After 24 hours the flask was examined under the microscope to visually confirm a 
sufficient number of healthy adherent cells had survived. The medium was aspirated 
to remove any dead cells and residual DMSO. Fresh pre-warmed medium was 
added, the flask returned to the incubator and standard sub-culture techniques, as 
previously described, carried out when necessary. 
 
 
2.7 Synthesis of complementary DNA for use in PCR analysis 
2.7.1 Total RNA isolation 
RNA isolation was completed using the TRI Reagent protocol from Sigma-Aldrich as 
summarised below. Cells were grown to a confluent monolayer, the medium was 
aspirated and replaced with TRI Reagent (1ml per 5-10 x 105 cells) to induce cell 
lysis. The cell lysate was transferred into a 1.8ml microfuge tube and incubated at 
4ºC for 5 minutes. This was followed by the addition of 0.2ml chloroform (per 1ml of 
TRI Reagent), the sample being vigorously shaken for 15 seconds, and 
subsequently incubated at 4ºC for 5 minutes. The resulting homogenate was 
centrifuged at 12,000rpm for 15 minutes at 4ºC (Boeco, Wolf Laboratories, York, 
UK). Following centrifugation, the upper aqueous phase containing RNA was 
carefully removed and added to a pre-labelled microfuge tube to which an equal 
volume (~500µl) of isopropanol was also added. The samples were then incubated 
for 10 minutes at 4ºC before centrifuging at 12,000rpm for 10 minutes at 4ºC. At this 
stage, RNA present in the sample precipitated out of solution and was visible as a 
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pellet at the bottom of the microfuge tube. The supernatant was discarded and the 
RNA pellet washed twice in 75% ethanol (Fisher Scientific, Leicestershire, UK), 
prepared in a 3:1 ratio of absolute ethanol:DEPC water. Each wash consisted of the 
addition of 1ml of 75% ethanol, vortexing and subsequent centrifugation at 
7,500rpm for 5 minutes at 4ºC. Following the final wash, the ethanol was removed 
and the RNA pellet was dried at 55⁰C for 5-10 minutes in a drying oven (Techne 
Hybridiser HB-1D, Wolf Laboratories, York, UK). The pellet was dissolved in 50-
100µl (dependent on pellet size) of DEPC water by vortexing, prior to quantification.  
 
2.7.2 RNA quantification 
Following RNA extraction, the concentration and purity of the resulting RNA was 
measured using an Implen Nanophotometer (Munchen, Germany) which had been 
configured to detect single strand RNA (µg/µl) in a 1 in 10 dilution, measuring the 
difference in absorbance at 260nm between the total RNA isolated sample and 
DEPC water (blank).   
 
2.7.3 RNA extraction from tissues.   
Breast sections were mixed and homogenised using a hand-held homogeniser in 
ice-cold RNA extraction solution (Sigma, Dorset, England, UK). The concentration 
of RNA was determined using UV1101 Biotech Photometer (WPA, Cambridge, UK). 
The photometer was set to detect single stranded RNA (µg/µl) at 1:10 dilution of the 
blank. Samples were measured using Stama glass cuvettes (Optiglass Limited, 
Essex, UK).   
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2.7.4 Reverse transcription of RNA 
Following RNA isolation and quantification, 250ng of RNA was converted into 
complementary DNA (cDNA) using a high capacity cDNA reverse transcription kit 
(Applied Biosystems, Manchester UK) following the protocol outlined below.  
A sufficient volume of RNA suspended in DEPC water (isolated previously) to 
supply the desired final quantity of RNA was added to a thin-walled 200µl PCR 
tube, additional PCR water was added to make a total volume of 10µl. An additional 
10µl of mastermix was added containing: 
 
 
Component 
 
 
Volume (µl) 
 
10x RT buffer 
 
 
2 
 
25x dNTP mix (100mM) 0.8 
 
10x RT random primers 2 
 
MultiScribe Reverse transcriptase 1 
 
RNase inhibitor 1 
 
Nuclease-free water 3.2 
 
Total 
 
10 
 
The tubes were placed in a T-Cy thermocycler (Creacon Technologies Ltd, 
Netherlands), under the following conditions:- 
 Step 1 - 25ºC for 10 minutes 
 Step 2 - 37ºC for 120 minutes 
 Step 3 - 85ºC for 5 minutes 
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Once completed the cDNA generated was diluted 1:4 with PCR water and tested 
using conventional PCR probing for GAPDH expression to confirm successful 
ubiquitous reverse transcription amongst standardised samples. Samples were 
stored at -20ºC until needed. 
 
2.7.5 Polymerase chain reaction (PCR) 
RT-PCR was carried out using a GoTaq Green master mix (Promega, Madison, 
USA). Reactions were set up for each sample as follows:- 
 
 
Component 
 
 
Volume (µl) 
 
2x GoTaq Green master mix 
 
8 
 
Forward primer (10pmol) 1 
 
Reverse primer (10pmol) 1 
 
Nuclease-free water 5 
 
cDNA template 1 
 
Total 
 
16 
 
 
All reactions were run alongside a negative control replacing the cDNA template 
with nuclease-free water to ensure there was no contamination.  
The RT-PCR reaction was set up in 200µl PCR tubes or a 96 well plate (Bio-Rad 
Laboratories, Hemel Hampstead, UK) (dependent on sample numbers), mixed 
briefly and centrifuged before being placed in a T-Cy Thermocycler and subjected to 
the follow temperature shifts:- 
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 Step 1: Initial denaturing period - 94ºC for 5 minutes 
Followed by 30-36 cycles of: 
 Step 2: Denaturing step - 94ºC for 1 minute 
 Step 3: Annealing step – reaction specific temperature for 40-60 seconds 
 Step 4: Extension step - 72ºC for 40 seconds   
And finally: 
 Step 5: Final extension period - 72ºC for 10 minutes 
Specific reaction annealing temperatures together with primer sequence data and 
predicted product size is detailed in table 2.2. Primer binding sites and predicted 
product sizes were verified using the Primer3 software available online.  RT-PCR 
products were run using agarose gel electrophoresis and stained.  
 
2.7.6 Agarose gel electrophoresis 
DNA was separated according to size using agarose gel electrophoresis. 
Dependent on the predicted size of the DNA produced, the samples were loaded 
onto either 0.8% (for DNA fragments 1-10kb), or 2% (for DNA fragments less than 
500bp) agarose gels. Agarose gels were made by adding the required amount of 
agarose (Melford Chemicals, Suffolk, UK) to 1xTBE solution. This was then heated 
to fully dissolve the agarose after which SYBR safe DNA gel stain (Invitrogen, 
Manchester, UK) diluted 1:10000 was added. The agarose was poured into the 
electrophoresis cassette and allowed to set around a plastic comb creating loading 
wells. Once set, the gel was submerged in 1xTBE buffer, the comb removed and 8µl 
of a 1Kb DNA ladder (Cat No. M106R; GenScript USA Inc), or 10µl of sample was 
loaded per well. The samples were then run electrophoretically using a power pack 
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(Gibco BRL, Life technologies Inc) at a constant voltage of ~100V for 30-50 minutes 
(dependent on predicted product size).  
 
2.7.7 DNA visualisation 
Gels were visualised and images captured using a blue light illuminator in the 
Syngene U:Genius 3 closed system (Geneflow, Elmhurst, Lichfield Staffs).   
Each RT-PCR was repeated three independent times and representative images 
illustrating the expression patterns are presented in this study.  
 
2.7.8 Quantitative RT-PCR (qPCR) 
qPCR is a sensitive technique that is capable of detecting very small quantities of 
cDNA within a sample whilst determining an accurate and reliable value of the 
template copy number. This current study used a molecular beacon method for 
quantitative PCR using the Amplifluor Uniprimer Universal system (Intergen 
Company, New York, USA) to quantify transcript copy number. The amplifluor probe 
consists of a 3’ region specific to the Z-sequence (ACTGAACCTGACCGTACA) 
present on the target specific primers (Table 2.2) and a 5’ hairpin structure labelled 
with a fluorophore (FAM). When the fluorophore hairpin structure is linked to an 
acceptor moiety (DABSYL) it acts as a fluorescence quencher which prevents any 
signal from being detected. During the qPCR reaction, the probe (Uniprobe, 
Millipore, Watford, UK) becomes incorporated and acts as a template for DNA 
polymerisation, in which DNA polymerase uses its 5’-3’ exonuclease activity to 
degrade and unfold the hairpin structure, thereby disrupting the energy transfer 
between the fluorophore and quencher, allowing sufficient fluorescence to be 
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emitted and hence detected. The fluorescent signal emitted during each qPCR cycle 
can then be directly correlated to the amount of DNA that has been amplified.  
 The cDNA used in qPCR was generated as described in section 2.7.3; this cDNA 
was then used to make up a reaction mixture outlined below: 
 
 
Component 
 
 
Volume (µl) 
 
2x iQ Supermix (Bio-Rad) 
 
5 
 
Forward primer (10pmol) 
 
0.3 
 
Reverse Z primer (1pmol) 
 
0.3 
 
Amplifluor probe (10pmol) 
 
0.3 
 
cDNA and Nuclease free water 
 
4 
 
Total 
 
10 
  
The degree of fluorescence within each sample was compared to a range of 
standards of known transcript copy number (Figure 2.1), allowing for the calculation 
of transcript copy number within each sample. Detection of GAPDH copy number 
within these samples was subsequently used to allow further standardisation and 
normalisation of the samples.  
Each sample was loaded into a 96 well plate (Bio-Rad Laboratories, Hemel 
Hampstead, UK) alongside standards (ranging from copy numbers of 101 – 108), 
covered and sealed with optically clear Microseal (Bio-Rad Laboratories, Hemel 
Hampstead, UK) and this was placed in an iCyclerIQ thermal cycler (Bio-Rad 
Laboratories, Hemel Hampstead, UK). Sample cDNA was amplified and quantified 
over a large number of shorter cycles using an iCycler thermal cycler and detection 
software and experimental conditions are outlined below:- 
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 Step 1: Initial denaturing period - 94ºC for 5 minutes 
 Step 2: Denaturing step - 94ºC for 10 seconds 
 Step 3: Annealing step - 55ºC for 15 seconds 
 Step 4: Extension step - 72ºC for 20 seconds 
 
Steps 2 - 4 were repeated over 80 cycles. In this established method, approximately 
20 cycles are required for the generation of Z-tagged products. The camera used in 
this system is set to detect signal during the annealing stage, its geometric increase 
directly correlates with the exponential increase of product.  
Subsequently, calculation of the sample copy number was dependent on the point 
at which the sample reached threshold cycle in comparison to the standards, 
automatically generated by the instrument software. Specific qPCR primers were 
verified using a positive control known to express the molecule of interest and a 
negative control, where PCR water replaced cDNA in a reaction, to rule out 
contamination before use. The experimental procedure was repeated independently 
three times and representative data of the expression trends is presented.  
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Figure 2.1: qPCR Standards  
(A) The detection range of the qPCR PDPL standards used throughout this study. 
Each standard was tested multiple times (n=12, representative data shown) and 
used to generate a standard curve (B). 
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2.8 SDS-PAGE and Western blotting 
2.8.1 Protein extraction and preparation of cellular lysates 
Upon reaching sufficient confluence, the cell monoloayer was detached from the 
flask using a sterile cell scraper, both the detached cells and medium were then 
transferred to a universal container. The cell suspension was centrifuged for 5 
minutes at 1,800rpm to pellet cells and protein at the bottom of the universal 
container. Following centrifugation, the supernatant was aspirated and the cells 
were lysed in 200 - 250µl  of lysis buffer (depending on pellet size), before being 
transferred to a 1.8ml microfuge tube and placed on a Labinco rotating wheel (Wolf 
Laboratories, York, UK) for 1 hour at room temperature. The resulting suspension 
was then centrifuged at 13,000rpm for 15 minutes to remove any unwanted cell 
debris. The supernatant was transferred to a fresh microfuge tube to await 
quantification for SDS-PAGE or stored at -20ºC until further use. 
 
2.8.2 Protein quantification 
Protein quantification was undertaken to standardise the concentrations of the 
protein samples prior to their use in SDS-PAGE and Western blotting. Protein 
concentration was determined using a Bio-Rad DC protein assay kit (Hemel 
Hampstead, UK) following the microplate method as outlined here. 
To set up a standard curve, in a 96 well plate, 50mg/ml of bovine serum albumin 
(BSA) was serially diluted from 10mg/ml to 0.005mg/ml in lysis buffer. Five 
microlitres of either the sample or standard was pipetted into a fresh well before 
adding 25µl of ‘working Reagent A’ (prepared by adding 20µl of Reagent S per 
millilitre of Reagent A), followed by 200µl of Reagent B. Following addition of 
Reagent B, samples were mixed briefly and then left for approximately 45 minutes 
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to allow the colorimetric reaction to occur. Once this was complete, the absorbance 
of each sample was measured at 620nm using an ELx800 plate reading 
spectrophotometer (Bio-Tek, Wolf Laboratories, York, UK). A standard curve was 
constructed based on the absorbance of the BSA standards and used to determine 
sample concentration.  An equation to calculate protein concentration based on the 
absorbance was established using the scatter line graph in Microsoft Excel. Protein 
concentration of each sample was determined using the corresponding absorbance 
and the equation of the standard curve. All samples were then normalised to the 
desired final concentration of between 1.0 – 1.5mg/ml through dilution in an 
appropriate amount of lysis buffer and further diluted in a 1:1 ratio with 2xLamelli 
sample buffer concentrate. Samples were then boiled at 100ºC for 5-10 minutes and 
stored at -20ºC until further use. 
 
2.8.3 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) 
SDS-PAGE was undertaken using an OmniPAGE VS10 vertical electrophoresis 
system (Wolf Laboratories, York, UK). Resolving gels of a required percentage 
(depending on the predicted protein size) were made up in a universal container. 
The amount of each ingredient required to make up 15ml (enough for two gels) for 
both 8% (for proteins ˃ 100kDa) and 10% (for proteins ˂ 100kDa) resolving gels is 
indicated below:- 
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The resulting mixture was then poured between glass plates, held in place in a 
loading cassette, until at a level 1.5cm below the top edge of the plate. To prevent 
gel oxidation the top of the resolving gel was covered with a 0.1% SDS solution. 
Once the resolving gel had polymerised (~30 minutes at room temperature), the 
excess SDS solution was poured off and replaced with a sufficient amount of 
stacking gel. The components and quantities required to prepare 5ml of stacking gel 
solution (enough for two gels) are shown below:- 
 
 
 
Component 
 
8% gel (ml) 
 
10% gel (ml) 
 
Distilled water 
 
 
6.9 
 
5.9 
30% acrylamide mix 4.0 5.0 
1.5M Tris (pH8.8) 3.8 3.8 
10% SDS 0.15 0.15 
10% ammonium persulphate 0.15 0.15 
TEMED 0.009 0.006 
 
Total 
 
15 
 
15 
 
Component 
 
Stacking gel (ml) 
 
Distilled water 
 
3.4 
 
30% acrylamide mix 
 
0.83 
 
1.0M Tris (pH 6.8) 
 
0.63 
 
10% SDS 
 
0.05 
 
10% ammonium 
persulphate 
 
0.05 
 
TEMED 
 
0.005 
 
Total 
 
5 
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A well forming Teflon comb was placed in the unset stacking gel and the mixture 
was left to polymerise (~20 minutes at room temperature). Once both resolving and 
stacking gels had set, the loading cassette was transferred into an electrophoresis 
tank and covered with 1x running buffer before the well comb was removed. Eight-
ten microlitres of broad range molecular weight marker (Santa Cruz Biotechnology, 
supplied by Insight Biotechnologies Inc, Surrey, England, UK) or 18µl of protein 
samples were loaded into the wells. The proteins were then separated according to 
molecular weight using electrophoresis at 100 - 125V, 50mA and 50W for varying 
lengths of time (dependent on protein size and gel percentage). 
 
2.8.4 Western blotting 
Following SDS-PAGE protein samples were transferred to a PVDF membrane by 
Western blotting. Electrophoresis equipment was disassembled, gels were removed 
from the loading cassette and the stacking gel cut away.  Pieces of filter paper were 
pre-soaked in 1x transfer buffer (Whatman International Ltd, Maidstone, UK) and 
the PVDF membrane (Santa Cruz Biotechnology Inc, UK) was pre-soaked in 
methanol and 1x transfer buffer before being arranged in an SD10 SemiDry Maxi 
System blotting unit (SemiDRY, Wolf Laboratories, York, UK) as outlined below:- 
Negative electrode: 3x pre-soaked filter paper: PVDF membrane: gel: 3x pre-
soaked filter paper: positive electrode 
Electroblotting was undertaken at 15V, 500mA, 8W for 20-60 minutes (depending 
on protein size).  
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2.8.5 Protein probing 
Protein probing was carried out using the Millipore SNAP i.d. protein detection 
system (Watford, UK) as outlined below. The blotted membrane was placed in the 
centre of a pre-wet blot holder and rolled gently to remove any air bubbles. A spacer 
was then added on top of the membrane and rolled again before the holder was 
securely closed and placed within the system. Blocking solution (10-30ml 
dependent on holder size) was added and a vacuum applied, after which the 
primary antibody solution (1-3ml dependent on holder size) was left to incubate for 
10 minutes at room temperature. The vacuum was then re-applied and the holder 
washed 3 times with wash buffer (10-30ml dependent on holder size). The 
secondary antibody solution was then added and left to incubate for 10 minutes at 
room temperature, after which the vacuum was then used again and the system 
was again flushed three times under vacuum with wash buffer. The membrane was 
then removed and stained for protein detection. 
 
2.8.6 Staining of proteins 
2.8.6.1 Polyacrylamide gel staining 
Coomassie blue was used to stain polyacrylamide gels following SDS-PAGE and 
electroblotting to verify transfer. The gel was immersed in Coomassie blue stain 
solution for approximately 30 minutes before being repeatedly washed in destaining 
solution until background staining disappeared, and the protein(s) of interest 
appeared as blue bands.  
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2.8.6.2 Chemiluminescent protein detection 
This technique was carried out using the chemiluminescence detection kit 
(Luminata, Millipore), consisting of a highly sensitive chemiluminescent substrate 
that detects the horseradish peroxidase (HRP) used during the western blot 
procedure.  
One millilitre of reagent was added onto the membrane and incubated for 5 minutes 
at room temperature with constant agitation.  Excessive solution on the membrane 
was then drained over a piece of tissue paper and the membrane was transferred to 
a plastic tray. The chemiluminescent signal was detected using an UVITech Imager 
(UVITech Inc, Cambridge, UK), which contains both an illuminator and a camera. 
Each membrane was subjected to varying exposure times until the protein bands 
were sufficiently visible. These images were then captured and further analysed 
with the UVI band software package (UVITEC, Cambridge, UK), which allows for 
protein band quantification. 
Throughout this study GAPDH was used a loading control and run alongside all 
other proteins being detected, allowing for additional normalisation of samples to 
occur. In order to verify the results, each western blot was carried out three times.  
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2.9 Manipulation of gene expression in prostate and breast cell lines  
To alter gene expression profiles in the mammalian cell lines hammerhead 
ribozyme transgenes were used (sequences detailed in Table 2.4). These primers 
were designed based on the predicted secondary structure of each gene transcript 
(Figure 2.2 and 2.3 respectively).  
 
2.9.1 Production of ribozyme transgenes sequences  
Hammerhead motifs contain a conserved secondary structure that consists of three 
helical stems (I, II and III), enclosing a junction known as the catalytic core, typified 
by various invariant nucleotides. The best codons demonstrated to be suitable for 
cleavage are AUC, GUC and UUC. In order to generate ribozyme transgenes 
specific to the molecules of interest, sequences were designed based on secondary 
structure of the target molecule predicted by Zuker’s RNA mFold programme 
(Zuker, 2003) (Figures 2.2 and 2.3). Subsequently, appropriate ribozyme target 
sites were chosen according to the secondary structure of each mRNA molecule.  
The ribozyme was created to specifically bind the sequence adjacent to the suitable 
target codon sequence, located within a loop structure of the transcript. This made it 
possible for the hammerhead catalytic region of the ribozyme to bind to and 
specifically cleave the codon sequence within the target mRNA transcript. Following 
ribozyme design, the sequences were ordered from Sigma-Aldrich as 
sense/antisense strands and the transgenes were then synthesised using 
touchdown PCR (Figure 2.5 A), reaction mix and conditions as below:- 
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Conditions as follows:- 
 Step 1: Initial denaturing period, 94ºC for 5 minutes 
 Step 2: Denaturing step, 94ºC for 10 seconds 
Step 3: Various annealing steps, 70ºC for 15 seconds, 65ºC for 15 seconds, 
60ºC for 15 seconds, 57ºC for 15 seconds, 55ºC  for 15 seconds and 50º for 
15 seconds  
 Step 4: Extension step, 72ºC for 20 seconds 
 Step 5: Final extension period, 72ºC for 7 minutes. 
Steps 2-4 were repeated over 48 cycles, each different annealing temperature 
comprising 8 cycles.  
Once combined, the transgenes were electophoretically run on a 2% agarose gel to 
confirm presence and correct size before being inserted into the pEF6 plasmid 
(Figure 2.4) in the TOPO cloning reaction (representative in Figure 2.5 A).  
 
 
 
Component 
 
Volume (μl) 
 
2x REDtaq ready mix PCR reaction with MgCl2 
 
10 
 
Forward Ribozyme sequence (pM) 
 
2 
 
Reverse Ribozyme sequence (pM) 
 
2 
 
Nuclease free water 
 
6 
 
Total 
 
20 
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Table 2.4: Primers designed for ribozyme synthesis 
 Target Ribozyme  Primer Name Primer Sequence (5’-3’) 
   
T7F 
 
TAATACGACTCACTATAGGG 
 
RBBMR 
 
TTCGTCCTCACGGACTCATCAG 
 
RBTPF 
 
CTGATGAGTCCGTGAGGACGAA 
 
 
 
 
OPG 
 
OPG 
ribozyme 1 
 
OPGRIB1F 
 
CTGCAGCTCCTTGCACACGGGGCTGCAGTATACT
GATGAGTCCGTGAGGA 
 
OPGRIB1R 
 
ACTAGTACACAGACAGCTGGCACACCAGTGACGA
GTGTTTCGTCCTCACGGACT 
 
OPG 
ribozyme 2 
 
OPGRIB2F 
 
CTGCAGACACTGCAATTTGTGTGTTTTCTACTGGG
TGCTTTACTGATGAGTCCGTGAGGA 
 
OPGRIB2R 
 
ACTAGTTCTTCTCAAATGAGACGTCATTTCGTCCT
CACGGACT 
 
OPG 
ribozyme 3 
 
OPGRIB3F 
 
CTGCAGGGTAACATCTATTCCACATTTTGAGTTCT
GATGAGTCCGTGAGGA 
 
OPGRIB3R 
 
ACTAGTTCCGGAAACAGTGAATTTCGTCCTCACGG
ACT 
 
 
 
 
 
 
 
RANK 
 
RANK 
ribozyme 1 
 
RANKRIB1F 
 
CTGCAGCGCGCGGGGCCATGGCGCGGCTGATGA
GTCCGTGAGGA 
 
RANKRIB1R 
 
ACTAGTGCCGCGGCGCCGCCAGCCTGTTTCGTCC
TCACGGACT 
 
 
RANK 
ribozyme 2 
 
RANKRIB2F 
 
CTGCAGCTCATAATGCTTCTCACTGGCTGATGAGT
CCGTGAGGA 
 
RANKRIB2R 
 
ACAGTCTTTGCAGATCGCTCCTCCATGTTTCGTCC
TCACGGACT 
 
RANK 
ribozyme 3 
 
RANKRIB3F 
 
CTGCAGGTACTTTCCTGGTTCACATTTGTCTGATG
AGTCCGTGAGGA 
 
RANKRIB3R 
 
ACTAGTAGCATTATGAGCATCTGGGACGGTGCTGT
TTCGTCCTCACGGACT 
 
RANK 
ribozyme 4 
 
RANKRIB4F 
 
CTGCAGTGCTGACCAAAGTTTGCCGTGTGTGCTG
ATGAGTCCGTGAGGA 
 
RANKRIB4R 
 
ACTAGTGGAGTCCTCAGGTGACAGTTGTGTCAGTT
TCGTCCTCACGGAC 
 
RANK 
ribozyme 5 
 
RANKRIB5F 
 
CTGCAGCTGGCATCTTCGCCTTGTGCGTAGGCTG
ATGAGTCCGTGAGGA 
 
RANKRIB5R 
 
ACTAGTGTCAGGGCACATGTGTAGGAGGTGGTTT
CGTCCTCACGGACT 
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Figure 2.2: Secondary structure of OPG transcript 
(As predicted Zuker’s RNA mFold programme) 
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Figure 2.3: Secondary structure of RANK transcript 
(As predicted by Zuker’s RNA mFold programme) 
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2.9.2 TOPO TA cloning reaction 
The TOPO TA expression system provides a highly efficient and simple one step 
cloning approach without the requirement of ligases, specific PCR primers, or any 
post PCR procedures. The process involves the effective cloning and direct 
insertion of Taq polymerase amplified PCR products into plasmid vectors for 
expression in mammalian cells following transfection. 
Cloning of all ribozyme transgenes was completed using the pEF6/V5-His TOPO TA 
expression kit (Life Technologies, Paisley, UK), in accordance with the protocol 
provided. This kit allows linearisation with a single 3’ Thymidine (T) overhang for TA 
cloning, and a covalently bound Topoisomerase. Due to its template independent 
terminal transferase activity, Taq polymerase catalyses the addition of a single 
deoxyadenosine (A) to the ends of PCR products allowing for efficient ligation of the 
PCR product into the plasmid vector due to its 3’ T overhang. The manufacturer’s 
protocol is outlined over the next few sections. 
The following TOPO cloning reaction was set up in a pre-labelled microfuge tube 
and mixed gently before being incubated for 5 minutes at room temperature: 
 
 
 
 
 
Component 
 
Volume (µl) 
 
Ribozyme PCR product 
 
4 
 
Salt solution 
 
1 
 
TOPO vector 
 
1 
 
Total 
 
6 
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This mixture was added and gently stirred (pipetting up and down could damage the 
bacteria) to a vial of chemically competent One Shot TOP10 Escherichia coli (E. 
coli), after which it was incubated on ice for 30 minutes.  
 
2.9.3 Transformation of chemically competent E. coli  
To transform the E.coli bacteria, the mixture was heat shocked at 42ºC for 30 
seconds and immediately placed back onto ice. SOC medium (250µl pre-warmed to 
room temperature) was added to each cell suspension and left to shake horizontally 
at 200rpm on a horizontal orbital shaker (Bibby Stuart Scientific, UK), at 37ºC for 1 
hour. Following this incubation period, the E.coli mixture was spread onto two pre-
warmed selective LB-agar plates (containing 100µg/ml ampicillin), at high and low 
seeding densities, before being incubated at 37ºC overnight. The pEF6 plasmid 
contains antibiotic resistance genes that allow cells containing the plasmid to grow 
in the presence of ampicillin and /or Blasticidin S selection, a schematic of the 
plasmid is shown in Figure 2.4. Any colonies which grew on the selective plates are 
positive for the pEF6 plasmid. However, to confirm that the ribozyme sequence has 
been inserted in the correct orientation to allow transcription, further testing was 
needed.  
 
2.9.4 Colony selection and orientation analysis  
Correct insertion and orientation of the ribozyme sequences in the plasmid were 
analysed to ensure that the resulting product would be viable. For each colony two 
RT-PCR reactions were performed. The colonies were tested using primers specific 
to either the plasmid (T7F, BGHR), or the ribozyme sequence (RbToPF, RbBMR). 
Whilst T7F vs BGHR will give an indication of whether the complete sequence had 
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inserted without degradation, it cannot be used to indicate the orientation of the 
sequence. There are approximately 90bp between the T7F promoter and the 
beginning of the insert whilst the reverse primer specific for the plasmid vector 
(BGHR) ends around 173bps downstream of the insertion site.   
In order to check the correct size and orientation of the sequence, a mixture of 
plasmid specific and sequence specific primers were used. RbToP and RbBMR 
recognise and bind to sequences within the ribozyme transgene common to all the 
ribozymes used in this study (See table 2.4). To check the ribozyme sequences a 
combination of T7F vs RbToPF was used, if this reaction was positive (~140bp), it 
indicated the insert has ligated in the wrong orientation. A band in the T7F vs 
RbBMR reaction, a reverse primer specific for the ribozyme transgene was 
indicative of the insert ligated in the correct orientation.  If bands were seen for both 
reactions then the colonies contained a mixture of plasmids with both insert 
orientations. Examples of each of the orientation results are shown in Figures 2.5 B 
and C.  
The protocol used was: 
Following overnight incubation, the plates were examined for colony growth. Eight 
individual colonies were randomly selected for orientation analysis and marked and 
labelled on the plates. For each colony, using a sterile pipette tip, a sample of the 
colony was use to inoculate both reactions before the addition of the primers. The 
two PCR reactions were carried out as follows (full primer sequences are given in 
table 2.4). 
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Figure 2.4: Schematic of the pEF6 plasmid 
Copied from the manufacturer’s handbook to show multiple insertion sites 
and orientation of the promoter sequence. 
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Component 
 
Volume (µl) 
 
Reaction 1 
 
2x GoTaq Green Master mix 
 
8 
 
Plasmid specific T7F 
 
1 
 
Ribozyme specific RbToP 
 
1 
 
Nuclease-free water 
 
6 
 
Reaction 2 
 
2x GoTaq Green Master mix 
 
8 
 
Plasmid specific T7F 
 
1 
 
Ribozyme specific RbBMR 
 
1 
 
Nuclease-free water 
 
6 
 
 
Each reaction mix was then placed in a thermal cycler and subjected to the 
following conditions:- 
 Step 1: Initial denaturing period - 95ºC for 10 minutes 
Followed by 35 cycles of:  
Step 2: Denaturing step - 94ºC for 1 minute 
 Step 3: Annealing step - 55ºC for 1 minute 
 Step 4: Extension step - 72ºC for 1 minute 
And finally  
Step 5: Final extension period - 72ºC for 10 minutes 
The mixture was run on a 2% agarose gel using electrophoresis and visualised as 
previously described in Section 2.7.6.  
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2.9.5 Plasmid amplification, purification and quantification 
Following colony orientation analysis, colonies showing correct insert orientation 
were removed from the LB-agar plate using a sterile pipette tip, used to inoculate  
10ml of ampicillin selective LB broth and incubated at 37ºC overnight under 
constant agitation (at 220rpm). The amplified E.coli were then pelleted by 
centrifugation at 4ºC for 15 minutes at 3000rpm and used for plasmid extraction. 
Plasmid extraction was carried out using the Sigma GenElute Plasmid Miniprep Kit 
according to the provided protocol outlined below.  
The supernatant was discarded and the bacterial pellet was resuspended in 200µl 
of re-suspension solution (containing RNase A), before being thoroughly mixed and 
transferred to a collection tube provided. This was followed by the addition of 200µl 
of lysis solution, and gentle mixing by inverting 5-6 times. The addition of 350µl of 
neutralising solution within 5 minutes of the addition of lysis buffer prevented DNA 
damage. The tubes were inverted 4-6 times and then centrifuged at 12,000rpm for 
10minutes. The resulting supernatant was then transferred into a fresh collection 
tube containing a Mini Spin Column, plasmid DNA bound to the column, after which 
it was spun at 12,000rpm for 1 minute, and the flow through was discarded. The 
column was washed with 750µl of wash solution (containing ethanol) and the 
column spun at 12,000rpm for 1 minute, with the flow through discarded. To dry the 
column it was spun again at 12,000rpm for 1 minute, before being transferred to a 
fresh collection tube. Plasmid DNA was eluted by the addition of 100µl of elution 
solution and spinning the column at 12,000rpm for 1 minute. The eluted plasmid 
solution was quantified and then an aliquot run on a 0.8% agarose gel using 
electrophoresis to confirm the presence and size of each of the plasmids of interest 
(Figure 2.5 D).  
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Figure 2.5: Orientation checking of ribozyme transgenes 
 
Initially ribozyme transgenes were screened after touchdown PCR (A). To verify that 
the ribozyme transgenes had been inserted in the correct orientation RT-PCRs were 
run (B and C). Once plasmid had been amplified and purified it was confirmed using 
gel electrophoresis and visualisation (D)   
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2.9.6 Transfection of mammalian cells using electroporation 
Following plasmid purification and quantification, 1-3 µg of the extracted empty 
control plasmid and ribozyme transgenes for OPG and RANK were used to 
transform the PC-3 prostate cancer cell line and the MDA-MB-231 breast cancer 
cell line used for this study, using the following protocol:-  
Confluent low passage wild type cells were detached from tissue culture flasks as 
described in section 2.6.3. Approximately 1x106 cells in 800µl per transfection were 
added to an electroporation cuvette (Eurenetech, Southampton, UK) together with 
3-5µl of purified plasmid, mixed briefly and left to stand at room temperature for 5 
minutes. This cell and plasmid suspension was then subjected to an electrical pulse 
from an electroporator (Easyject, Flowgene, Surrey, UK). 
 
Cell line Voltage (V) Capacitance 
 
PC-3 
 
310 
 
1500 
 
MDA-MB-231 
 
310 
 
1500 
 
 
Following this pulse, the cell and plasmid suspension was quickly transferred into 
10ml of pre-warmed medium added to a 25cm2 tissue culture flask and left in an 
incubator at 37ºC overnight to allow cells to recover and adhere.  
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2.9.7 Establishment of stable transfected mammalian cell lines 
Following transfection, in order to obtain a stable cell line carrying the constructed 
vector, the electroporated and cultured cells needed to be selected. The pEF6 
TOPO plasmid used to transform the cell, encodes two antibiotic resistance genes. 
As previously described, the ampicillin resistance gene allows initial selection of 
prokaryotic bacterial colonies containing the plasmid (Section 2.9.4). The plasmid 
also contains a Blasticidin S resistance gene. Blasticidin S is a potent microbial 
antibiotic that inhibits protein synthesis in both prokaryotes and eukaryotes and 
therefore, for this study was used to specifically select the mammalian cells 
containing the pEF6 TOPO plasmid.  
Following overnight incubation, the cells were subjected to an initial 5 day period of 
intense selection, by incubating them in medium supplemented with 5µg/ml of the 
Blasticidin S. After this initial intense selection, to ensure the cells maintained the 
plasmid and therefore long term transformation, cells were maintained in 
maintenance medium containing 0.5µg/ml of Blasticidin S. 
All cells were tested initially and routinely following revival to verify the efficacy and 
stability of ribozyme transformation cell lines using RT-PCR, qPCR and Western 
blot analysis. Once the cells had been verified to stably express the desired 
molecule; they were subjected to various in vitro function assays in order to test the 
effect altered expression of the molecule of interest had on biological cancer cell 
properties.  
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2.10 Tumour cell functional assays 
For all the cell function assays, final volume per well or insert was 200μl of 
Blasticidin S free media. Cell volumes were calculated in 100μl, the additional 100μl 
was a 2x concentrate of any additional treatment made in medium or medium alone.  
 
2.10.1 In vitro tumour cell growth assay 
Cells were detached and cell concentration (per millilitre) was established as 
previously described (Section 2.6.3 and 2.6.4 respectively). Cells were then seeded 
into three 96 well plates at a seeding density of 3x103 cells/100μl, supplemented 
with an additional 100μl of Blasticidin S free medium or treatment and incubated for 
1, 3 and 5 day periods respectively at 37ºC with 5% CO2. Following the appropriate 
incubation period, medium was removed and cells were fixed in 4% formaldehyde 
(v/v) in BSS for 10 minutes before being subsequently stained in 0.5% crystal violet 
(w/v) in distilled water, for 10 minutes. The stain was washed off with water and the 
plates left to dry at room temperature for 24 hours. For analysis the dye was 
solubilised using 200µl 10% acetic acid and cell density determined by measuring 
the absorbance at 540nm on a plate reading spectrophotometer (BIO-TEK, Elx800, 
UK).  Cell growth rates were initially presented, from the individual repeats, as a 
percentage increase calculated by comparing the absorbance obtained for each 
incubation period against the absorbance taken after day 1 as a baseline, using the 
following equation: 
Percentage increase = ((day 3 or 5 absorbance) – day 1 absorbance/ day 1 
absorbance x100) 
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Within each experiment triplicate wells were set up and the entire experimental 
protocol was repeated at least three independent times. Data from all the repeats 
were combined and presented as mean percentage control with SEM.  
 
2.10.2 In vitro tumour cell Matrigel adhesion assay 
The ability of tumour cells to adhere to an artificial Matrigel basement membrane 
was examined using an in vitro Matrigel adhesion assay technique modified from 
Jiang et al, 1995a. 
Wells in a 96 well plate were coated with 5µg of Matrigel in serum free medium and 
left to dry for 2 hours at 55⁰C in a drying oven. This membrane was then rehydrated 
in 100µl of serum free medium for 40 minutes at room temperature. The medium 
was aspirated and 4.5x104 cells/100μl were seeded into each well and 
supplemented with a further 100μl of Blasticidin S free medium or treatment. Cells 
were left to adhere to the Matrigel for 40 minutes at 37ºC with 5% CO2.  After 
incubation, the medium was removed and the wells washed with 150µl of BSS 
solution to remove any non-adherent cells. Adherent cells were then fixed in 4% 
formaldehyde (v/v) in BSS for 10 minutes before being stained in 0.5% crystal violet 
solution (w/v) in distilled water for 10 minutes. Crystal violet was then washed off 
with distilled water and the plates left to dry for 24 hours at room temperature. 
Adherent cells were then visualised under the microscope under x20 objective 
magnification and 4 random fields per well were captured and counted. 
Within each experiment all wells were prepared in triplicate per sample and the 
entire experimental procedure was repeated at least three independent times. Data 
from all the repeats were combined and presented as mean percentage control with 
SEM.  
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2.10.3 In vitro tumour motility assays 
Cellular motility was assessed using one of two methods as described below based 
on tumour cell behaviour. 
 
2.10.3.1 Cytodex-2 bead motility assay 
Cellular motility was assessed using a cytodex-2 bead motility assay as described 
previously (modified from Jiang et al 1995b; Rosen et al 1990). 
Overnight, 1x106 cells in 10ml of growth medium and 100µl of cytodex-2 beads 
(20mg/ml) were incubated at 37ºC and 5% CO2, to allow cells to adhere to the 
beads. The beads were then washed twice in 5ml of growth medium to remove any 
non-adherent cells and resuspended in 1ml of growth medium. One hundred 
microliters of the bead suspension was then added, in triplicate, to a 96 well plate 
containing a further 100µl of Blasticidin S free medium, or treatment, and incubated 
for 4 hours at 37⁰C and 5% CO2. Following incubation, the medium was removed 
and the wells washed with 150µl BSS to remove any remaining beads or non-
adherent cells.  Adherent cells were fixed in 4% formaldehyde (v/v) in BSS for 10 
minutes and then stained with 0.5% crystal violet (w/v) in distilled water for 10 
minutes. The crystal violet was washed off with distilled water and the plates left to 
dry for 24 hours at room temperature. Stained cells were then visualised under x20 
objective magnification, where at least 4 random fields were captured and counted 
per well.  
Within each experiment each sample was prepared in triplicate. The entire 
experimental procedure was repeated a minimum of three independent times. Data 
from all the repeats were combined and presented as mean percentage control with 
SEM. 
150 
 
2.10.3.2 Electric Cell-substrate Impedance Sensing (ECIS) 
ECIS is a technique designed and licensed by Applied Biophysics which monitors 
cell attachment and migration, on gold electrodes in 96 well arrays, using changes 
in resistance and impedance over time. 
This study used 96W1E arrays (ECIS cultureware, Applied Biophysics Inc, NY, 
USA) which were stabilised by adding 200µl of stabilising solution (Applied 
Biophysics Inc, NY, USA) to each well and leaving them at room temperature for 20 
minutes. This medium was aspirated off and replaced with 8x104 cells/100µl of 
HEPES buffered medium and 100µl of treatments.  The array was then placed in 
the ECIS incubator at 37ºC connected to the Theta ECIS controller system (Applied 
Biophysics Inc, NY, USA). The software was configured so resistance of the current 
flow was measured at 4000Hz. Data was normalised using resistance from the first 
time point.  
Within each experiment each sample was prepared in triplicate. The entire 
experimental procedure was repeated a minimum of three independent times. Data 
from all the repeats were combined and presented as change in resistance over a 4 
hour period with SEM. 
 
2.10.4 In vitro tumour cell Matrigel invasion assay 
The invasive capacity of the cells used in this study was determined using an in vitro 
Matrigel invasion assay (modified from Albini et al 1987, Parish et al 1992), 
measuring the cells ability to degrade and invade through an artificial basement 
membrane and migrate through 8µm pores. Transwell inserts containing 8µm pores 
(Falcon, pore size 8.0µm, 24 well format, Greiner Bio-One, Germany) were placed 
into wells of a 24 well plate (NUNC, Greiner Bio-One, Germany) using sterile 
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forceps in order to prevent contamination. Each insert was subsequently coated in 
50µg of Matrigel (BD Matrigel Matrix, Matrigel Basement Membrane Matrix, 
Biosciences) in a serum free medium solution and left to dry for 2 hours at 55⁰C. 
The Matrigel artificial membrane was rehydrated in 100µl of serum free medium for 
approximately 40 minutes at room temperature. Once rehydrated, the serum free 
medium was removed and 1ml of Blasticidin S free medium was added to the 
bottom of the well containing the insert in order to sustain any cells that invaded 
through the insert. Subsequently, 2 - 3 x 104 cells/100µl and 100µl of Blasticidin S 
free medium or treatment were added into the Matrigel coated insert and incubated 
for 72 hours at 37ºC, 5% CO2 and 95% humidity. 
After 72 hours, the inserts were removed from the plate and any non-invaded cells 
and the Matrigel were cleaned thoroughly with tissue paper, prior to fixing. The 
underside of the insert was fixed in 4% formaldehyde (v/v) in BSS for 10 minutes 
before being stained in 0.5% crystal violet solution (w/v) in distilled water for 10 
minutes. The crystal violet solution was washed off using distilled water and the 
inserts left to dry at room temperature for 24 hours.  Cells were visualised under a 
light microscope under x20 objective magnification and at least 5 random fields per 
insert were captured and counted. This experimental procedure was repeated a 
minimum of three independent times. Data from the independent repeats were 
combined and are presented as percentage control with SEM. 
 
2.11 In vivo tumour growth and development model 
The project license (PPL 30/2591) under which all in vivo work was carried out was 
approved by both the Cardiff University School of Medicine JBIOS Committee and 
the UK Home Office under the Animals (Scientific Procedures) Act 1986, as issued 
by the Secretary of State for the UK Home Office. In vivo work was carried out 
152 
 
under the strict guidelines of the UK Home Office to ensure that the 3R’s were 
strictly adhered to. Thus, the minimum number of animals was used in the 
experiment, with a minimum of suffering and maximum attention to animal welfare. 
The maximum severity band allowed was moderate, although the procedures 
carried out in this work were ostensibly only mild. Animals were checked daily and 
their behaviour and health monitored. Animals were weighed and measured twice 
weekly to ascertain loss of health (as determined by weight loss greater than 20% 
or tumour burden greater than 1cm3). Adverse effects resulted in sacrifice via UK 
Schedule One procedures.   
The in vivo tumour progression model was adapted from similar previously 
described protocols (Jiang et al 2005a; Kuba et al 200; Martin et al 2003). A 
suspension of 100µl containing one million breast cancer cells and 0.5mg/ml 
Matrigel was subcutaneously injected into the left and right flanks of 4-6 week old 
athymic nude mice (CD-1) and allowed to develop. The mice were maintained in 
filter top units according to House Office regulations. The mice were weighed and 
the size of the developing tumour measured using vernier callipers under sterile 
conditions each week. At the conclusion of the experiment animals were weighed, 
humanely killed under Schedule One and tumours were dissected out if sufficiently 
sized. Thus, tumour volume was determined, at each time point, using the following 
formula:- 
 Tumour volume = 0.523 x width2 x length 
 
2.12 Statistical analysis 
For statistical analysis experiments were repeated at least three independent times. 
Resultant data was then analysed using the Sigma plot 11.0 statistical software 
package. In ribozyme transgene manipulated cell lines, data was compared to the 
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pEF6 control cell line (cells containing a closed pEF6 plasmid only); as this control 
confirmed that it was the ribozyme/expression sequence that was responsible for 
any changes seen and not the pEF6 plasmid itself. Where appropriate non-
manipulated cell lines were compared to untreated cells. The statistical comparisons 
between the test and control cell lines were made using either a Students two tailed 
t-test if the data was found be normalised and have equal variances or a non-
parametric Mann-Whitney test if the data was not normalised. In all cases p-values 
of ≤0.05 were regarded as being significant.  
Cytotoxicity assays and ECIS were assessed using ANOVA tests with post hoc 
analysis (Holm-Sidak method). In all cases p-values of ≤0.05 were regarded as 
being significant.  
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Chapter 3 
Expression profile of OPG, RANK and RANKL  
in breast and prostate cancer 
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3.1 Introduction 
The complexity of the dysregulated bone response in breast and prostate cancer is 
underpinned by the vast number of soluble factors, signalling pathways and 
transcription regulators involved. In order to clarify the dysregulation that occurs to 
both extremes, osteoblastic and osteoclastic, of the bone remodelling process, 
particular focus must be given to each individual aspect in turn. Elucidation of this 
process will hopefully result in improved therapeutic intervention and patient 
management.  
The OPG/RANK/RANKL system has already been linked to cancer cells through the 
inhibition of TRAIL-apoptosis (Holen et al 2002). However, much still remains 
unknown about the interplay and influence tumour cells, the factors they produce 
and bone have on each other during osteotropic cancer progression. 
In the literature it has been well characterised that unlike most other osteotrophic 
cancers, prostate cancer presents with a predominantly osteoblastic phenotype 
though osteolytic activity is also present (Lynch et al 2005, Lu et al 2009). In 
contrast, it is mainly the osteolytic phenotype which is associated with breast cancer 
(Roodman 2001). It has been shown that prostate and breast cancer cells produce 
a variety of factors which influence the bone environment, including OPG, RANK 
and RANKL, all of which can affect bone re-modelling. OPG, RANK and RANKL 
have also been linked to signalling cascades which can also initiate cell 
proliferation, differentiation and survival.  
The aim of this section of the study was to determine the expression levels of OPG, 
RANK and RANKL in the available prostate and breast cancer cell lines. Additionally 
the aim was to characterise the proliferative response of the prostate and breast 
cancer cells to exogenous HGF stimulation and isolated bone proteins (BME) and 
how these factors affected OPG and RANK transcript expression levels.    
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3.2 Transcript expression profiles in prostate cancer cell lines 
Six prostate cancer cell lines were screened during the course of this study. 
PZHPV-7 is considered an immortalised cell line which is representative of normal 
prostate epithelium. CAHPV-10, is an immortalised cell line derived from primary 
prostate cancer. PC-3, DU-145, LNCaP and MDA-PCa-2b are all cell lines derived 
from metastatic sites associated with prostate cancer, all of which have differing 
tumourigenic potential in in vivo models. The most aggressive of these cell lines is 
considered to be the PC-3 cell line, which in vivo presents with osteolytic bone 
lesions. DU-145 cells also generate osteolyic bone lesions in pre-clinical models. In 
contrast, MDA-PCa-2b cells are one of the few commercially available cell lines 
which result in osteoblastic bone lesions whilst LNCaP cells generate mixed 
osseous (osteoblastic and osteolytic) bone lesions. 
    
3.2.1 Transcript expression of OPG, RANK and RANKL in prostate cancer cell 
lines 
OPG transcript expression was detected in all the available cell lines tested (Figure 
3.1). It appeared to be strongest in the normal prostate epithelium cell line (PZHPV-
7) and primary cancer cell line (CAHPV-10), and weakest in the mixed osteoblastic-
osteolytic androgen dependent LNCaP cell line, where only minimal expression was 
detected.  RANK transcript was also detected in all the prostate cancer cell lines 
tested but appeared strongest in the osteolytic PC-3 and DU-145 cell lines. In 
contrast RANKL transcript expression was only detected in the DU-145 and LNCaP 
cell lines, whilst a very weak expression was detected in the CAHPV-10 cells.    
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Figure 3.1: Transcript expression levels of OPG, RANK and RANKL 
Control = Nuclease free water and all gels were ran with a molecular weight marker 
used to identify band sizes.   
 
 
Figure 3.2: Transcript expression levels of HGF and its receptor c-MET 
Control = Nuclease free water and all gels were ran with a molecular weight marker 
used to identify band sizes. 
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3.2.2 Transcript expression of HGF and its receptor, c-MET in prostate cancer 
cell lines 
All the prostate cancer cell lines were also screened for HGF transcript and its 
receptor c-MET. None of the prostate cancer cell lines produced any detectable 
HGF transcript levels. In contrast all were positive for its receptor c-MET (Figure 
3.2). c-MET expression appeared particularly strong in the PC-3, DU-145 and 
PZHPV-7 cell lines. In contrast the weakest transcript expression was seen in the 
mixed osteoblastic-osteolytic androgen dependent LNCaP cell line.  
For the purposes of this study PC-3 and LNCaP cell lines were chosen for further 
investigation.  
 
3.3 Impact of HGF treatment on prostate cancer cell proliferation 
3.3.1 Effect of HGF treatment on PC-3 cell proliferation 
PC-3 cells were treated with 3 concentrations of HGF (10ng/ml, 40ng/ml or 80ng/ml) 
and proliferation rates were assessed over both 3 and 5 days incubation (Figure 
3.3). Treatment of PC-3 cells with HGF, after 3 day incubation, appeared to bring 
about an initial enhancement of PC-3 cell proliferation at the higher concentrations 
(40ng/ml and 80ng/ml), though none of these changes reached significant levels 
(Figure 3.3 A). This trend did not continue over the 5 day incubation period, in which 
similar PC-3 cell proliferation levels were seen between the control and treated cells 
(Figure 3.3 B).  
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Figure 3.3: Impact of HGF treatments on prostate cancer cell proliferation 
Impact of HGF treatment was assessed on PC-3 cells (A and B) and LNCaP cells 
(C and D) over both 3 and 5 days incubation. Data represents mean of 3 
independent repeats, error bars represent SEM. * - p=<0.05, ** - p=<0.01 and *** - 
p=<0.001. 
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3.3.2 Effect of HGF treatment on LNCaP cell proliferation 
In LNCaP cells, treatment with HGF brought about a reduction in cell proliferation 
after both 3 days incubation (Figure 3.3 C) and 5 days incubation (Figure 3.3 D). No 
significant differences were seen after 3 days incubation with each of the HGF 
concentrations compared to the untreated control. However, after 5 days incubation, 
both the 40ng/ml HGF treatment (p=0.002) and 80ng/ml treatment (p<0.001) 
resulted in a significant decrease in LNCaP cell proliferation compared to the 
untreated control.  
 
3.4 Impact of BME treatment on prostate cancer cell proliferation 
3.4.1 Effect of BME treatment on PC-3 cell proliferation 
Treatment of PC-3 cells with BME (1μg/ml, 10μg/ml and 50μg/ml) did not greatly 
impact PC-3 cell proliferation after 3 days incubation (Figure 3.4 A). After 5 days 
incubation PC-3 cell proliferation was significantly increased at all the 
concentrations tested (Figure 3.4 B, p=0.012, <0.001 and 0.015 respectively vs 
untreated control).  Whilst these changes were deemed to be significant, changes 
were only approximately increased 10% compared to the control cells. 
 
3.4.2 Effect of BME treatment on LNCaP cell proliferation   
LNCaP cells treated with BME showed no difference in cell proliferation after 3 days 
incubation compared to the untreated control (Figure 3.4 C). However, after 5 days 
incubation LNCaP cell proliferation was increased at the higher concentrations 
compared to the untreated control (Figure 3.4 D, 10μg/ml and 50μg/ml), though this 
did not reach statistical significance.  
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Figure 3.4: Impact of BME treatments on prostate cancer cell proliferation 
Impact of BME treatment was assessed on PC-3 cells (A and B) and LNCaP cells 
(C and D) over both 3 and 5 days incubation. Data represents mean of 3 
independent repeats, error bars represent SEM. * - p=<0.05, ** - p=<0.01 and *** - 
p=<0.001. 
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Based on these observations for the remainder of this study all subsequent 
treatments were carried out with 40ng/ml HGF and 50μg/ml BME. 
 
3.5 Prostate cancer cell transcript expression of OPG and RANK after 
treatment with HGF and BME treatment in a time course 
OPG and RANK transcript expression levels were examined in PC-3 and LNCaP 
prostate cancer cells, in response to 40ng/ml HGF, 50μg/ml BME and combined 
40ng/ml HGF and 50μg/ml BME over a 2 hour period by qPCR.  
 
3.5.1 Transcript analysis of OPG expression in PC-3 prostate cancer cells 
following treatment with HGF and BME 
Treatment of PC-3 cells with 40ng/ml HGF increased OPG transcript expression 
levels after 1 hour incubation and this was increased further after 2 hours 
incubation, however both of these increases did not reach statistical significance 
compared to the untreated control (Figure 3.5 A).  
In the PC-3 cells, peak OPG transcript levels were seen in cells treated with 
50μg/ml BME for 1 hour, however this did not reach significance compared to the 
untreated control (Figure 3.5 B). However, after 2 hours incubation with 50μg/ml 
BME, OPG transcript levels appeared to have been restored to similar levels seen 
in the untreated control. 
When HGF and BME were administered in combination, OPG transcript levels 
appeared to increase, peaking after 2 hours incubation, though again this increase 
failed to reach significance compared to the untreated control (Figure 3.5 C). 
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Figure 3.5: OPG transcript analysis following treatment with HGF and BME in 
PC-3 cells 
Response of OPG transcript expression following time course treatment with 
40ng/ml HGF (A), 50μg/ml BME (B) or combined 40ng/ml HGF and 50μg/ml BME 
(C). Data represents mean values of 3 independent repeats normalised against 
GAPDH, error bars represent SEM. * - p=<0.05, ** - p=<0.01 and *** - p=<0.001. 
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3.5.2 Transcript analysis of OPG expression in LNCaP prostate cancer cells 
following treatment with HGF and BME 
In the androgen dependent LNCaP cell line, when incubated with HGF, OPG 
transcript levels increased after 1 hour (Figure 3.6 A). However at both of the other 
time points analysed (30 minutes and 2 hours) OPG transcript levels appeared 
reduced in comparison to the control levels. None of these results reached 
statistically significant levels and due to the large standard deviation bars these 
must be interpreted with caution. 
When the LNCaP cells were treated with BME, OPG transcript levels were found to 
be reduced at all the time points assessed compared to the untreated control 
(Figure 3.6 B). However, none of these reductions in OPG transcript levels were 
found to be statistically significant. 
When HGF and BME were combined as a treatment, OPG transcript levels in 
LNCaP cells appeared to reduce at all the time points analysed (Figure 3.6 C).  
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Figure 3.6: OPG transcript analysis following treatment with HGF and BME in 
LNCaP cells 
Response of OPG transcript expression following time course treatment with 
40ng/ml HGF (A), 50μg/ml BME (B) or combined 40ng/ml HGF and 50μg/ml BME 
(C). Data represents mean values of 3 independent repeats normalised against 
GAPDH, error bars represent SEM. * - p=<0.05, ** - p=<0.01 and *** - p=<0.001. 
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3.5.3 Transcript analysis of RANK expression in PC-3 prostate cancer cel ls 
following treatment with HGF and BME 
Treatment of PC-3 cells with 40ng/ml HGF, increased RANK transcript expression 
levels after 2 hour incubation, however this increase did not reach statistical 
significance compared to the untreated control (Figure 3.7 A).  
In the PC-3 cells, peak RANK transcript levels were seen in cells treated with BME 
for 1 hour, which was a significant increase compared to the untreated control 
(Figure 3.7 B, p<0.001). However, after 2 hours incubation with BME, RANK 
transcript levels appeared to have been restored to similar levels seen in the 
untreated control. 
When HGF and BME were administered in combination, RANK transcript levels 
appeared to increase, peaking after 1 hour incubation which reached significance 
compared to the untreated controls (p<0.001) (Figure 3.7 C). However, RANK 
transcript levels returned to control levels after 2 hours incubation.  
 
3.5.4 Transcript analysis of RANK expression in LNCaP prostate cancer cells 
following treatment with HGF and BME 
HGF treatment of LNCaP cells appeared to have no impact on RANK transcript 
levels at each of the time points analysed (Figure 3.8 A). In contrast, when treated 
with BME, RANK transcript expression in LNCaP cells appeared to increase 
compared to the untreated cells, peaking after 1 hour incubation, though this 
increase did not reach statistical significance (Figure 3.8 B). This increase in RANK 
transcript was sustained after 2 hours incubation with BME. 
When HGF and BME were added in combination, increases in RANK transcript 
levels were seen after both 30 minutes and 1 hour incubation periods compared to  
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Figure 3.7: RANK transcript analysis following treatment with HGF and BME in 
PC-3 cells 
Response of RANK transcript expression following time course treatment with 
40ng/ml HGF (A), 50μg/ml BME (B) or combined 40ng/ml HGF and 50μg/ml BME 
(C). Data represents mean values of 3 independent repeats normalised against 
GAPDH, error bars represent SEM. * - p=<0.05, ** - p=<0.01 and *** - p=<0.001. 
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Figure 3.8: RANK transcript analysis following treatment with HGF and BME in 
LNCaP cells 
Response of RANK transcript expression following time course treatment with 
40ng/ml HGF (A), 50μg/ml BME (B) or combined 40ng/ml HGF and 50μg/ml 
BME(C). Data represents mean values of 3 independent repeats normalised against 
GAPDH, error bars represent SEM. * - p=<0.05, ** - p=<0.01 and *** - p=<0.001. 
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the untreated controls, however neither of these reached significance (Figure 3.8 
C). After 2 hours incubation with a combination of HGF and BME, RANK transcript 
levels appeared to be at similar levels to those observed in the untreated cells.    
 
3.6 Transcript expression profiles in breast cancer cell lines 
3.6.1 Expression profiles of OPG, RANK and RANKL in breast cancer cell lines 
In the laboratory, ZR-75-1, MCF-7 and MDA-MB-231 cells were available. 
Therefore, as an initial step, all 3 of the breast cancer cell lines were screened using 
RT-PCR (Figure 3.9). All three cell lines showed strong expression of RANK 
transcript, however only the metastatic and ER negative MDA-MB-231 cell line 
showed RANKL transcript expression. All the cell lines were also positive for OPG 
expression, although, the weakly tumourigenic ZR-75-1 cell line displayed weak 
expression levels compared to the more aggressive MCF-7 and MDA-MB-231 cell 
lines. 
 
3.6.2 Expression profiles of HGF and c-MET receptor in breast cancer cell 
lines 
As was seen in the prostate cancer cell lines, all three breast cancer cell lines did 
not express the HGF transcript at detectable levels, however they were all found to 
be positive for the HGF receptor, c-MET (Figure 3.10). 
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Figure 3.9: Expression of RANK, RANKL and OPG in breast cancer cell lines 
Control = Nuclease free water and all gels were ran with a molecular weight marker 
used to identify band sizes.  
 
Figure 3.10: Expression of HGF and c-MET in breast cancer cell lines 
Control = Nuclease free water and all gels were ran with a molecular weight marker 
used to identify band sizes.   
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3.7 Impact of HGF and BME on MDA-MB-231 cell proliferation 
Treatment of MDA-MB-231 breast cancer cells with HGF (10ng/ml, 40ng/ml and 
80ng/ml) did not result in any significant changes in cell proliferation after 3 days 
incubation (Figure 3.11 A). After 5 days incubation all of the HGF treatment 
concentrations tested resulted in increased cell proliferation though none of these 
reached significance (Figure 3.11 B).  
Following incubation of MDA-MB-231 cells with BME (1μg/ml, 10μg/ml and 50μg/ml) 
for 3 days, no significant effects were seen on cell proliferation (Figure 3.11 C). After 
5 days incubation at the higher concentrations (10μg/ml and 50μg/ml) MDA-MB-231 
cell proliferation increased, though again this did not reach significance (Figure 3.11 
D). 
 
3.8 Transcript analysis of OPG and RANK expression in MDA-MB-231 breast 
cancer cells following treatment with HGF and BME over a time course 
OPG and RANK expression were assessed in MDA-MB-231 breast cancer cells in 
response to 40ng/ml HGF, 50μg/ml BME and combined 40ng/ml HGF and 50μg/ml 
BME over a 2 hour period by qPCR.  
 
3.8.1 Transcript analysis of OPG expression in MDA-MB-231 breast cancer 
cells following treatment with HGF and BME 
OPG transcript levels were significantly reduced after 30 minutes (p=0.02) and 2 
hours (p<0.001) incubation with 40ng/ml HGF compared to control cells (Figure 
3.12 A).  
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Figure 3.11: Impact of HGF and BME treatments on MDA-MB-231 cell 
proliferation 
MDA-MB-231 cells were incubated with 10ng/ml, 40ng/ml and 80ng/ml HGF for 3 
and 5 days (A and B).Treatment of MDA-MB-231 cells with 1μg/ml, 10μg/ml and 
50μg/ml BME for 3 and 5 days (C and D). Data represents mean of 3 independent 
repeats, error bars represent SEM. * - p=<0.05, ** - p=<0.01 and *** - p=<0.001. 
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Figure 3.12: OPG transcript analysis following treatment with HGF and BME in 
MDA-MB-231 cells 
Response of OPG transcript expression following time course treatment with 
40ng/ml HGF (A), 50μg/ml BME (B) or combined 40ng/ml HGF and 50μg/ml BME 
(C). Data represents mean values of 3 independent repeats normalised against 
GAPDH, error bars represent SEM. * - p=<0.05, ** - p=<0.01 and *** - p=<0.001. 
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A general reduction in OPG expression was also seen in response to 50μg/ml BME 
treatment (Figure 3.12 B). The largest reduction was seen after 1 hour incubation 
with BME which also reached significance (p=0.02).  
When HGF and BME were combined as a treatment, initially after 30 minutes 
incubation a significant decrease in OPG transcript levels was seen compared to 
the untreated cells (p=0.02) (Figure 3.12 C). However, after 1 hour incubation OPG 
transcript levels were increased in comparison to the untreated cells, a response 
which was maintained over the 2 hour incubation period, though neither reached 
significant levels compared to the untreated control.  
 
3.8.2 Transcript analysis of RANK expression in MDA-MB-231 breast cancer 
cells following treatment with HGF and BME 
Treatment of MDA-MB-231 cells with 40ng/ml HGF resulted in increased RANK 
transcript expression at every time point assessed compared to the untreated 
control, however none of these increases reached statistical significance (Figure 
3.13 A). A similar response in RANK transcript expression was observed following 2 
hours incubation with the BME treatment (Figure 3.13 B).  
In contrast, when HGF and BME were combined as a treatment, an initial increase 
in RANK transcript levels was seen after 30 minutes. This appeared to return to 
control levels after 1 hour, before another increase, though not as big as the 30 
minute response, was noted after 2 hours incubation (Figure 3.13 C). However, 
none of these alterations in RANK transcript levels reached statistical significance 
and due to the large standard deviation bars these trends must be interpreted with 
caution.   
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Figure 3.13: RANK transcript analysis following treatment with HGF and BME 
in MDA-MB-231 cells 
Response of RANK transcript expression following time course treatment with 
40ng/ml HGF (A), 50μg/ml BME (B) or combined 40ng/ml HGF and 50μg/ml BME 
(C). Data represents mean values of 3 independent repeats normalised against 
GAPDH, error bars represent SEM. * - p=<0.05, ** - p=<0.01 and *** - p=<0.001. 
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3.9 Discussion 
Tumours secrete factors which can influence the bone environment, whilst cells and 
factors within the bone environment reciprocally influence the tumour cells 
themselves, thus contributing to the ‘vicious cycle’ described in bone metastases.  
OPG, RANK and RANKL as integral regulators of the bone remodelling process 
have been shown to be affected by the presence of tumour cells, however little is 
understood on how the bone environment might influence these factors produced by 
tumour cells themselves, or how these may impact cellular function of cancer cells.  
 
3.9.1 Expression profiles of OPG, RANK and RANKL in breast and prostate 
cancer cell lines 
Of the six prostate cancer cell lines available for this study, all expressed OPG 
transcript levels, to varying degrees. This correlates with the literature which has 
also highlighted that the androgen dependent, weakly metastatic LNCaP cell line 
produced approximately 10 fold less OPG than the more aggressive androgen 
independent cell line, PC-3 (Holen et al 2002).  
RANK expression has also been shown to be ubiquitously expressed in all cell lines 
both, in this study, and in the literature (Armstrong et al 2008). Interestingly, 
expression was strongest in the aggressive osteolytic PC-3 and DU-145 cell lines 
and the LNCaP cell line, which forms mixed osteoblastic and osteolytic bone 
lesions. This is also of interest because all three cell lines originate from different 
prostate associated metastatic sites (DU-145 from the brain, LNCaP from the lymph 
node and PC-3 from the bone).  
RANKL transcript expression levels were only detected in the DU-145 and LNCaP 
cell lines in the course of this study, both of which have been shown to have strong 
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osteolytic components in associated bone lesions. In the literature, LNCaP cells 
have also been shown to produce membrane bound and soluble forms of RANKL 
making it an interesting model for further study (Zhang et al 2001). It is therefore 
surprising that the aggressive osteolytic PC-3 cell line studied here did not also 
express detectable levels of RANKL. The literature does suggest that RANKL 
transcript levels and protein expression have been detected in prostate cancer 
samples and in the PC-3 cell line, the exact reason for this discrepancy is unknown 
(Chen et al 2006, Brown et al 2001). To ensure that all the products seen were the 
expected molecules of interest placenta cDNA could potentially be used as a 
positive control for future experiments. 
Unfortunately, there are very few purely osteoblastic prostate cancer cell lines 
commercially available. Unlike PC-3 and LNCaP prostate cancer cells, MDA-PCa-
2b cells are difficult to culture due to their growth in sparse colonies with loose 
adherence to culture flasks. Routine culture of this cell line to generate sufficient 
numbers for subsequent study has proved problematic and time consuming.  
In the 3 breast cancer cell lines tested, ZR-75-1, MCF-7 and MDA-MB-231, all 
expressed transcript levels of RANK and OPG. RANK transcript levels appeared to 
be consistent throughout the cell lines irrespective of oestrogen receptor status and 
metastatic potential. OPG transcript levels appeared strongest in the osteolytic 
metastatic MDA-MB-231 cell line and weakest in the primary breast cancer cell line 
(ZR-75-1). RANKL expression was only detected in the aggressive osteolytic breast 
cancer cell line MDA-MB-231. 
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3.9.2 Expression profiles of OPG and RANK in breast and prostate cancer cell 
lines treated with HGF and BME 
In the first two hours tested in this study, OPG and RANK transcript levels appeared 
to be influenced by both HGF and BME to varying degrees in the PC-3 and LNCaP 
prostate cancer cell lines and the MDA-MB-231 breast cancer cell line.  
In the PC-3 prostate cancer cell line HGF treatment appeared to increase OPG and 
RANK transcript levels, with the highest levels observed after 2 hours incubation. In 
contrast, BME treatment of PC-3 cells resulted in peak OPG and RANK transcript 
levels after 1 hour incubation, with restoration to normal levels observed after 2 
hours incubation. OPG transcript levels appeared to fluctuate in the LNCaP cell line 
under stimulation from HGF for 2 hours. However, a similar trend was not seen in 
the RANK transcript levels. BME treatment also appeared to result in differing 
transcript level responses. Under the influence of BME, OPG transcript levels 
decreased and did not show any sign of recovery after 2 hours incubation. However, 
BME appeared to induce RANK transcript expression after 1 hour incubation, a 
response which was also maintained after 2 hours incubation. 
In the MDA-MB-231 breast cancer cells, OPG transcript levels significantly 
decreased under the influence of HGF, particularly after 2 hours incubation, a 
pattern which was also mimicked when these cells were incubated with BME. In 
contrast, RANK transcript levels appeared to increase after treatment with HGF or 
BME. 
Thus, our current data suggests that OPG and RANK expression may be influenced 
by the presence of HGF or bone like proteins which may have implications in the 
metastatic process, particularly concerning the potential involvement of these 
molecules in the homing and colonisation of cancer cells to the bone.  However, 
further work is required to fully establish this theory. If subsequent work from this 
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study suggests that BME, as a protein rich factor, influences cell behaviour to 
isolate the component(s) which may result in these observations, further work could 
be carried out by using synthetic cocktail of growth factors and proteins or 
conditioned medium from a range of cell types in the bone environment to fully 
understand these complex and multifaceted interactions.   
Preliminary work in this chapter was conducted over an initial 2 hour time period 
because HGF has previously been demonstrated to have phosphorylation and 
transcriptional changes 30 minutes after exposure.  Some bi-directional changes in 
expression were observed over this period, further investigation, without time 
constraints, would have allowed this to be extended for up to a 24hour period, 
providing information on the long term alterations which may be induced.  It would 
therefore be of interest to test longer time points (possibly up to 24hours) to fully 
evaluate the long term effects that exposure to these external cell factors and 
proteins may have on OPG and RANK transcript expression profiles.  Additionally, 
further repeats are required to clarify some of the trends, as in some of the 
experiments (particularly the LNCaP model) there is a high degree of standard 
error, therefore further repeats are necessary. 
Based on the data obtained in these early experiments the following model systems 
were chosen for further investigation. Given the strong expression of OPG and 
RANK in the PC-3 and MDA-MB-231 cell lines, ribozyme targeting of these 
molecules were chosen to assess their impact on these osteolytic prostate and 
breast cancer cells. The LNCaP cell line showed strong expression for RANKL but 
only weak expression for OPG therefore the addition of a recombinant form of OPG 
and a neutralising antibody for RANKL were chosen to assess their impact on the 
mixed osseous prostate cancer cell line. These findings will be presented in full in 
the following results chapters.  
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Chapter 4 
Role of OPG and RANK in osteolytic prostate cancer 
 
 
 
 
 
 
 
 
 
181 
 
4.1 Introduction 
Treatment of localised prostate cancer has significantly improved in recent years, 
despite this, once metastases have been detected patient prognosis still remains 
poor (Lee et al 2011). Although prostate cancer is initially an androgen dependent 
disease, the tumour ultimately becomes hormone refractory and resistant to therapy 
(Feldman and Feldman 2001). Generally it is this androgen independent phenotype 
which develops at metastatic sites.  The main metastatic site associated with 
prostate cancer is the bone, of which the osteoblastic phenotype is most commonly 
reported (Roudier et al 2004). However, there is strong evidence to suggest that 
bone resorption may play a vital role in the establishment of the micro-metastases in 
the bone (Lynch et al 2005). What remains unclear is whether, in prostate cancer, 
bone turnover shifts to favour bone formation or if the ‘vicious’ bone cycle, created 
in prostate cancer bone metastases, helps nullify the bone resorption process. 
The links between OPG and RANK and their roles in bone turnover are well 
established. Since their discoveries in the late 1990’s, the understanding of bone 
physiology has led to some major therapeutic interventions in several chronic 
orthopaedic and rheumatologic conditions, including rheumatoid arthritis and 
osteoporosis (Lacey et al 2012). However, despite the elucidation of their potential 
roles in several other cancers, particularly breast and melanoma, there remains 
poor understanding of the roles and mechanisms by which OPG and RANK can 
influence other osteotrophic cancer cell behaviour, particularly in the prostate.   
There are several articles in the literature which clinically link OPG and RANK to 
prostate cancer progression and the presence of bone metastases, however the 
potential mechanisms by which this occurs have yet to be fully explained, and 
therefore possible exploitation of these changes therapeutically has never been 
explored (Brown et al 2001, Corey et al 2002).  
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Despite the predominance of osteoblastic bone metastases in prostate cancer, few 
established osteoblastic models exist. One of the most common prostate cancer cell 
lines used for in vitro studies is the osteolytic PC-3 cell line.  Given that it is 
predominantly castrate resistant cells which are associated with bone metastases, 
and that the cell line is derived from a metastatic bone site, it provided an interesting 
model to investigate the potential implications targeting OPG and RANK expression 
may have on prostate cancer cell behaviour.   
Given previous observations that the aggressive osteolytic prostate cancer cell line 
PC-3 produces 10 fold more OPG than LNCaP cells (Holen et al 2002), we aimed to 
explore the potential implications targeting OPG and RANK expression might have 
on PC-3 cancer cell behaviour. This section of the study therefore aimed to 
establish if targeting OPG or RANK, using hammerhead ribozyme transgenes, 
influenced PC-3 prostate cancer cell behaviour in vitro. Subsequently, this section 
also aimed to explore the potential effects treatment with exogenous HGF or BME 
might further impose on the manipulated cancer cell behaviour. 
 
4.2 Materials and Methods 
4.2.1 Cell line 
In this study, the PC-3 prostate cancer cell line was used to generate empty plasmid 
control cells (PC-3pEF6) and transfectants for either OPG or RANK knockdown (PC-
3OPGKD, PC-3RANKKD). Cells were maintained in DMEM medium supplemented with 
10% FCS and ABS as described previously (Section 2.6.1). All transfectants were 
initially exposed to selection medium (DMEM complete medium supplemented with 
5µg/ml Blasticidin S) for 10 days. All transfectants were subsequently maintained in 
DMEM complete medium supplemented with 0.5µg/ml Blasticidin S, to ensure the 
plasmid vector was retained.  
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All in vitro function assays were conducted in Blasticidin S free medium. 
 
4.2.2 Treatment(s) 
Transfectants were treated with 40ng/ml HGF and/or 50µg/ml BME. For 
experimental purposes all treatments were prepared at a 2x concentrate and added 
in 100µl volumes in each in vitro function assay carried out. 
 
4.2.3 Generation of OPG and RANK ribozyme transgenes, cloning into pEF6 
plasmid vectors, PC-3 cell transfection and generation of stable transfectants 
Hammerhead ribozymes targeting OPG and RANK were designed and generated 
as previously described in Section 2.9.1 and Table 2.4. Following verification of the 
touchdown PCR, OPG and RANK transgenes were cloned into pEF6 plasmid 
vectors and subsequently transformed into E.coli (Section 2.9.3 and 2.9.4). 
Correctly oriented constructs were then amplified, purified and verified (Section 
2.9.5) before being transfected into PC-3 prostate cancer cells using electroporation 
(Section 2.9.6).  
 
4.2.4 RNA isolation, cDNA synthesis, RT-PCR and qPCR 
RNA isolation was carried out using the TRI reagent kit as described in Section 2.7 
after which reverse transcription was completed using a high capacity RT kit (full 
details Section 2.7.3). Following RT-PCR, products were separated 
electrophoretically on an agarose gel and representative images, normalised 
against GAPDH, are shown. All qPCRs were performed and normalised against 
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GAPDH as described in Section 2.7.7. Data presented represents results from at 
least 3 independent repeats.  
  
4.2.5 Protein isolation, SDS-PAGE, Western blotting and ICC 
Protein lysates were isolated and quantified as described previously (Section 2.8). 
After SDS-PAGE, protein was transferred onto PVDF membrane and subsequently 
probed with specific primary antibody (anti-GAPDH, anti-OPG, anti-RANK) and 
corresponding peroxidase conjugated secondary antibodies (1:1000). Protein bands 
were visualised using the chemiluminescent protein detection kit. At least 3 
independent repeats were carried out of which a representative image is shown. 
 
4.2.6 In vitro cell proliferation assay 
PC-3 transfectant(s) were seeded at 3x103 cells/well into triplicate 96 well plates and 
incubated for 1, 3 and 5 days with treatments as described in Section 2.10.1. 
Following incubation, cells were fixed in 4% formalin (v/v) and stained with 0.5% 
crystal violet (v/v). Subsequently, crystal violet stain was extracted from the cells 
using 10% acetic acid (v/v) and the absorbance at 540nm was determined using a 
spectrophotometer. Data presented is mean percentage control of a minimum of 4 
independent repeats with SEM. 
 
4.2.7 In vitro cell Matrigel adhesion assay 
A 96 well plate was coated with 5ug/well of Matrigel and left to dry as described in 
Section 2.10.2.  PC-3 transfectant(s) were seeded at 4.5x104 cells/well and left to 
adhere for 45 minutes before being fixed in 4% formalin (v/v) and stained with 0.5% 
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crystal violet (v/v). Four representative images were captured for each well and 
subsequently counted using Image J software. Data presented is mean percentage 
control of a minimum of 3 independent repeats with SEM. 
 
4.2.8 In vitro cell migration assay 
The cytodex bead motility assay was used to assess PC-3 cell motility (Section 
2.10.3) where briefly, 1x106 cells in 10ml were left to incubate with cytodex beads 
(100µl) overnight. The following day, cells were washed twice with fresh medium 
before being re-suspended in 1.5ml and added to a 96 well plate in triplicate 
(100µl/well) and the necessary treatments added. Cells were incubated for 4 hours 
after which the plate was washed, fixed in 4% formalin (v/v) and stained with 0.5% 
crystal violet (v/v).   Four representative images were captured for each well and 
subsequently counted using Image J software.  Data presented is the mean 
percentage control of a minimum of 3 independent repeats with SEM. 
 
4.2.9 In vitro Matrigel cell invasion assay 
Transwell inserts were coated with 50μg/insert of Matrigel and dried before PC-3 
cell transfectants were seeded (2x104/100µl) into each insert and incubated for 3 
days with respective treatments (100µl), as described in Section 2.10.4. Following 
incubation, invaded cells were fixed in 4% formalin (v/v) and stained with 0.5% 
crystal violet (v/v). Five representative images were captured per transwell insert 
and subsequently counted using Image J software. Data presented is the mean 
percentage control of a minimum of 3 independent repeats with SEM.   
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4.3 Results 
4.3.1 Role of OPG in PC-3 Prostate Cancer Cells in vitro 
4.3.1.1 Confirmation of ribozyme transgene knockdown of OPG expression in 
PC-3 prostate cells 
Expression of OPG was successfully targeted in PC-3 prostate cancer cells 
following transfection with an anti-OPG ribozyme transgene contained within a pEF6 
plasmid. Following RNA isolation, RT-PCR and qPCR showed significantly reduced 
OPG transcript expression in PC-3OPGKD cells compared to the PC-3pEF6 control cells 
(Figures 4.1 A and B respectively). Western blot subsequently confirmed the 
knockdown of OPG at a protein level in comparison to the PC-3pEF6 cells (Figures 
4.1 C). 
 
4.3.1.2 OPG suppression enhances PC-3 cell proliferation 
 Reduced OPG expression in PC-3 prostate cancer cells resulted in increased cell 
proliferation after 3 days incubation (232% compared to control) (Figure 4.2A) and 
significantly so after 5 days incubation (205% compared to control) (Figure 4.2 B, 
p=0.008) compared to the control PC-3pEF6 cells. 
The impact of reduced OPG expression in PC-3 prostate cancer cells was further 
examined following treatment with 40ng/ml HGF, 50µg/ml BME or a combination of 
40ng/ml HGF and 50µg/ml BME. In the PC-3pEF6 control cells, treatment with 
40ng/ml HGF, 50µg/ml BME or a combination of 40ng/ml HGF and 50µg/ml BME all 
resulted in increases in PC-3pEF6 cell proliferation, after both 3 day incubation 
(112%, 132% and 132% of untreated control respectively) (Figure 4.2 C) and 5 days 
incubation (122%, 136% and 139% of untreated control respectively) (Figure 4.2 D). 
Treatment of PC-3pEF6 cells with 50µg/ml BME reached significant levels after 3 days  
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Figure 4.1: Verification of ribozyme transgene knockdown of OPG in PC-3 
cells 
Reduced expression of OPG was confirmed at a transcript level using RT-PCR (A) 
and qPCR (B) compared to the control cell line. Western blot (C) was used to 
confirm knockdown of OPG at a protein level. PCR and Western blot were 
normalised against GAPDH. Control = Nuclease free water and all gels were ran 
with a molecular weight marker used to identify band sizes.  Representative images 
and data shown. * - p=<0.05, ** - p=<0.01 and *** - p=<0.001. 
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Figure 4.2: Impact of OPG knockdown on PC-3 cell proliferation in vitro 
Reduced OPG expression resulted in increased PC-3 cell proliferation after 3 days 
(A) and 5 days incubation (B) compared to control cells. Treatment of the PC-3pEF6 
control cell line with 40ng/ml HGF, 50μg/ml BME or a combination of 40ng/ml HGF 
and 50μg/ml BME resulted in an increase in cell proliferation after 3 days incubation, 
the BME treatment resulted in a significant increase in cell proliferation (C), all other 
treatments reached significant levels after 5 days incubation in comparison to 
untreated PC-3 pEF6 cells (D). Treatment of PC-3OPGKD cells with 40ng/ml HGF, 
50μg/ml BME or a combination of 40ng/ml HGF and 50μg/ml BME resulted in 
further increases in cell proliferation after 3 days (E) which were not seen after 5 
days (F). Data represents mean of 5 independent repeats, error bars represent 
SEM. * - p=<0.05, ** - p=<0.01 and *** - p=<0.001. 
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incubation (p=0.008 vs untreated PC-3pEF6 control cells) and this trend was 
maintained after 5 days incubation (p=<0.001 vs untreated PC-3pEF6 control cells). 
Treatments with 40ng/ml HGF or combined 40ng/ml HGF and 50µg/ml BME did not 
result in significant increases in PC-3pEF6 cell proliferation until 5 days incubation 
(p=0.004 and 0.008 respectively vs untreated PC-3pEF6 control cells). Similar 
patterns of cell proliferation were seen in PC-3OPGKD under treatment with 40ng/ml 
HGF, 50µg/ml BME or a combination of 40ng/ml HGF and 50µg/ml BME, all of 
which appeared to initially further enhance cell proliferation.  After 3 days incubation 
(Figure 4.2 E), the effect of 40ng/ml HGF treatment, resulted in an increase in PC-
3OPGKD cell proliferation which reached significance (114% of untreated PC-3OPGKD 
cells, p=0.001). However, after 5 days incubation, treatments with 40ng/ml HGF, 
50µg/ml BME or a combination of 40ng/ml HGF and 50µg/ml BME were not found 
to have any significant effects and the initial increases in PC-3OPGKD cell proliferation 
following treatment appeared to have been negated (99%, 100% and 92% of 
untreated PC-3OPGKD cells). Under the influence of the combined 40ng/ml HGF and 
50µg/ml BME treatment, PC-3OPGKD cell proliferation decreased in comparison to the 
untreated cells, though this trend was not significant (change of less than 10%) 
(Figure 4.2 F).      
 
4.3.1.3 Exogenous stimuli can influence cell-matrix adhesion of PC-3OPGKD 
cells  
Reduced OPG expression in PC-3 prostate cancer cells appeared to have little 
impact on cell-matrix adhesion in vitro compared to the PC-3pEF6 control cells (less 
than 5% change from control) (Figure 4.3 A).  
Treatment of PC-3pEF6 control cells with 40ng/ml HGF appeared to marginally 
reduce cell-matrix adhesion (less than 5% of control), whilst treatment with 50µg/ml  
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Figure 4.3: Impact of reduced OPG expression in PC-3 cells on cell-matrix 
adhesion in vitro 
Reduced OPG expression resulted in no noticeable effect on PC-3 cell-matrix 
adhesion compared with control cells (A). When PC-3pEF6 control cells were treated 
with 50μg/ml BME or 50μg/ml BME and 40ng/ml HGF small increases in cell-matrix 
adhesion were seen (B), however 40ng/ml HGF resulted in no notable change in 
cell-matrix adhesion. In the PC-3OPGKD cells treated with 40ng/ml HGF cell-matrix 
adhesion increased, however under 50μg/ml BME or combined HGF and BME 
treatment cell matrix adhesion decreased (C). Representative images from one 
repeat (D). Data represents mean of a minimum 3 independent repeats, error bars 
represent SEM. * - p=<0.05, ** - p=<0.01 and *** - p=<0.001. 
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BME or combined treatment of 40ng/ml HGF and 50µg/ml BME increased cell-
matrix adhesion compared to the untreated PC-3pEF6 control cells, these trends were 
not significant (114% and 111% change from untreated control respectively) (Figure 
4.3 B). When PC-3OPGKD cells were treated with 40ng/ml HGF, a slight increase in 
cell-matrix adhesion was observed compared to the untreated PC-3OPGKD cells 
(107% of untreated control), however as in the PC-3pEF6 cells this change was not 
significant. Interestingly, when PC-3OPGKD cells were treated with 50µg/ml BME a 
significant decrease in cell-matrix adhesion was observed (84% of untreated 
control) (Figure 4.3 C, p=0.031). Of greater interest was the observation that under 
the combined treatment of 40ng/ml HGF and 50µ/ml BME an even greater reduction 
in cell-matrix adhesion was seen compared to the untreated PC-3OPGKD cells (59% 
of untreated control, p=0.003). Representative images for these changes are shown 
in Figure 4.3 D.  
 
4.3.1.4 Effect of OPG suppression on PC-3 prostate cell motility 
Knockdown of OPG in PC-3 cells appeared to produce a non-significant decrease in 
cell motility compared to the PC-3pEF6 control cells (less than 5% decrease 
compared to control) as shown in the representative images (Figure 4.4 A and 4.4 D 
respectively).  
When PC-3pEF6 control cells were treated with 40ng/ml HGF, 50µg/ml BME or a 
combination of 40ng/ml HGF and 50µg/ml BME, PC-3 cell motility from the cytodex 
beads was increased compared to the untreated PC-3pEF6 control cells (134%, 
149% and 181% compared to untreated control respectively) (Figure 4.4 B). Though 
none of these changes in motility reached significance, the 40ng/ml HGF treatment 
was close to the threshold (p=0.081).  
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Figure 4.4: Effect of OPG knockdown on PC-3 cell motility 
PC-3OPGKD cells showed no noticeable changes in motility compared with PC-3pEF6 
control cells (A). Treatment of PC-3pEF6 control cells with 40ng/ml HGF, 50μg/ml 
BME or a combination of 40ng/ml HGF and 50μg/ml BME increased cell motility (B). 
Treatment of PC-3OPGKD cells with 40ng/ml HGF appeared to have no effect on cell 
motility (C). However, treatment with 50μg/ml BME or 40ng/ml HGF and 50μg/ml 
BME resulted in an increase in cell motility. Representative images from one repeat 
(D). Data represents mean of 3 independent repeats, error bars represent SEM. * - 
p=<0.05, ** - p=<0.01 and *** - p=<0.001. 
 
193 
 
The same effect was not seen when PC-3OPGKD cells were treated with 40ng/ml 
HGF, there appeared to be no notable additional response to HGF in these cells 
(less than 5% increase compared to untreated control) (Figure 4.4 C). Interestingly, 
the 50µg/ml BME treatment appeared to increase PC-3OPGKD cell motility compared 
to the untreated PC-3OPGKD cells, a change which almost reached significance 
(172% compared to untreated control, p=0.084). The combined treatment of 
40ng/ml HGF and 50µg/ml BME also resulted in an increase in PC-3OPGKD cells 
(138% of untreated control); however this was not as notable as the individual 
50µg/ml BME treatment. Representative images of these trends are shown in Figure 
4.4 D. 
 
 4.3.1.5 OPG suppression significantly increases PC-3 cell invasion 
Suppression of OPG in PC-3 prostate cancer cells resulted in a significant increase 
in in vitro cell invasion compared to PC-3pEF6 control cells (Figure 4.5 A, 210% 
compared to control, p=0.02). 
When PC-3pEF6 control cells were treated with 40ng/ml HGF a significant increase in 
PC-3 cell invasion was observed (Figure 4.5 B, 117% of untreated control, p=0.02). 
The 50µg/ml BME treatment resulted in a negligible increase in PC-3pEF6 control cell 
invasion however; this trend was not significant (106% of untreated control). When 
40ng/ml HGF and 50µg/ml BME treatments were combined, PC-3pEF6 control cell 
invasion was generally decreased compared to the untreated control cells (81% of 
untreated control), though this did not reach significance (Figure 4.5 B).  
In contrast to the PC-3pEF6 control cell response to 40ng/ml HGF treatment, PC-
3OPGKD cells, when treated with 40ng/ml HGF, resulted in a decrease in cell invasion, 
a trend which was very close to significance (Figure 4.5 C, 81% of untreated control,  
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 Figure 4.5: Impact of reduced OPG expression on PC-3 cell invasion in vitro 
PC-3OPGKD cells showed significantly increased cell invasion compared with PC-3pEF6 
control cells (A). Treatment of PC-3pEF6 control cells with 40ng/ml HGF or 50μg/ml 
BME increased cell invasion, HGF significantly so, but a combination of 40ng/ml 
HGF and 50μg/ml BME resulted in a general decrease in cell invasion in 
comparison to untreated PC-3pEF6 control cells (B). Treatment of PC-3OPGKD cells 
with 40ng/ml HGF or combined 40ng/ml HGF and 50μg/ml BME resulted in a 
decrease in cell invasion (C). Treatment with 50μg/ml BME resulted in an increase 
in cell invasion. None of these effects were found to be significant. Representative 
images from one repeat (D). Data represents mean of 3 independent repeats, error 
bars represent SEM. * - p=<0.05, ** - p=<0.01 and *** - p=<0.001. 
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p=0.065). Treatment of PC-3OPGKD cells with 50µg/ml BME resulted in an increase in 
cell invasion, however this enhancement in invasion was slight and did not reach 
significance (116% of untreated control). Surprisingly, when 40ng/ml HGF and 
50µg/ml BME were combined, PC-3OPGKD cells appeared to show a reduced 
invasive ability compared to untreated PC-3OPGKD cells (91% of untreated control), 
however, this was less notable than that which had been observed under the 
individual 40ng/ml HGF treatment. 
 
4.3.2 Role of RANK in PC-3 Prostate Cancer Cells in vitro 
4.3.2.1 Confirmation of ribozyme transgene knockdown of RANK expression 
in PC-3 prostate cells 
Expression of RANK was successfully targeted in PC-3 prostate cancer cells 
following transfection with an anti-RANK ribozyme transgene contained within a 
pEF6 plasmid. Following RNA isolation, RT-PCR and qPCR showed significantly 
reduced RANK transcript expression in PC-3RANKKD cells compared to the PC-3pEF6 
control cells (Figures 4.6 A and B respectively). Western blot analysis subsequently 
confirmed the knockdown of RANK at a protein level in comparison to the PC-3pEF6 
control cells (Figures 4.6 C). 
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Figure 4.6: Verification of successful ribozyme transgene knockdown of 
RANK expression in PC-3 cells 
Reduced expression of RANK was confirmed at a transcript level using RT-PCR (A) 
and qPCR (B) compared to the control cell line. Western blot (C) was used to 
confirm knockdown of RANK at a protein level. PCR and Western blot were 
normalised against GAPDH. Control = Nuclease free water and all gels were ran 
with a molecular weight marker used to identify band sizes.   Representative images 
and data shown. * - p=<0.05, ** - p=<0.01 and *** - p=<0.001. 
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4.3.2.2 RANK suppression enhances PC-3 cell proliferation 
Suppression of RANK expression significantly enhanced PC-3 prostate cancer cell 
proliferation after 3 days incubation (Figure 4.7 A, 166% compared to control, 
p=0.008) and after 5 days incubation (Figure 4.7 B, 124% compared to control, 
p=0.008) compared to PC-3pEF6 control cells.  
Treatment of PC-3pEF6 control cells with 40ng/ml HGF, 50µg/ml BME or combined 
40ng/ml HGF and 50µg/ml BME resulted in increases in PC-3pEF6 control cell 
proliferation compared to untreated cells after 3 days incubation (112%, 132% and 
132% respectively of untreated control) (Figure 4.7 C) and 5 days incubation (122%, 
136% and 139% respectively of untreated control) (Figure 4.7 D). The 50µg/ml BME 
treatment resulted in a significant increase in PC-3pEF6 control cell proliferation after 
3 days incubation (p=0.008) which was maintained after 5 days incubation 
(p=<0.001). PC-3pEF6 control cell proliferation under the influence of treatment with 
40ng/ml HGF or a combination of 40ng/ml HGF and 50µg/ml BME reached a 
significant level after 5 days incubation compared to the untreated PC-3pEF6 control 
cells (p=0.004 and 0.008 respectively).  
When PC-3RANKKD cells were incubated for 3 days with 40ng/ml HGF or 50µg/ml 
BME, no further increases in cell proliferation were observed, trends suggested very 
small insignificant decreases (97% and 94% of untreated control respectively) 
(Figure 4.7 E). The combined treatment of 40ng/ml HGF and 50µg/ml BME did 
result in a notable increase in cell proliferation after 3 days incubation (178% of 
untreated control); however, this did not reach a significant level. After 5 days 
incubation a slight increase in PC-3RANKKD cell proliferation was observed in the 
40ng/ml HGF treated cells however no difference was seen in the 50µg/ml BME 
treated PC-3RANKKD cells compared to the untreated PC-3RANKKD cells (110% and 
103% of untreated control respectively) (Figure 4.7 F). However combined  
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Figure 4.7: Effects of reduced RANK expression on PC-3 cell proliferation in 
vitro 
Reduced RANK expression in PC-3 cells resulted in a significant increase in cell 
proliferation after 3 days (A) and 5 days incubation (B) compared with control cells. 
Treatment of the PC-3pEF6 control cell line with 40ng/ml HGF, 50μg/ml BME or a 
combination of 40ng/ml HGF and 50μg/ml BME resulted in an increase in cell 
proliferation after 3 days, the BME treatment significantly so (C) and 5 days 
incubation at which all treatments resulted in significant increases (D). Treatment of 
PC-3RANKKD cells with 40ng/ml HGF or 50μg/ml BME resulted in negligible increases 
in cell proliferation over 3 and 5 day incubations (E and F respectively). A 
combination of 40ng/ml HGF and 50μg/ml BME resulted in an increase in cell 
proliferation after 3 days incubation (E), however this trend was not maintained over 
a 5 day incubation period (F). Data represents mean of 5 independent repeats, error 
bars represent SEM. * - p=<0.05, ** - p=<0.01 and *** - p=<0.001. 
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treatment with 40ng/ml HGF and 50µg/ml BME resulted in a slight decrease in PC-
3RANKKD cell proliferation compared to the untreated PC-3RANKKD cells though again 
this did not reach significance (88% of untreated control).  
 
4.3.2.3 RANK suppression enhances cell-matrix adhesion in PC-3 prostate 
cancer cells  
Suppression of RANK expression in PC-3 prostate cancer cells significantly 
increased cell-matrix adhesion compared to PC-3pEF6 control cells (Figure 4.8 A, 
171% of control, p=0.02).  
Treatment of PC-3pEF6 control cells with 40ng/ml HGF, 50µg/ml BME or a 
combination of 40ng/ml HGF and 50µg/ml BME all resulted in increases in cell-
matrix adhesion (119%, 144% and 143% of untreated control respectively); however 
none of these changes were deemed significant (Figure 4.8 B). 
Cell-matrix adhesion in the PC-3RANKKD cells was further increased following 
treatment with 40ng/ml HGF (119% of untreated control), however, this did not 
reach significance compared to the untreated PC-3RANKKD cells. In contrast, when 
PC-3RANKKD cells were treated with 50µg/ml BME there appeared to be no further 
impact on PC-3 cell-matrix adhesion (103% of untreated control). When PC-3RANKKD 
cells were treated with 40ng/ml HGF and 50µg/ml BME cell-matrix adhesion was 
reduced compared to the untreated PC-3RANKKD cells (93% of untreated control) 
however again this change did not reach significance (Figure 4.8 C). Representative 
images are shown in Figure 4.8 D.  
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Figure 4.8: Effect of RANK knockdown on cell-matrix adhesion in PC-3 cells in 
vitro 
Reduced RANK expression resulted in a significant increase in PC-3 cell-matrix 
adhesion compared with control cells (A). When PC-3pEF6 control cells were treated 
with 40ng/ml HGF or 50μg/ml BME or a combination of these treatments increases 
in cell-matrix adhesion were seen (B). PC-3RANKKD cells treated with 40ng/ml HGF 
resulted in a further increase in cell-matrix adhesion. Treatment with 50μg/ml BME 
appeared to have little influence on PC-3RANKKD cell-matrix adhesion. The combined 
HGF and BME treatment resulted in a small decrease in cell-matrix adhesion 
compared with untreated PC-3RANKKD cells (C). Representative images from one 
repeat (D). Data represents mean of a minimum of 3 independent repeats, error 
bars represent SEM. * - p=<0.05, ** - p=<0.01 and *** - p=<0.001. 
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4.3.2.4 RANK suppression enhances PC-3 prostate cancer cell motility 
The cytodex bead assay was used to quantify the impact RANK suppression had on 
PC-3 prostate cell motility. PC-3 cells with suppressed RANK expression exhibited 
increased cell motility compared to the PC-3pEF6 control cells (Figure 4.9 A, 206% of 
control). This increase almost reached a significant level (p=0.057).  
The most notable change observed in the PC-3RANKKD cells was how aggregated 
they appeared to be compared to the control PC-3pEF6 cells (Representative images 
shown in Figure 4.9 D). When PC-3pEF6 control cells were treated with 40ng/ml HGF, 
50µg/ml BME or a combination of 40ng/ml HGF and 50µg/ml BME, PC-3 cell 
motility was increased compared to the untreated PC-3pEF6 control cells (136%, 
164% and 185% of untreated control) (Figure 4.9 B), though none of these trends 
reached significance the 40ng/ml HGF treatment was close (p=0.057).  
When RANK suppressed PC-3 cells were exposed to treatment with 40ng/ml HGF, 
PC-3 cell motility was further enhanced (131% of untreated control); however, this 
trend did not reach a significant level (Figure 4.9 C). When PC-3RANKKD cells were 
treated with 50µg/ml BME or a combined treatment of 40ng/ml HGF and 50µg/ml 
BME, cell motility was increased though not significantly or as dramatically as had 
been observed under the 40ng/ml HGF treatment (112% and 106% of untreated 
control respectively). 
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Figure 4.9: Effect of reduced RANK expression on PC-3 cell motility 
Reduced RANK expression resulted in an increase in PC-3 cell motility compared to 
PC-3pEF6 control cells (A). PC-3pEF6 control cells treated with 40ng/ml HGF, 50µg/ml 
BME or a combination of 40ng/ml HGF and 50µg/ml BME resulted in increased cell 
motility (B). A similar response was observed when PC-3RANKKD cells were treated 
with 40ng/ml HGF but not with 50µg/ml BME or a combination of 40ng/ml HGF and 
50µg/ml BME (C). Representative images from one repeat (D). Data represents 
mean of a minimum of 3 independent repeats, error bars represent SEM. * - 
p=<0.05, ** - p=<0.01 and *** - p=<0.001. 
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4.3.2.5 RANK suppression enhances PC-3 prostate cell invasion 
When RANK expression was reduced in PC-3 prostate cancer cells their in vitro 
invasive potential was increased (197% of control) (Figure 4.10 A), however this 
trend did not reach a significant level.  
PC-3pEF6 control cells treated with 40ng/ml HGF showed a significant increase in cell 
invasion compared to the untreated cells (Figure 4.10 B, 117% of untreated control, 
p=0.02). The 50µg/ml BME treatment also resulted in a slight increase in PC-3pEF6 
control cell invasion (106% of untreated control) however this did not reach 
significance. When 40ng/ml HGF and 50µg/ml BME were combined, PC-3pEF6 
control cell invasion was decreased compared to the untreated control cells (81% of 
untreated control), though again this trend did not reach a significant level (Figure 
4.10 B).  
Treatment of PC-3RANKKD cells with 40ng/ml HGF resulted in a small non-significant 
decrease in cell invasion (95% of untreated control) (Figure 4.10 C and 
representative images Figure 4.10 D). Treatment with 50µg/ml BME resulted in no 
change in PC-3RANKKD cell invasion (101% of untreated control) and therefore did not 
reach significance.  As was seen with the PC-3pEF6 control cells the combined 
treatment of 40ng/ml HGF and 50µg/ml BME reduced PC-3RANKKD cell invasion 
compared to the untreated PC-3RANKKD cells (76% of untreated control), though 
again this trend did not reach significance. 
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Figure 4.10: Effect of RANK knockdown on PC-3 cell invasion in vitro 
PC-3RANKKD cells showed increased cell invasion compared with PC-3pEF6 control 
cells (A). When PC-3pEF6 control cells were treated with 40ng/ml HGF or 50μg/ml 
BME cell invasion increased, under the influence of HGF significantly so, however 
the combined 40ng/ml HGF and 50μg/ml BME treatment decreased cell invasion 
(B).  PC-3RANKKD cells treated with 40ng/ml HGF or combined 40ng/ml HGF and 
50μg/ml BME showed small decreases in cell invasion compared to untreated PC-
3RANKKD cells (C), however the 50μg/ml BME treatment resulted in a marginal 
increase in cell invasion. Representative images from one repeat (D). Data 
represents mean of a minimum of 3 independent repeats, error bars represent SEM. 
* - p=<0.05, ** - p=<0.01 and *** - p=<0.001. 
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4.4 Discussion 
OPG and RANK are part of the TNFRSF and have been clinically implicated in 
prostate cancer progression, where increased transcript and protein levels have 
correlated with increasing tumour burden, metastatic bone involvement and 
androgen status. Elevated serum OPG levels have also been frequently reported in 
metastatic or relapsed prostate cancer patients. However, the potential explanations 
for these have never been well explored.  
 
4.4.1 Effect of reduced OPG expression on PC-3 prostate cancer cell 
behaviour 
The impact of targeting OPG was assessed using several in vitro function assays 
after successful knockdown of OPG using ribozyme transgenes. In the PC-3 cell 
line, reduced OPG expression resulted in increased cell proliferation after 3 days, a 
trend which reached significance after 5 days incubation. However, reduced OPG 
expression did not appear to have an impact on PC-3 cell matrix adhesion or 
motility in vitro. PC-3OPGKD cells were also found to have significantly increased 
invasive properties. Therefore based on these observations it appears that OPG 
plays a role in PC-3 cell proliferation and invasion.     
There is mixed evidence on the potential roles OPG may have in prostate tumour 
growth, though there is currently little doubt that it plays a role in prostate cancer 
progression and bone metastases. Therefore the current hypothesis remains that 
proposed by Corey et al (2005), that altered OPG expression may not be a direct 
causation factor in prostate cancer development, but it is one which may define the 
disease progression.  
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Brown et al (2001) have previously shown that OPG is detectable in normal prostate 
epithelium; however this expression is lost during primary prostate cancer. Of 
greater interest, it appeared that in the small cohort studied, the bone metastases 
associated with prostate cancer appeared to show re-established OPG expression. 
A further observation by Brown et al (2001) was that in the stained bone metastases 
sections OPG appeared to be co-localised to both the cell nucleus and the 
cytoplasm, suggesting there may be further alterations to OPG itself. In this study, 
though PC-3 cells are not a representative primary prostate cancer cell model, 
reducing OPG expression in these cells resulted in increased cell proliferation and 
cell invasion, both characteristics which are associated with cancer progression and 
metastases. Corey et al (2005) have speculated that loss of OPG itself may not 
have a direct impact on prostate cancer cell proliferation, but may affect other 
pathway(s) and molecules which in turn influence this particular cancer cell 
behaviour trait. This study might speculatively support this theory, since after 3 days 
incubation there was an increase in PC-3OPGKD cell proliferation however this trend 
did not reach significance until after 5 days incubation. This trend might be as a 
result of alterations in other signalling cascades of which the net outcome may not 
be evident until after 5 days incubation.  
Given the rich microenvironment which is associated with bone, it is possible that 
other factors, such as BMPs, are pivotal to disseminating prostate cancer cells 
settling in the bone. Brubaker et al (2003) have also previously demonstrated that 
OPG expression can be up-regulated in PC-3 cells by BMPs. The observations in 
this study, whereby reducing OPG expression in its own right promotes PC-3 cell 
proliferation is interesting in itself but, of further note is the observation that no 
further significant increase in this response was seen when cells were treated with 
50µg/ml BME, as had been observed with the PC-3pEF6 control cell line. This again 
supports the idea that OPG may be pivotal to prostate cancer cells homing to the 
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bone therefore influencing disease progression, particularly bone metastases. This 
is potentially supported by results in this study, including the significantly reduced 
cell-matrix adhesion and greater (almost significant) motility which was observed in 
the PC-3OPGKD cells treated with 50μg/ml BME.  
The other main observation that may support this theory is the increased invasion 
which was seen in the PC-3OPGKD cells. Though these cells are not the ideal model 
to explore the EMT process, it does support the idea that OPG may be important to 
the EMT process at the bone site. Though none of the subsequent treatments 
yielded significant results, the trends in themselves generate interest. It appeared 
that in PC-3OPGKD cells under the influence of 40ng/ml HGF, cell invasion was 
decreased. This trend was very near to being a significant result (p=0.065) and was 
of particular interest as the change in response was from an increase to a decrease 
compared to the PC-3pEF6 control. Given the strong wealth of evidence that HGF is 
such a pleiotropic growth factor, more investigation is required to determine why this 
unexpected response has occurred. A further increase in PC-3OPGKD cell invasion, 
under the 50µg/ml BME treatment was somewhat anticipated due to the potential 
restoration of some exogenous OPG, since the complete composition of the in-
house bone mix (BME) has never been quantified.   Therefore, this may, in an in 
vitro model, be one of the best ways of representing physiological conditions. 
Further work could focus on isolating the signalling pathway(s) in which these 
stimuli exert their effects. 
 
4.4.2 Effect of reduced RANK expression on PC-3 prostate cancer cell 
behaviour 
Reduced RANK expression was successfully achieved in PC-3 cells using ribozyme 
transgene.  Reduced RANK expression resulted in significant increases in PC-3 cell 
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proliferation and cell-matrix adhesion. However, when PC-3RANKKD cells were 
exposed to HGF or BME no further increases in cell proliferation were seen, unlike 
those which were seen in the PC-3pEF6 control cells.  In contrast, PC-3RANKKD cells 
under the influence of HGF appeared to have further enhanced cell-matrix 
adhesion, a pattern which was not mirrored under the influence of BME. Though 
increases were seen in both PC-3RANKKD cell motility and invasion compared to the   
PC-3pEF6 control cells, these trends did not reach a statistically significant level. 
These findings agree with data from Casimiro et al (2013), who showed that 
knocking down RANK using siRNA inhibited RANKL induced JNK phosphorylation. 
Despite this it was interesting to observe that the PC-3RANKKD cells appeared to be 
more aggregated during the motility assay compared to the PC-3pEF6 control cells, 
though more investigation is needed to understand this observation.  
Much of the previous work studying the role of RANK in PC-3 prostate cancer cells 
has focused on its interaction with stromal RANKL (Armstrong et al 2008). This has 
led many to hypothesise that the rich soil of RANKL in the bone microenvironment 
attracts RANK expressing tumour cells (Armstrong et al 2008).  In the current study, 
though reduced RANK expression in the PC-3 cells did result in enhanced 
tumourigenic behaviour in vitro, when these cells were exposed to a bone like 
environment (BME), no further effect was seen, suggesting that RANK expression 
may also be integral to the bone homing phenotype associated with prostate cancer 
cells. In this study, by targeting RANK expression in PC-3 cells, interesting 
increases in tumourigenic cell behaviour were seen. This poses the question of 
what advantageous influence RANK expression might also have on prostate cancer 
itself? This appears particularly apt given the aggregated appearance which was 
observed in the motility assay.  Further work might focus on looking at several 
surface markers which may affect such cell behaviour. 
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Chapter 5 
Role of OPG and RANKL in mixed osseous prostate cancer 
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5.1 Introduction 
In the unravelling of the complex interactions which occur between prostate cancer 
cells and the bone environment, in vitro and in vivo studies have highlighted the 
roles of both direct and indirect interactions which contribute to prostate cancer 
progression (Blaszczyk et al 2004, Dai et al 2004, Dai et al 2005, Bryden et al 
2002a). However it remains unclear if disseminating prostate cancer cells already 
possess osteomimetic properties or if molecular characteristics are induced by 
factors in the bone microenvironment which allow the disseminated cancer cells to 
colonise and invade into the bone. Androgen ablation therapy, the mainstay of 
current prostate cancer therapy, has been associated with increased risk of 
osteoporosis, decreased bone mineral density and increased bone resorption 
(Orwoll and Klein 1995). This coupled with in vitro evidence that androgens play a 
role in the regulation of pro- and anti- resorptive bone factors, further highlights 
some of the clinical challenges in this area (Bellido et al 1995, Hofbauer and Khosla 
1999, Hofbauer et al 2004, Pederson et al 1999). 
There have been several in vivo studies which have shown that the mildly 
tumourigenic prostate cancer cell line LNCaP, can acquire androgen independence 
and progress to develop a mixed osseous phenotype metastasis, therefore 
providing a more representative experimental model of metastatic prostate cancer 
disease progression (Wu et al 1994, Thalmann et al 1994, Gleave et al 1991, 
Thalmann et al 2000). In agreement with the literature, it has been previously shown 
in this study (Figure 3.1) that the majority of prostate cancer cell lines strongly 
express OPG but the androgen dependent LNCaP cell line only weakly expresses 
OPG (Penno et al 2002, Holen et al 2002). 
This section of the study aimed to investigate the impact of treating LNCaP cells 
with rhOPG and/or nRANKL had on prostate cancer cell behaviour in vitro, before 
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subsequently investigating the potential roles HGF and/or BME may have in 
enhancing or negating these responses. Based on our LNCaP cell line observations 
and given the secreted nature of OPG, a recombinant protein form was purchased 
after initial efforts to produce a stable expression model proved problematic. 
Generation of reduced RANKL expression in LNCaP cells was also unsuccessful 
and, given the time sensitivity of this study, the recently licensed neutralising 
RANKL antibody, Denosumab, was also subsequently purchased.   
 
5.2 Materials and Methods  
5.2.1 Cell line 
The LNCaP (FGC clone) cell line was purchased from the ATCC and was 
maintained in RPMI 1640 medium supplemented with 10% FCS and ABS as 
described in Section 2.6.  
 
5.2.2 Treatments 
Denosumab was sourced from Amgen Limited, recombinant human OPG was 
sourced from PeproTech. LNCaP cells throughout this section were treated with 
25ng/ml rhOPG and/or 100ng/ml nRANKL, 40ng/ml HGF and/or 50µg/ml BME. All 
treatments were prepared initially at a 4x concentrate and added to each 
experiment in 50µl volumes. 
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5.2.3 In vitro cell proliferation assay 
  LNCaP cells were seeded at 3x103/well in triplicate 96 well plates and incubated 
for 1, 3 and 5 days respectively as described in Section 2.10.1. Following 
incubation, cells were fixed in 4% formalin (v/v) and stained with 0.5% crystal violet 
(v/v). Subsequently, crystal violet stain was extracted from the cells using 10% 
acetic acid (v/v) and the absorbance at 540nm was determined using a 
spectrophotometer. Data presented is mean percentage control of a minimum of 4 
independent repeats with SEM. 
 
5.2.4 In vitro cell Matrigel adhesion assay 
A 96 well plate was coated with 5μg/well of Matrigel and left to dry as described in 
Section 2.10.2. Then 4.5x104 LNCaP cells/well with respective treatments (final 
volume 200μl) were left to adhere for 45 minutes before being fixed in 4% formalin 
(v/v) and stained with 0.5% crystal violet (v/v). Four representative images were 
captured for each well and subsequently counted using Image J software. Data 
presented is mean percentage control of a minimum of 3 independent repeats with 
SEM. 
 
5.2.5 In vitro cell migration assay 
For the LNCaP cell line, the cytodex bead assay was considered to be inappropriate 
to analyse cell motility as LNCaPWT cells did not migrate from the cytodex beads 
within the 4 hour incubation period thus being unquantifiable. Therefore an 
alternative method was found. Due to the number of treatments required, the 
traditional scratch-wounding assay was considered to be too time consuming. 
Fortunately, in the laboratory, the ECIS system was available.  
213 
 
8x104 LNCaP cells were seeded with/without treatment and left to form a monolayer 
and the resistance to plateau prior to wounding as described in Section 2.10.3. The 
resistance at 4KHz was recorded for 4 hours after wounding. 
 
5.2.6 In vitro Matrigel cell invasion assay 
Transwell inserts were coated with 50μg/insert of Matrigel and dried before 3x104 
cells/50µl were seeded into each insert and incubated for 3 days with respective 
treatments (Final volume 200μl), as described in Section 2.10.4. Following 
incubation, cells were fixed in 4% formalin (v/v) and stained with 0.5% crystal violet 
(v/v). Five representative images were captured per transwell insert and 
subsequently counted using Image J software. Data presented is the mean 
percentage control of 3 independent repeats with SEM. 
 
5.3 Results 
5.3.1 The effect of exogenous rhOPG and nRANKL on LNCaP cell proliferation 
at different concentrations 
From the initial prostate cancer cDNA screen (Figure 3.1), LNCaP cells showed 
very weak expression of OPG but were one of the few cell lines exhibiting RANKL 
expression. After sourcing rhOPG and nRANKL and carrying out a literature search, 
cytotoxicity assays were conducted analysing LNCaP cell proliferation at a range of 
concentrations (Figure 5.1). After 3 days incubation with each of the individual 
concentrations of rhOPG, no notable cytotoxic effects were observed (Figure 5.1 A). 
After 5 days incubation, though no significant cytotoxic effects on LNCaP cells were 
seen, at the highest concentration (500ng/ml) a drop off in cell proliferation was 
observed (Figure 5.1 B).  
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Figure 5.1: rhOPG and nRANKL concentration gradients 
A range of rhOPG concentrations were tested on LNCaP cells, no noticeable 
cytotoxic effects were observed on LNCaP cell proliferation after 3 days incubation 
(A) or after 5 days incubation (B). LNCaP cells treated with a range of 
concentrations of nRANKL; cells treated with 50ng/ml showed a significant increase 
in cell proliferation compared to the untreated cells and all other nRANKL 
concentrations after 3 days incubation (C). This trend was not continued after 5 
days incubation (D); no concentrations appeared to have significant cytotoxic 
effects. Data represents mean values of 3 independent repeats and error bars 
represent SEM. * - p=<0.05, ** - p=<0.01 and *** - p=<0.001. 
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After 3 days incubation with nRANKL, 50ng/ml resulted in an initial significant 
increase in LNCaP cell proliferation compared to all other tested concentrations and 
the untreated LNCaP cells (Figure 5.1 C). All other concentrations tested did not 
appear to have any significant cytotoxic effects. However, after 5 day incubation all 
nRANKL concentrations had no significant biological effects on LNCaP cell 
proliferation (Figure 5.1 D). The initial increase observed after 3 days incubation 
with 50ng/ml was no longer evident. As a result of these assays, all future 
experiments were carried out using 25ng/ml rhOPG and 100ng/ml nRANKL based 
on other literature (Lane et al 2012).    
 
5.3.2 Effect of exogenous rhOPG and nRANKL treatment on LNCaP cell 
proliferation 
LNCaP cells treated with 25ng/ml rhOPG showed an initial increase in cell 
proliferation compared to the untreated LNCaP cells (Figure 5.2 A, 135% of 
untreated cells); however this did not reach a significant level. This pattern was 
continued, though less pronounced, after 5 day incubation with the LNCaP cells 
treated with 25ng/ml rhOPG which showed slightly increased cell proliferation 
compared with the untreated cells (Figure 5.2 B, 109% of untreated cells).  
LNCaP cells treated with 100ng/ml nRANKL showed an initial increase in cell 
proliferation compared to the untreated LNCaP cells (Figure 5.2 C, 174% of 
untreated cells), however this difference appeared to have been negated after 5 day 
incubation with 100ng/ml nRANKL (Figure 5.2 D, 105% of untreated cells). 
LNCaP cells treated with a combination of 25ng/ml rhOPG and 100ng/ml nRANKL 
resulted in an increase in cell proliferation after 3 days incubation compared with 
untreated LNCaP cells (153% of untreated cells), though again this difference did  
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Figure 5.2: Effect of rhOPG and nRANKL on LNCaP cell proliferation 
LNCaP cells incubated with 25ng/ml rhOPG showed an increase in cell proliferation 
compared to the untreated cells after 3 days (A) however this did not reach 
significance and was negated after 5 days incubation (B). When LNCaP cells were 
incubated for 3 days with 100ng/ml nRANKL (C) or a combination of 25ng/ml 
rhOPG and 100ng/ml nRANKL (E) increases in LNCaP cell proliferation were 
observed, though these did not reach significance.  After 5 days incubation with 
100ng/ml nRANKL LNCaP cell proliferation was similar to that of the untreated cells 
(D). LNCaP cells incubated with 25ng/ml rhOPG and 100ng/ml nRANKL still 
showed increased cell proliferation compared to the untreated cells, however this 
still did not reach significance (F). Data represents mean values of 4 independent 
repeats, error bars represent SEM. * - p=<0.05, ** - p=<0.01 and *** - p=<0.001. 
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not reach a significant level (Figure 5.2 E). As with the individual treatments this 
difference was less pronounced after 5 days incubation, though the combined 
treatment with 25ng/ml rhOPG and 100ng/ml nRANKL resulted in increased LNCaP 
cell proliferation (Figure 5.2 F 116% of untreated cells).  
 
5.3.3 Effect of exogenous HGF and BME on LNCaP cell proliferation 
Treatment of LNCaP cells with 40ng/ml HGF, appeared to have no impact on cell 
proliferation after 3 days incubation (99% of untreated cells) (Figure 5.3 A), however 
after 5 days incubation a significant reduction in cell proliferation was seen 
compared with the untreated cells  (62% of untreated cells) (Figure 5.3 B, p=0.029). 
However, treatment of LNCaP cells with 50µg/ml BME resulted in an increase in 
LNCaP cell proliferation after 3 days incubation (178% of untreated cells) (Figure 
5.3 A), though this increase did not reach a significant level until after 5 days 
incubation (120% of untreated cells) (Figure 5.3 B, p=0.029). When a combined 
treatment of 40ng/ml HGF and 50µg/ml BME were added to LNCaP cells an 
increase in cell proliferation was observed after 3 days incubation and 5 days 
incubation (155% and 115% of untreated cells) (Figures 5.3 A and B). These 
increases in cell proliferation did not reach significant levels and were not as 
pronounced as those observed with the individual 50µg/ml BME treatment, 
especially after 3 days incubation, but the combined treatment did appear to nullify 
the effects of the individual 40ng/ml HGF treatment.  
LNCaP cells treated with 25ng/ml rhOPG and 40ng/ml HGF showed reduced cell 
proliferation after both 3 day and 5 day incubation (Figure 5.3 C and D respectively). 
After 5 days incubation this reduction in LNCaP cell proliferation reached 
significance (p=0.009) compared with the rhOPG treated cells (66% of 25ng/ml 
rhOPG treated cells). Treatment of LNCaP cells with 25ng/ml rhOPG and 50µg/ml 
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BME did not seem to have an initial impact on cell proliferation after 3 days 
incubation (Figure 5.3 C, 98% compared to 25ng/ml rhOPG treated cells). However, 
after 5 days incubation, LNCaP cell proliferation was increased compared to 
25ng/ml rhOPG treated cells, although this did not reach a significant level (Figure 
5.3 D, 120% compared to 25ng/ml rhOPG treated cells). When 40ng/ml HGF and 
50µg/ml BME were used in combination with 25ng/ml rhOPG, after 3 days 
incubation  LNCaP cell proliferation was initially increased, though not significantly 
compared to the rhOPG only treated cells (Figure 5.3 C, 149% compared to 
25ng/ml rhOPG treated cells). However, after 5 day incubation there was no 
apparent difference between the combined 25ng/ml rhOPG, 40ng/ml HGF and 
50µg/ml BME treated cells and the 25ng/ml rhOPG only treated cells (Figure 5.3 D). 
LNCaP cells treated with 100ng/ml nRANKL and 40ng/ml HGF also resulted in a 
significant decrease in cell proliferation after 3 days incubation (Figure 5.3 E, 65% of 
nRANKL treated cells, p=0.029) and 5 days incubation (Figure 5.3 F, 49% of 
nRANKL treated cells, p=0.029). Combined treatment of 100ng/ml nRANKL and 
50µg/ml BME, after 3 days incubation resulted in an initial non-significant decrease 
in LNCaP cell proliferation (Figure 5.3 E, 86% compared to nRANKL treated cells). 
Incubation with 100ng/ml nRANKL and 50µg/ml BME for 5 days resulted in a slight 
increase in LNCaP cell proliferation compared to 100ng/ml nRANKL treated cells 
(Figure 5.3 F, 109% compared to nRANKL cells). However, when 100ng/ml 
nRANKL, 40ng/ml HGF and 50μg/ml BME were used in combination to treat LNCaP 
cells, they appeared to have little impact on cell proliferation (Figures 5.3 E and F 
respectively). After 3 days incubation there was a slight reduction in LNCaP cell 
proliferation after treatment with 100ng/ml nRANKL, 40ng/ml HGF and 50μg/ml 
BME compared to the 100ng/ml nRANKL only treated cells (Figure 5.3 E, 89% of 
nRANKL treated cells). This decrease in LNCaP cell proliferation appeared negated  
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Figure 5.3: Effect of HGF and BME on LNCaP cell proliferation 
LNCaP cells incubated with 40ng/ml HGF, 50µg/ml BME or 40ng/ml HGF and 50µg/ml BME 
after 3 days incubation (A) and after 5 days incubation (B). LNCaP cell proliferation when 
cells were treated with 25ng/ml rhOPG and 40ng/ml HGF, 50µg/ml BME or 40ng/ml HGF 
and 50µg/ml BME after 3 days incubation (C) and after 5 days incubation (D). LNCaP cell 
proliferation when cells were treated with 100ng/ml nRANKL and 40ng/ml HGF, 50µg/ml 
BME or 40ng/ml HGF and 50µg/ml BME after 3 days incubation (E) and after 5 days 
incubation (F). LNCaP cell proliferation when cells were treated with 25ng/ml rhOPG and 
100ng/ml nRANKL and 40ng/ml HGF, 50µg/ml BME or 40ng/ml HGF and 50µg/ml BME after 
3 days incubation (G) and after 5 days incubation (H). Data represents mean of 4 
independent repeats, error bars represent SEM. * - p=<0.05, ** - p=<0.01 and *** - 
p=<0.001. 
220 
 
after 5 days incubation compared to the 100ng/ml nRANKL treated cells (Figure 5.3 
F, 97% of nRANKL treated cells). None of these patterns reached significant 
levels.100ng/ml nRANKL and 25ng/ml rhOPG were also used in combination with 
40ng/ml HGF on LNCaP cells. After 3 and 5 days incubation, LNCaP cell 
proliferation was again significantly reduced (Figure 5.3 G and H, 86% and 58% of 
rhOPG and nRANKL treated cells, p=0.029 and 0.029 respectively). 100ng/ml 
nRANKL and 25ng/ml rhOPG used in combination with 50μg/ml BME initially after 3 
days incubation appeared to significantly increase LNCaP cell proliferation (Figure 
5.3 G, 141% of rhOPG and nRANKL treated cells, p=0.029), however this increase 
was negated after 5 days incubation (Figure 5.3 H, 104% of rhOPG and nRANKL 
treated cells). When all 4 treatments were combined, initially LNCaP cell 
proliferation appeared significantly increased compared to the 25ng/ml rhOPG and 
100ng/ml nRANKL treated cells (Figure 5.3 G, 245% of rhOPG and nRANKL treated 
cells, p=0.029). However, after 5 days incubation cell proliferation appeared to be 
reduced in comparison to the 25ng/ml rhOPG and 100ng/ml nRANKL treated cells, 
though this did not reach a significant level (Figure 5.3 H, 85% of rhOPG and 
nRANKL treated cells). 
 
 5.3.4 Effect of exogenous rhOPG and nRANKL treatment on LNCaP cell-
matrix adhesion 
LNCaP cells treated with 25ng/ml rhOPG showed increased cell-matrix adhesion 
compared to untreated LNCaP cells (Figure 5.4 A, 178% of untreated control), 
however, this trend did not achieve significance. Similar patterns for the 100ng/ml 
nRANKL treated cells (202% of untreated control) and combined 25ng/ml rhOPG 
and 100ng/ml nRANKL cells (239% of untreated control) were also seen (Figures 
5.4 C and E respectively). Again, however, both of these trends failed to reach  
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Figure 5.4: Effect of rhOPG and nRANKL on LNCaP cell-matrix adhesion 
LNCaP cells treated with 25ng/ml rhOPG showed increased cell-matrix adhesion 
compared to untreated cells (A). Treatment with 100ng/ml nRANKL also appeared 
to increase LNCaP cell-matrix adhesion compared to untreated cells (C). When 
LNCaP cells were treated with combined 25ng/ml rhOPG and 100ng/ml nRANKL an 
increase in cell-matrix adhesion was observed (E). Representative images from one 
repeat for rhOPG, nRANKL and rhOPG and nRANKL in B, D and F respectively. 
Data shown is the mean of 3 independent repeats, error bars represent SEM. * - 
p=<0.05, ** - p=<0.01 and *** - p=<0.001. 
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significance. Representative images for each of the treatments compared to 
untreated LNCaP cells are also shown (Figure 5.4 B, D and F). 
 
5.3.5 Effect of exogenous HGF and BME on LNCaP cell-matrix adhesion 
Treatment of LNCaP cells with 40ng/ml HGF appeared to slightly increase cell-
matrix adhesion in vitro (109% of untreated control), whereas treatment with 
50μg/ml BME resulted in a more prominent increase (124% of untreated control).  
However, a combination of 40ng/ml HGF and 50μg/ml BME resulted in a 
considerable increase in LNCaP cell-matrix adhesion (165% of untreated control) 
(Figure 5.5 (1) A). However none of these notable changes gave significant results. 
(Representative images shown in Figure 5.5 (1) B).  
When 40ng/ml HGF treatment was added in combination with 25ng/ml rhOPG, the 
cell-matrix adhesive properties of LNCaP cells appeared reduced (79% of rhOPG 
treated control) (Figure 5.5 (1) C, representative images shown in Figure 5.5 (1) D). 
Treatment with 50μg/ml BME appeared to have no additional effect when added in 
combination with 25ng/ml rhOPG (93% of rhOPG treated control). However, of 
interest was the significant reduction in cell-matrix adhesion which was observed 
when 25ng/ml rhOPG, 40ng/ml HGF and 50μg/ml BME were added in combination 
to LNCaP cells (64% of rhOPG treated control) (Figure 5.5 (1) C, representative 
images 5.5 (1) D, p = 0.003). 
When 40ng/ml HGF was added in combination with 100ng/ml nRANKL to LNCaP 
cells there was no effect on cell-matrix adhesion (100% of nRANKL treated control) 
(Figure 5.5 (2) E). The 50μg/ml BME treatment or the 40ng/ml HGF and 50μg/ml 
BME treatment in combination with 100ng/ml nRANKL, appeared to further enhance 
cell-matrix adhesion (124% and 124% of nRANKL treated control respectively), 
however  
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Figure 5.5 (1): Effect of HGF and BME on LNCaP cell matrix adhesion 
LNCaP cells treated with 40ng/ml HGF, 50µg/ml BME or 40ng/ml HGF and 50µg/ml 
BME showed slight increases in cell-matrix adhesion (A, representative images B). 
LNCaP cells treated with 25ng/ml rhOPG and 40ng/ml HGF or 40ng/ml HGF and 
50µg/ml BME showed reductions in cell-matrix adhesion whilst the 50µg/ml BME 
and 25ng/ml rhOPG appeared to have little effect on LNCaP cell-matrix adhesion 
(C, representative images D). Data represents mean of 3 independent repeats, error 
bars represent SEM. * - p=<0.05, ** - p=<0.01 and *** - p=<0.001. 
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Figure 5.5 (2): Effect of HGF and BME on LNCaP cell matrix adhesion 
LNCaP cells treated with 100ng/ml nRANKL and 40ng/ml HGF were added together 
there was no effect on cell-matrix adhesion however, when 100ng/ml nRANKL and 
either 50μg/ml BME or 40ng/ml and 50μg/ml BME were added non-significant 
increases in cell-matrix adhesion were observed (E, representative images F). 
LNCaP cells treated with 25ng/ml rhOPG, 100ng/ml nRANKL and 40ng/ml HGF or 
50μg/ml BME had little impact on cell-matrix adhesion but a combination of 25ng/ml 
rhOPG, 100ng/ml nRANKL, 40ng/ml HGF and 50μg/ml BME showed a non-
significant decrease in cell-matrix adhesion (G, representative images H). Data 
represents mean of 3 independent repeats, error bars represent SEM. * - p=<0.05, 
** - p=<0.01 and *** - p=<0.001. 
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neither of these results reached a significant level (Figure 5.5 (2) E, representative 
images 5.5 (2) F). 
LNCaP cell-matrix adhesion appeared slightly reduced when 25ng/ml rhOPG, 
100ng/ml nRANKL and 40ng/ml HGF were added together compared to just the 
25ng/ml rhOPG and 100ng/ml nRANKL treated cells (92% of rhOPG and nRANKL 
treated control) (Figure 5.5 (2) G), though this was not statistically significant. A 
similar response was seem when 50μg/ml BME was added in combination with 
25ng/ml rhOPG and 100ng/ml nRANKL (94% of rhOPG and nRANKL treated 
control). The most noticeable effect on cell-matrix adhesion was when 25ng/ml 
rhOPG, 100ng/ml nRANKL, 40ng/ml HGF and 50μg/ml BME were all added in 
combination (83% of rhOPG and nRANKL treated control). However again this 
failed to reach significance (Figure 5.5 (2) G, representative images Figure 5.5 (2) 
H). 
 
 
 
5.3.6 Effect of exogenous rhOPG and nRANKL treatment on LNCaP cell 
migration 
LNCaP cells treated with 25ng/ml rhOPG had a very slight decrease in cell 
migration compared to untreated LNCaP cells over a 4 hour period (Figure 5.6 A). 
When LNCaP cells were treated with 100ng/ml nRANKL there appeared to be no 
difference in cell migration, over 4 hours, compared with untreated LNCaP cells, 
following electrical wounding using ECIS (Figure 5.6 B). However, when 25ng/ml 
rhOPG and 100ng/ml nRANKL treatments were combined LNCaP cell migration 
increased compared to untreated cells, though this was not significant after 4 hours 
(Figure 5.6 C). 
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Figure 5.6: Effect of rhOPG and nRANKL on LNCaP cell migration 
Using ECIS, treatments of 25ng/ml rhOPG (A), 100ng/ml nRANKL (B) or 25ng/ml 
rhOPG and 100ng/ml nRANKL (C) had little effect on LNCaP cell migration, after 
wounding, over a 4 hour period compared to untreated LNCaP cells. Data 
represents mean of 3 independent repeats, error bars represent SEM. * - p=<0.05, 
** - p=<0.01 and *** - p=<0.001. 
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5.3.7 Effect of exogenous HGF and BME on LNCaP cell migration 
Under the influence of 40ng/ml HGF or 50μg/ml BME, LNCaP cell migration over a 
4 hour period was unaffected compared to the untreated cells. However, when a 
combination of 40ng/ml HGF and 50μg/ml BME was added to the LNCaP cells, a 
significant increase in cell migration compared to the untreated cells was observed 
(Figure 5.7 A, p=0.014).  
When 25ng/ml rhOPG and 40ng/ml HGF were added to LNCaP cells, cell migration 
was significantly increased over a 4 hour period compared to 25ng/ml rhOPG 
treated cells (Figure 5.7 B, p=0.007). However, when 25ng/ml rhOPG and 50μg/ml 
BME were added in combination to LNCaP cells, cell migration was significantly 
decreased over a 4 hour period compared to the 25ng/ml rhOPG treated cells 
(Figure 5.7 B, p=<0.001). Conversely, when 25ng/ml rhOPG, 40ng/ml HGF and 
50μg/ml BME were added in combination, the decreased effects of 50μg/ml BME 
were negated, and an increase in LNCaP cell migration was seen, however, this 
increase was less than that seen under the influence of the individual 40ng/ml HGF 
treatment. 
LNCaP cells treated with 100ng/ml nRANKL and 40ng/ml HGF showed a significant 
increase in cell migration over a 4 hour period compared to 100ng/ml nRANKL 
treated LNCaP cells (Figure 5.7 C, p=0.018). When 100ng/ml nRANKL and 50μg/ml 
BME were added in combination to the LNCaP cells, cell migration was decreased 
compared to the 100ng/ml nRANKL treated cells, however this did not reach a 
significant level. However, when 100ng/ml nRANKL, 40ng/ml HGF and 50μg/ml 
BME were added in combination to LNCaP cells, cell migration was significantly 
increased compared to 100ng/ml nRANKL treated cells (Figure 5.7 C, p=0.019). 
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Figure 5.7: Effect of HGF and BME on LNCaP cell migration 
LNCaP cell migration after treatment with 40ng/ml HGF or 50μg/ml BME showed little 
change but cell migration significantly increased after treatment with 40ng/ml HGF and 
50μg/ml BME compared to the untreated LNCaP cells (A). LNCaP cell migration after 
treatment with 25ng/ml rhOPG and 40ng/ml HGF significantly increased compared to the 
rhOPG treated cells. Treatment with 25ng/ml rhOPG, 40ng/ml HGF and 50μg/ml BME also 
increased LNCaP migration however this was not significant compared to the rhOPG treated 
cells. Treatment with 25ng/ml rhOPG and 50μg/ml BME significantly decrease LNCaP cell 
migration compared to the rhOPG treated cells (B). LNCaP cell migration after treatment 
with 100ng/ml nRANKL and 40ng/ml HGF or 40ng/ml HGF and 50μg/ml BME significantly 
increased compared to the 100ng/ml nRANKL treated cells. However, treatment with 
100ng/ml nRANKL and 50μg/ml BME non-significantly decreased LNCaP cell migration (C). 
LNCaP cell migration after being treated with 25ng/ml rhOPG, 100ng/ml nRANKL and 
40ng/ml HGF or 50μg/ml BME showed little difference in cell migration compared to the 
25ng/ml rhOPG and 100ng/ml nRANKL treated cells, but treatment with 25ng/ml rhOPG, 
100ng/ml nRANKL, 40ng/ml HGF and 50μg/ml BME resulted in a non-significant increase in 
cell migration (D). Data represents mean of 3 independent repeats, error bars represent 
SEM. * - p=<0.05, ** - p=<0.01 and *** - p=<0.001. 
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When 25ng/ml rhOPG and 100ng/ml nRANKL were added in combination with 
40ng/ml HGF, unlike the effects seen with the individual rhOPG or nRANKL 
treatments there appeared to be little effect on LNCaP cells compared to the 
25ng/ml rhOPG and 100ng/ml nRANKL treated cells (Figure 5.7 D). LNCaP cell 
migration over a 4 hour period when treated with 25ng/ml rhOPG, 100ng/ml 
nRANKL and 50μg/ml BME showed a slight decrease compared to the 25ng/ml 
rhOPG and 100ng/ml nRANKL treated cells. This pattern was less dramatic than 
those seen in the individual 25ng/ml rhOPG or 100ng/ml nRANKL treated cells 
further treated with 50μg/ml BME.  The combination of 25ng/ml rhOPG, 100ng/ml 
nRANKL, 40ng/ml HGF and 50μg/ml BME appears to increase LNCaP cell 
migration over 4 hours compared to the 25ng/ml rhOPG or 100ng/ml nRANKL 
treated cells.  However, as was noted with the 40ng/ml HGF and 50μg/ml BME 
treatments these responses were not as pronounced in the combined group as 
seen in the individual treatment groups, and these did not reach significant levels.  
 
5.3.8 Effect of exogenous rhOPG and nRANKL treatment on LNCaP cell 
invasion 
LNCaP cells treated with 25ng/ml rhOPG showed significantly reduced cell invasion 
compared to the untreated LNCaP cells (67% of untreated cells) (Figure 5.8 A, p = 
0.017, representative images B). LNCaP cells treated with either 100ng/ml nRANKL 
or a combination of 25ng/ml rhOPG and 100ng/ml nRANKL also showed reduced 
cell invasion compared with untreated cells (59% and 68% of untreated cells 
respectively); however neither of these were statistically significant (Figures 5.8 C 
and E respectively, representative images D and F).  
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Figure 5.8: Effect of rhOPG and nRANKL on LNCaP cell invasion 
Incubation of LNCaP cells with 25ng/ml rhOPG resulted in a significant decrease in 
cell invasiveness (A, representative images B). Treatment with 100ng/ml nRANKL 
(C, representative images D) and 25g/ml rhOPG and 100ng/ml nRANKL (E, 
representative images F) resulted in non-significant decreases in LNCaP cell 
invasion. Data represents mean of 3 independent repeats, error bars represent 
SEM.  * - p=<0.05, ** - p=<0.01 and *** - p=<0.001. 
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5.3.9 Effect of exogenous HGF and BME on LNCaP cell invasion 
Incubation of LNCaP cells with 40ng/ml HGF resulted in a significant decrease in 
cell invasion compared to untreated LNCaP cells (43% of untreated cells) (Figure 
5.9 (1) A, p=0.015 representative images 5.9 B). Treatment with 50μg/ml BME also 
resulted in a decrease in LNCaP cell invasion, though this did not reach a significant 
level (69% of untreated cells). A combined treatment of 40ng/ml HGF and 50μg/ml 
BME resulted in a significant decrease in LNCaP cell invasion compared to the 
untreated cells (34% of untreated cells) (Figure 5.9 (1) A, p = 0.012).  
Treatment of LNCaP cells with 25ng/ml rhOPG combined with 40ng/ml HGF 
appeared to show slightly reduced cell invasion compared to the 25ng/ml rhOPG 
treated cells (89% of rhOPG treated cells) (Figure 5.9 (1) C). Interestingly, a 
combined treatment of 25ng/ml rhOPG and 50μg/ml BME resulted in an increase in 
LNCaP cell invasion compared to the 25ng/ml rhOPG treated cells (157% of rhOPG 
treated cells), however this change did not reach significance. A combined 
treatment of 40ng/ml HGF and 50μg/ml BME with 25ng/ml rhOPG resulted in a 
significant decrease in LNCaP cell invasion (38% of rhOPG cells) (Figure 5.9 (1) C, 
p = 0.004, representative images 5.9 (1) D).  
When LNCaP cells were treated with 100ng/ml nRANKL together with 40ng/ml HGF 
little effect was seen on cell invasion (97% of nRANKL treated cells) (Figure 5.9 (2) 
E). Treatment with 50μg/ml BME in addition to 100ng/ml nRANKL showed an 
increase in LNCaP cell invasion which almost reached significance (136% of 
nRANKL treated cells, p=0.06) (representative images shown in Figure 5.9 (2) F). 
Combining all the treatments, 100ng/ml nRANKL, 40ng/ml HGF and 50μg/ml BME 
resulted in a significant decrease in LNCaP cell invasion (42% of nRANKL treated 
cells) (Figure 5.9 (2) E, p = <0.001).  
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Figure 5.9 (1): Effect of HGF and BME on LNCaP cell invasion 
LNCaP cells treated with 40ng/ml HGF (p=0.015), 50μg/ml BME or 40ng/ml HGF 
and 50μg/ml BME (p=0.012) resulted in decreased cell invasion (A, representative 
images B). LNCaP cells treated with 25ng/ml rhOPG and 40ng/ml HGF or  40ng/ml 
HGF and 50μg/ml BME resulted in decrease invasion, the latter significantly so 
(p=0.004) but 25ng/ml rhOPG and 50μg/ml BME treatment non-significantly 
increased LNCaP cell invasion (C, representative images D). Data represents 3 
independent repeats, error bars represent SEM. * - p=<0.05, ** - p=<0.01 and *** - 
p=<0.001. 
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Figure 5.9 (2): Effect of HGF and BME on LNCaP cell invasion 
LNCaP cells treated with 100ng/ml nRANKL together with either 40ng/ml HGF or a 
combination of 40ng/ml HGF and 50μg/ml BME decreased cell invasion, the latter 
significantly so (<0.001). Treatment with 100ng/ml nRANKL combined with 50μg/ml 
BME non-significantly increased LNCaP cell invasion (E, representative images F). 
LNCaP cells treated with a combination of 25ng/ml rhOPG and 100ng/ml nRANKL, 
together with 40ng/ml HGF resulted in significantly decreased cell invasion (p=0.02) 
whilst treatment with 25ng/ml rhOPG and 100ng/ml nRANKL together with 50μg/ml 
BME or both 40ng/ml HGF and 50μg/ml BME resulted in non-significant increased 
cell invasion (G, representative images H). Data represents mean of 3 independent 
repeats, error bars represent SEM. * - p=<0.05, ** - p=<0.01 and *** - p=<0.001. 
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Combination of both 25ng/ml rhOPG and 100ng/ml nRANKL together with 40ng/ml 
HGF resulted in a significant decrease in LNCaP cell invasion (48% of rhOPG and 
nRANKL treated cells) (Figure 5.9 (2) G, p = 0.02). The combination of 25ng/ml 
rhOPG and 100ng/ml nRANKL when supplemented with 50μg/ml BME resulted in 
an increase in LNCaP cell invasion in comparison to 25ng/ml rhOPG and 100ng/ml 
nRANKL treated cells, however this did not reach significance (243% of rhOPG and 
nRANKL treated cells). When all the treatments, 25ng/ml rhOPG, 100ng/ml 
nRANKL, 40ng/ml HGF and 50μg/ml BME were applied in combination the effects 
seen with the individual 40ng/ml HGF treatment were nullified, and invasion 
increased in comparison to the 25ng/ml rhOPG and 100ng/ml nRANKL treated 
cells. However, this increase was not as large as that seen with the individual 
50μg/ml BME treatment (156% of 25ng/ml rhOPG and 100ng/ml nRANKL treated 
cells).  
 
5.4 Discussion 
The competing effects of androgens on prostate cancer and bone cells within the 
bone environment can result in a local niche which either favours bone resorption or 
protection of the bone. The absolute levels of OPG and RANKL expression fluctuate 
during the progression of many cancers, including prostate cancer. In vivo models 
have linked RANKL in bone lesion formation and progression associated with 
prostate cancer, with strong evidence that RANKL and RANK are integral to cancer 
cells homing to the bone. This therefore offers pharmacological targets for which a 
recombinant formation of OPG and nRANKL provide interesting potential novel 
therapies.  
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5.4.1 Effect of exogenous rhOPG treatment on LNCaP prostate cancer cells 
Treating the androgen dependent prostate cancer cell line, LNCaP, with exogenous 
rhOPG resulted in a small initial increase in LNCaP cell proliferation which was not 
maintained over 5 days incubation, a similar pattern to that seen in the cytotoxicity 
assay. Of interest was the response of LNCaP cell proliferation, treated with rhOPG, 
to HGF which was similar to the cell proliferation response seen in the non-rhOPG 
treated LNCaP cells to HGF. However, the addition of BME with rhOPG appeared to 
maintain the increase in LNCaP cell proliferation however this trend did not reach 
statistical significance. It again highlights the possibility that OPG may not directly 
affect prostate cancer cell proliferation however; it may facilitate and influence other 
factors, particularly in the bone environment, which ultimately culminate in an 
increase in prostate cancer cell proliferation.  
Corey et al (2005), with variants of LNCaP cells, demonstrated that when C4-2 
prostate cancer cells, which over expressed OPG, were subcutaneously injected 
into mice there was no impact on tumour take rate or tumour growth rate compared 
to the control cells. However, when these OPG over-expressing cells were 
implanted in the bone, tumour volume was significantly decreased. Vandyke et al 
(2007) concluded that androgen stimulation decreased mRNA expression of OPG. 
Therefore, other unidentified modulations, possibly post-transcriptional, might also 
affect the production of OPG and may additionally affect prostate cancer 
progression. This is of particular interest because the C4-2 cell line is believed to be 
the more tumourigenic, androgen responsive, though not dependent, sub-clone of 
the parental LNCaP cell line. This difference in cell behaviour under the influence of 
OPG as the cancer cells switch between androgen dependence and independence 
as replicated in these sub-clones, poses more questions than answers, especially 
when taken into consideration with the evidence by Vandyke et al (2007).   
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Nyambo et al (2004) demonstrated that bone marrow stromal cells in vitro could 
produce enough OPG to protect PC-3 prostate cancer cells from TRAIL induced 
apoptosis. This pattern of behaviour may also be seen in this section of the study 
when the LNCaP cells were treated with both rhOPG and BME though further 
investigation with the addition of TRAIL would be required to confirm this.  Based on 
these observations there therefore needs to be further investigation into which 
pathways may be affected and result in this ultimate increase in prostate cancer cell 
proliferation, whilst also trying to isolate the potential roles androgen sensitivity and 
inhibition of TRAIL apoptosis may play.  
Exogenous rhOPG appeared to have little influence on LNCaP cell-matrix adhesion 
and migration on its own. However, when LNCaP cells were treated individually with 
HGF, BME or HGF and BME in combination both cell-matrix adhesion and migration 
appeared to be affected. HGF treatment appeared to be a pro-migratory factor for 
the LNCaP cell line which was further enhanced when added in addition to 
exogenous rhOPG. This was accompanied by the observation that rhOPG and HGF 
appeared to make the LNCaP cells less adhesive to the artificial matrix (Matrigel). In 
contrast, the more interesting observation was that the addition of rhOPG and BME 
together resulted in a reduced migratory response in the LNCaP cells, whilst cell-
matrix adhesion appeared unaffected. Sikes et al (2004) investigated the 
interactions between bone derived cells and LNCaP and C4-2 prostate cancer cells. 
They concluded that there was no apparent difference between the LNCaP cells 
and the more tumorigenic subclone C4-2, despite the propensity for C4-2 cells to be 
able to spontaneously form ostoeblastic lesions in vivo. Though several integrins 
were noted to have been affected between both cell lines, no evident consequence 
of this was found in their study. Due to the complexity of the bone environment, 
paracrine factors may play a pivotal role in the metastatic process of prostate 
237 
 
cancer cells. This study has therefore provided some evidence to suggest OPG may 
be a factor involved in prostate cancer cells homing to the bone. 
Though in this study, in its own right, rhOPG did not appear to affect LNCaP cell 
migration and resulted in increased cell-matrix adhesion our results potentially 
highlight that OPG could stimulate prostate cancer cell arrest in the bone 
microenvironment, as cells were less migratory under the influence of the inhouse 
bone mix (BME) which would not necessarily be favourable in all clinical settings. 
This has been demonstrated by Kiefer et al (2004) who showed that the 
administration of OPG decreased the growth of LuCAP23.1 cells intra-tibially 
however it did not prevent the establishment of prostate-derived tumours in bone.  
This in vitro and in vivo data may therefore present somewhat of a challenge, as 
there are ongoing clinical trials into the potential of recombinant OPG as a 
pharmaceutical intervention for prostate cancer.  
The most intriguing observation from this section of the study was that the addition 
of rhOPG to the androgen dependent LNCaP cells resulted in a significant decrease 
in LNCaP invasion in vitro. However, this pattern was reversed under the combined 
influence of rhOPG and BME. Of further note was the observation that combined 
HGF and BME under the influence of rhOPG resulted in a significant decrease in 
LNCaP cell invasion in vitro. This pattern of observations supports that of Kiefer et 
al (2004), despite the different cell lines and the fact that this study has only used an 
in vitro model it does appear that there is parity in the overall conclusions that can 
be drawn. OPG may play multiple roles during the course of prostate cancer cells 
metastasising to the bone, influencing a variety of traits, though the impact of these 
treatments also appears, at least somewhat, to vary depending on environmental 
conditions and factors present (e.g. HGF, bone proteins). Therefore using rhOPG as 
a potential therapy may be a double edged sword, further research is required to 
fully understand the complete role OPG plays in prostate cancer, how such a 
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treatment might impact disease progression both in the immediate and long term 
clinical settings and the potential rhOPG may have as a combination therapy.  
 
5.4.2 Effect of exogenous nRANKL treatment on LNCaP prostate cancer cells 
Neutralising RANKL antibody, Denosumab, was licensed in October 2012 for the 
treatment of SREs associated with solid tumours except prostate cancer. The 
purpose of this study was to investigate if targeting RANKL would prevent prostate 
cancer cells from settling in the bone environment and establishing bone 
metastases in vitro.  
The LNCaP prostate cell line used in this study expressed RANKL (Figure 3.1). Hu 
et al (2013) and Chu et al (2014) have demonstrated that RANKL is prevalently 
expressed in human prostate cancer specimens with increasing levels correlating 
with higher tumour grade, metastasis and association with clinical outcome. 
Treating the LNCaP cells with a neutralising RANKL antibody appeared to have little 
effect on LNCaP cell proliferation. As has been previously noted, exogenous HGF 
treatment appeared to result in reduced LNCaP cell proliferation, and this pattern 
continued irrespective of the presence of nRANKL, but was more pronounced in the 
presence of nRANKL. Of interest was the lack of further response in LNCaP cell 
proliferation when nRANKL and BME treatment were combined. There also 
appeared to be little impact on cell-matrix adhesion of LNCaP cells which were also 
under the influence of nRANKL on its own, or under the influence of HGF or BME.  
In contrast, though individually nRANKL treatment appeared to have little impact on 
LNCaP cell migration, the addition of HGF or a combination of HGF and BME both 
resulted in a pro-migratory response in the LNCaP cells. Despite observations that 
the individual HGF treatment in this study was anti-proliferative, its pro-migratory 
response remained present, especially under the influence of nRANKL. This also 
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appeared the case when HGF and BME were added in combination with nRANKL 
to LNCaP cells. Therefore it would be interesting to further investigate by which 
other pathway(s) HGF in combination with nRANKL exerted this pro-migratory 
response in LNCaP cells. It would also be interesting to investigate the pathway(s) 
in which BME and nRANKL appeared to result in a reduced migratory response.    
Addition of nRANKL to LNCaP cells resulted in a notable decrease in cell invasion. 
Huang et al (2006) showed that β2-microglobulin promoted prostate cancer cell 
osteomimicry by inducing RANKL expression. Zhau et al (2008) subsequently 
demonstrated that this induction of RANKL expression promoted EMT in prostate 
cancer cells. These observations agree with the anticipated responses observed in 
this study, with the individual nRANKL treatment, through potential inhibition of EMT 
processes, resulting in significantly decreased LNCaP cell invasion. However, the 
most interesting observations were that the nRANKL response was negated under 
the influence of HGF, whilst BME treatment combined with nRANKL resulted in 
noticeable and almost significant increase in LNCaP cell invasion. Further 
investigation is required to isolate the predominant factors in the bone environment 
which might facilitate this pro-invasive phenotype.    
Unfortunately given the time constraints of this study it was not possible to establish 
stable suppression of RANK in LNCaP cells. Establishment of this cell line in the 
future would allow investigation on how targeting RANK individually and in 
combination with the various treatments, would impact LNCaP cell tumourigenic 
potential.  
Given the complex nature of the metastatic cascade the fight continues to identify 
those individual factors which are pivotal to prostate cancer disease progression 
and therefore provide novel specific therapeutic targets. This section of the study 
has potentially highlighted rhOPG may in the bone environment result in reduced 
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LNCaP cell migration and increased cell invasion, however further investigation into 
how this occurs, and other factors which facilitate this, is required. The role RANKL 
plays in prostate cancer is coming under greater and greater scrutiny, this study has 
provided several cellular traits, migration and invasion, which warrant further 
investigation into how several environmental factors (e.g. HGF and bone proteins) 
influence cellular responses to RANKL.    
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Chapter 6 
Role of OPG, RANK and RANKL in breast cancer 
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6.1 Introduction 
Despite the advancements in breast cancer care and treatments it still remains a 
major health burden in the Western world. Like prostate cancer it is also associated 
with latent disease states and high relapse rates which can re-present clinically as 
bone metastasis, as well as lung, liver and brain metastases. Breast cancer bone 
metastasis, unlikely prostate cancer, generally present phenotypically as osteolytic, 
which are detectable by x-ray. This has been shown to be accompanied by an 
increased number of osteoclasts, which further enhances tumour growth in bone.  
The TNFRSF have previously been studied in breast cancer, especially circulating 
RANKL and OPG, due to their potential as biomarkers for predicting bone 
metastases (Ibrahim et al 2011, Mercatali et al 2011). Reinholz et al (2002) 
examined gene expression of TNF family members, including RANKL and OPG in 
normal, non-invasive, invasive and metastatic human breast cancer specimens. 
OPG expression was unchanged between normal and non-invasive breast tissues 
whilst tissue from liver metastases exhibited increased OPG expression, though no 
other forms of metastases exhibited similar patterns. Van Poznak et al (2006) 
detected OPG expression in 55% of the breast cancer cases studied also noticing a 
correlation with oestrogen status and OPG protein localisation. Several in vitro 
studies have been published demonstrating that OPG expression in breast cancer 
cell lines, MDA-MB-231, MDA-MB-436, MCF-7 and T47D enhance tumour cell 
survival by inhibiting TRAIL induced apoptosis (Neville-Webbe et al 2004, Park et al 
2003, Holen et al 2005). It has also been demonstrated in vitro that the oestrogen 
receptor negative cell line, MDA-MB-231, produces enough OPG to bind TRAIL and 
in turn upregulate RANKL expression thus contributing to the ‘vicious’ bone cycle 
between tumour and bone cells (Nicolin and Narducci 2010). This taken into 
consideration with results from Neville-Webbe et al (2004) and Holen et al (2005) 
suggests that OPG may through this mechanism aid breast cancer cell survival. 
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However, Morony et al (2001) showed that, in vivo, the addition of recombinant 
OPG in a SCID mouse model inhibited tumour growth in bone. Therefore the role 
played by OPG may switch during the course of breast cancer progression.  
Both RANK and RANKL have been implicated in mammary gland development and 
lactation accompanied by other growth factors and cytokines.  Fata et al (2000) 
demonstrated that mice deficient in RANK or RANKL exhibited disturbed mammary 
gland morphogenesis due to decreased differentiation and proliferation as well as 
increased apoptosis in mammary epithelial cells during lactation.  Subsequent 
evidence has also shown that RANK and RANKL are also implicated in mammary 
gland ductal side-branching, alveolar differentiation and lumen formation 
(Fernandez-Valdivia et al 2009, Gonzalez-Suarez et al 2007). Evidence has shown 
that both progesterone and prolactin stimulate RANKL expression in mouse 
mammary and human breast epithelial cells and therefore promote mammary gland 
morphogenesis by stimulating mammary epithelial cell proliferation and inhibiting 
apoptosis (Beleut et al 2010, Tanos et al 2013).  
 The TNFRSF have previously been studied in breast cancer especially, in recent 
years, under the influence of the progesterone axis (Joshi et al 2010, Seifert-Klauss 
et al 2012). A better understanding of the role osteoclasts, RANKL, and its 
association with PTHrP, in a variety of conditions, has led to the exploration of the 
potential to exploit these in therapies, this approach remains under intense 
investigation. This is pivotal given recent evidence that RANKL positively correlates 
with breast cancer cell proliferation and acts in a paracrine manner on RANK 
expressed in oestrogen negative/progesterone negative breast cancer cells 
(Dougall et al 2014). RANKL has also been shown to control the responsiveness of 
mammary gland stem cell and luminal progenitors (Dougall et al 2014).  In 
preclinical breast cancer models targeted RANKL therapies have been shown to 
reduce tumour burden and prevent osteolysis. This has led to the licensing of the 
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neutralising RANKL antibody, Denosuamab for the treatment of breast cancer 
associated SREs. Besides this RANKL, both in vitro and in vivo, has been 
implicated in RANK-expressing breast cancer cell migration and upregulation of 
MMPs which can promote distant metastases (Dougall et al 2014). Taking this into 
consideration, with the knowledge that most clinical options for bone metastases still 
remain management only, a better understanding of the interplay between these 
family members in breast cancer may provide prophylactic opportunities in the 
future.  
The interactions between bone stromal cells and tumour cells are critical in 
metastasis formation (Reddi et al 2003, Neville-Webbe et al 2004). Early work in co-
culture models with breast cancer cells and bone stromal cells showed that primary 
breast cancer specimens and cultured breast tumour cells did not express RANKL, 
but this expression could be induced with stromal or osteoblast interactions, by 
several different tumour secreted factors, and result in enhanced osteoclast 
formation (Thomas et al 1999, Dougall et al 2012).  There is also some evidence 
that interaction with bone marrow stromal cells inhibits OPG production, due to the 
presence of PTHrP, thus altering the RANKL:OPG ratio to favour 
osteoclastogenesis with the net result of aggressive osteolytic bone destruction. 
This can provoke osteoclast formation and metastatic growth (Kakonen and Grundy 
2003, Park et al 2003, Thomas et al 1999).    
In this section of the study, the transcript expression profiles of OPG, RANK and 
RANKL were screened in our clinical breast cancer cohort to assess the 
implications of these molecules in disease progression and prognosis using qPCR. 
This study aimed to establish if targeting OPG or RANK using hammerhead 
ribozyme transgenes influenced MDA-MB-231 breast cancer cell behaviour in vitro. 
Subsequently, this section also aimed to explore the potential effects treatment with 
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exogenous HGF or BME might further impose on the manipulated breast cancer cell 
behaviour in the establishment of osteolytic bone metastases. 
    
6.2 Materials and Methods 
6.2.1 Cell lines and breast cancer tissue 
All data of breast cancer tissues was analysed anonymously and informed verbal 
consent given. As the tissues were collected before the introduction of the Human 
Tissue Act, UK 2004, no written consent was necessary and documentary 
measures not required. Primary breast cancer tissue and matching non-neoplastic 
mammary tissue were collected from the same mastectomy specimens’ immediately 
after surgery and stored at -80oC until use. All the specimens were verified and 
graded by a consultant pathologist, “Normal” is considered background tissue from 
matching mastectomy specimens’ which showed no pathological signs of cancer. At 
time of use RNA concentrations were measured as previously stated in Section 
2.7.3. Based on these concentrations all samples for this study were standardised 
to 50ng and reverse transcription carried out. 
In this study ZR-75-1, MCF-7 and MDA-MB-231 breast cancer cells were used for 
screening. The MDA-MB-231 breast cancer cell line was also used to generate 
empty plasmid control cells (MDA-MB-231pEF6) and transfectants for either OPG or 
RANK knockdown (MDA-MB-231OPGKD, MDA-MB-231RANKKD). Cells were maintained 
in DMEM medium supplemented with 10% FCS and ABS as described previously 
(Section 2.6.1). All transfectants were initially exposed to selection medium (DMEM 
complete medium supplemented with 5µg/ml Blasticidin S) for 10 days. All 
transfectants were subsequently maintained in DMEM complete medium 
supplemented with 0.5µg/ml Blasticidin S, to ensure the plasmid vector was 
retained.  
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All in vitro function assays were conducted in Blasticidin S free medium. 
 
6.2.2 Treatment(s) 
MCF-7 and MDA-MB-231 breast cancer cells, pre-starved in serum free medium for 
12 hours, were treated with a variety of β-oestradiol concentrations (prepared in 
serum free medium). MDA-MB-231 transfectants were treated with 40ng/ml HGF 
and/or 50µg/ml BME. For experimental purposes all treatments were prepared at a 
2x concentrate and added in 100µl volumes in each in vitro function assay carried 
out. 
 
6.2.3 Generation of OPG and RANK ribozyme transgenes and cloning into 
pEF6 plasmid vectors, MDA-MB-231 cell transfection and generation of stable 
transfectants 
Hammerhead ribozymes targeting OPG and RANK were designed and generated 
as previously described in Section 2.9.1 and Table 2.4. Following verification of the 
touchdown PCR, OPG and RANK transgenes were cloned into pEF6 plasmid 
vectors and subsequently transformed in E.coli (Section 2.9.3 and 2.9.4). Correctly 
oriented constructs were then amplified, purified and verified (Section 2.9.5) before 
being transfected into MDA-MB-231 cells using electroporation (Section 2.9.6). 
 
6.2.4 RNA isolation, cDNA synthesis, RT-PCR and qPCR 
RNA isolation was carried out using the TRI reagent kit as described in Section 2.7, 
after which reverse transcription was completed using a high capacity RT kit (full 
details Section 2.7.3). Following RT-PCR, products were separated 
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electrophoretically on an agarose gel and representative images, normalised 
against GAPDH, are shown. All qPCRs were performed and normalised against 
GAPDH as described in Section 2.7.7. Data presented represents results from at 
least 3 independent repeats.  
 
6.2.5 Protein isolation, SDS-PAGE and Western blotting  
Protein lysates were isolated and quantified as described previously (Section 2.8). 
After SDS-PAGE, protein was transferred onto PVDF membrane and subsequently 
probed with specific primary antibody (anti-GAPDH, anti-OPG, anti-RANK) and 
corresponding peroxidase conjugated secondary antibodies (1:1000). Protein bands 
were visualised using the chemiluminescent protein detection kit. At least 3 
independent repeats were carried out of which a representative image is shown. 
 
6.2.6 In vitro cell proliferation assay 
MDA-MB-231 transfectant(s) were seeded at 3x103 cells/well into triplicate 96 well 
plates and incubated for 1, 3 and 5 days with treatments as described in Section 
2.10.1. Following incubation, cells were fixed in 4% formalin (v/v) and stained with 
0.5% crystal violet (v/v). Subsequently, crystal violet stain was extracted from the 
cells using 10% acetic acid (v/v) and the absorbance at 540nm was determined 
using a spectrophotometer. Data presented is the mean percentage control of 4 
independent repeats with SEM. 
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6.2.7 In vitro cell Matrigel adhesion assay 
A 96 well plate was coated with 5ug/well of Matrigel and left to dry as described in 
Section 2.10.2. MDA-MB-231 transfectant(s) were seeded at 4.5x104 cells/well and 
left to adhere for 45 minutes before being fixed in 4% formalin (v/v) and stained with 
0.5% crystal violet (v/v). Four representative images were captured for each well 
and subsequently counted using Image J software. Data presented is the mean 
percentage control of 3 independent repeats with SEM. 
 
6.2.8 In vitro cell migration assay 
The cytodex bead motility assay was used to assess MDA-MB-231 cell motility 
(Section 2.10.3) where briefly, 1x106 cells in 10ml of medium were left to incubate 
with cytodex beads (100µl) overnight. The following day, cells were washed twice 
with fresh medium before being re-suspended in 1.5ml of medium and added to a 
96 well plate in triplicate (100µl/well) and the necessary treatments added. Cells 
were left in an incubator for 4 hours after which the plate was washed, fixed in 4% 
formalin (v/v) and stained with 0.5% crystal violet (v/v). Four representative images 
were captured for each well and subsequently counted.  Data presented is the 
mean percentage control of 3 independent repeats with SEM. 
 
6.2.9 In vitro Matrigel cell invasion assay 
Transwell inserts were coated with 50μg/insert of Matrigel and dried before MDA-
MB-231 cell transfectants were seeded (2x104/100µl) into each insert and incubated 
for 3 days with respective treatments (100µl), as described in Section 2.10.4. 
Following incubation, invaded cells were fixed in 4% formalin (v/v) and stained with 
0.5% crystal violet (v/v). Five representative images were captured per transwell 
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insert and subsequently counted. Data presented is the mean percentage control of 
3 independent repeats with SEM. 
  
6.2.10 In vivo xenograft tumour growth and development model 
The in vivo model was carried out under the strict guidelines of the UK Home Office 
to ensure that the 3R’s were strictly adhered to.  In brief, a 100µl suspension 
containing 1x106 MDA-MB-231 transfectant cells and 0.5mg/ml Matrigel were 
subcutaneously injected into the left and right flanks of 4-6 week old athymic nude 
mice (CD-1) and allowed to develop. The mice were maintained in filter top units 
according to House Office regulations. The mice were weighed and the size of the 
developing tumour measured using vernier callipers under sterile conditions each 
week. At the conclusion of the experiment animals were humanely killed under 
Schedule One and tumours were dissected out if sufficiently sized. 
 
6.3 Results 
6.3 Clinical implications of OPG, RANK and RANKL in breast cancer 
A breast cancer cohort of 133 primary breast cancer tissues specimens and 31 non-
neoplastic matching mammary tissues with 120 months follow up data was available 
for use in this study. This provided the opportunity to explore the potential 
implications OPG, RANK and RANKL may have at a clinical level in breast cancer 
disease progression. Full details of the patient cohort are found in Table 6.1.  
With regards those that were classified as “Died of breast cancer” these were 
identified as a group of patients who had died from the disease irrespective of the 
presence of metastases. For those that were classified as “Died with metastases”, 
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though they had died of breast cancer, this group incorporated those patients in 
which metastases had been detected prior to their deaths.  
 
6.3.1 Expression profiles of OPG, RANK and RANKL in breast cancer samples  
In our cohort, the transcript expression levels of OPG, RANK and RANKL were 
quantified using qPCR. Using this method, transcript levels of OPG, RANK and 
RANKL were found to be reduced in the cancer samples compared to the transcript 
levels detected in the matching non-neoplastic specimens’ (Figure 6.1). However 
none of these reductions in transcript expression were found to be statistically 
significant.  
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Table 6.1: Patients’ clinicopathological information 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Clinical information Patient numbers 
Grade 
Well differentiated 
Moderately differentiated 
Poorly differentiated 
 
24 
43 
7 
TNM stage 
TNM 1 
TNM 2 
TNM 3 
TNM 4 
 
2 
40 
7 
4 
NPI staging 
NPI ˂3.4 
NPI 3.4 –5.4 
NPI ˃5.4 
 
77 
38 
16 
ER status 
Negative (α) 
Positive (α) 
Negative (β) 
Positive (β) 
 
 
75 
38 
91 
24 
Clinical outcome 
Disease free 
Metastasis 
Local recurrence 
Died of breast cancer 
Bone metastasis 
Died with metastasis 
 
90 
7 
5 
16 
8 
23 
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Figure 6.1: Expression profiles of OPG, RANK and RANKL in clinical breast 
cancer 
OPG transcript levels were reduced in malignant breast specimens compared to 
matching non-neoplastic samples (A).  Lower levels of RANK transcript were also 
detected in malignant breast specimens compared with matching non-neoplastic 
samples (B). RANKL transcripts were also reduced in malignant breast specimens 
compared to matching non-neoplastic samples (C). All are normalised against 
GAPDH. Data are mean ± SEM. N= Normal – 28, Tumour – 104. * - p=<0.05, ** - 
p=<0.01 and *** - p=<0.001. 
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Figure 6.2: ER status correlation with RANK and RANKL transcript levels in 
clinical breast cancer 
RANK transcript levels were significantly reduced in breast cancer patients who 
were ERβ positive compared with those who were ERβ negative (A). RANKL 
transcript levels were significantly reduced in breast cancer patients who were ERα 
positive (B) or ERβ positive (C) compared with those who were ERα negative or 
ERβ negative respectively. All are normalised against GAPDH. Data are mean ± 
SEM. N = ERα negative – 67, ERα positive – 34, ERβ negative – 80, ERβ positive – 
24. * - p=<0.05, ** - p=<0.01 and *** - p=<0.001. 
 
 
 
 
 
 
 
 
 
 
254 
 
6.3.2 Oestrogen receptor (ER) status 
The link between oestrogen status and breast cancer progression and prognosis is 
well established. In our cohort RANK transcript levels were found to be significantly 
reduced in ERβ positive samples compared with ERβ negative samples (Figure 6.2 
A p=0.026). RANKL transcripts were shown to be significantly reduced in ERα 
positive samples compared with ERα negative samples (Figure 6.2 B, p=0.039). A 
similar trend was also seen with RANKL transcript levels in ERβ positive samples 
compared with ERβ negative samples (Figure 6.2 C, p=0.036). Similar trends for 
OPG transcript levels were seen in ERα positive and ERβ positive samples 
compared with the ER negative samples, however neither of these reached a 
statistically significant level (Data not shown). 
 
6.3.3 Clinical outcomes of RANK and RANKL in breast cancer 
Given the morbidity and mortality rates associated with osteolytic metastases in 
breast cancer, the potential prognostic implications of OPG, RANK and RANKL 
transcripts in our cohort were also assessed using their survival outcomes. After the 
120 month follow-up of this patient cohort was complete (June 2004), patients were 
divided into four categories: disease free, with metastasis, with local recurrence or 
died due to breast cancer.  
RANK transcript levels were found to be significantly lower in patients with 
metastases (p=0.039) or patients who had died from breast cancer (p=0.0052) 
compared with those who had remained disease free (Figure 6.3 A). In patients who 
had local recurrence however, RANK transcript levels appeared increased 
compared to those who had remained disease free, though this did not reach 
significance. Those who had metastases were further sub-divided into patients with 
or without bone metastases. Patients with bone metastases, displayed the same  
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Figure 6.3: Clinical outcomes based on RANK and RANKL transcript 
expression in clinical breast cancer 
RANK transcript levels were significantly reduced in patients who had metastases 
and those who had died from breast cancer compared with patients who had 
remained disease free (A). Isolating those patients that had bone metastases, 
RANK transcript levels were significantly reduced compared with patients who had 
remained disease free (B). RANKL transcript levels were significantly reduced in 
patients with local recurrence or who had died from breast cancer (C); however in 
those with metastases transcript levels were increased. Isolating those patients that 
had bone metastases, though the trend remained, RANKL transcript levels were 
significantly increased compared with patients who had remained disease free (D). 
All are normalised against GAPDH. Data are mean ± SEM.N= Disease free – 78, 
Metastases – 7, Local recurrence – 5, Died of breast cancer – 14, Bone metastases 
- 8. * - p=<0.05, ** - p=<0.01 and *** - p=<0.001. 
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trend as the general metastases group, showing significant reductions in RANK 
transcript level compared to those patients who remained disease free (Figure 6.3 
B, p=0.022). 
RANKL transcript levels were found to be significantly reduced in patients with local 
recurrence (p=0.035) and patients who had died of disease (p=0.035). In contrast, 
patients with metastases appeared to have increased RANKL transcript levels 
compared with those who had remained disease free, although this did not reach 
significant levels (Figure 6.3 C). However when patients with bone metastases were 
isolated from other metastases groups and compared with those who had remained 
disease free, RANKL transcript levels were significantly increased in the bone 
metastases samples compared with those with other metastases (Figure 6.3 D, 
p=0.05). 
 
6.3.4 Kaplien Meier survival model for OPG, RANK and RANKL in breast 
cancer 
Kaplan Meier survival analysis (Figure 6.4)  showed that patients with higher RANK 
transcripts had significantly longer mean survival rates compared with patients with 
lower RANK transcripts (Figure 6.4 A; 140 months (95% CI 131-148 months) v 125 
months (95% CI 110-139 months) p=0.031). Patients with high RANKL transcripts 
also had significantly longer mean survival rates compared with those with lower 
RANKL transcripts (Figure 6.4 B; 147 months (95% CI 138-156 months) v 117 
months (95% CI 102 – 132months)  p= 0.024). In contrast, high expression levels of 
OPG transcript were found to correlate with significantly poorer mean overall 
survival (108 months (95% CI 84-132 months) compared to patients with lower 
levels of OPG transcript (Figure 6.4 C; 142 months (95% CI 132-151 months) 
p=0.023). Taking these into account, low levels of OPG transcript combined with  
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Figure 6.4: Kaplien Meier survival curves for RANK, RANKL and OPG in 
clinical breast cancer 
Patients with low RANK transcript levels had significantly poorer overall survival 
compared with patients with high RANK transcript levels (A). Low RANKL transcript 
levels also resulted in significantly poorer long term survival compared with high 
RANKL transcript levels (B). Low OPG transcript levels correlated with significantly 
better long term survival compared with patients with high OPG transcript levels (C). 
As a combined power, low RANK and RANKL transcripts but high OPG transcripts 
resulted in poorer long term survival compared with patients who had high RANK 
and RANKL transcript levels but low OPG transcript expression (D). Individual N 
numbers unknown.  * - p=<0.05, ** - p=<0.01 and *** - p=<0.001. 
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high levels of RANK and RANKL transcript expression were used to look at the 
potential combined power which OPG, RANK and RANKL transcripts might have on 
overall survival (Figure 6.4 D). When these factors were combined, patients with low 
OPG and high RANK and RANKL transcripts had significantly longer mean overall 
survival (148 months (95% CI 140-156 months p=0.01)) compared with those 
patients that had high OPG transcript levels and low RANK and RANKL transcript 
levels (112 months (95% CI 94-129 months) p=0.01). 
 
6.4.1 Expression profiles of OPG, RANK and RANKL in β-oestradiol 
treated Breast Cancer cells 
Based on some of the interesting trends which were seen in the breast cancer 
cohort, further investigation into the roles of OPG, RANK and RANKL in breast 
cancer disease progression were investigated in vitro.  
 
6.4.1.1 Expression profiles of OPG, RANK and RANKL in breast cancer cells 
treated with a concentration gradient of β-oestradiol 
Noting the observations of ER status and significant difference in RANK and RANKL 
transcript levels in the clinical cohort, MCF-7 (ER positive) and MDA-MB-231 (ER-
negative) breast cancer cells were treated with several concentrations (10-7, 10-8,   
10-9 and 10-10M) of β-oestradiol for a 2 hour period after which RANK, RANKL and 
OPG transcript levels were assessed using qPCR (Figure 6.5).  
MCF-7 breast cancer cells after treatment with each concentration, exhibited 
significant decreases in RANK transcript levels. The biggest decreases were seen 
in MCF-7 breast cancer cells treated with 10-7M or 10-8M β-oestradiol (Figure 6.5 A, 
p=<0.001 in both cases vs untreated control cells). At the lower treatment 
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concentrations (10-9M and 10-10M), the decreases in RANK transcript were not as 
dramatic, though these were still significant (p=0.01 and 0.04 respectively vs 
untreated control cells). In contrast, in the ER negative breast cancer cell line, MDA-
MB-231 all treatments resulted in an increase in RANK transcript expression (Figure 
6.7 B). RANK transcript expression appeared to increase significantly under 
treatment from 10-8, 10-9 and 10-10M β-oestradiol, though most notably so at 10-8M 
(p=0.01, 0.03 and 0.008 respectively vs untreated control cells).  
Treatment of MCF-7 breast cancer cells with each concentration of β-oestradiol also 
appeared to significantly reduce RANKL transcript levels (Figure 6.5 C). The biggest 
reduction in RANKL transcript expression was seen in MCF-7 cells treated with    
10-8M β-oestradiol (p=<0.001 vs untreated control cells). At all other concentrations 
tested (10-7, 10-9 and 10-10M) RANKL transcript expression also appeared to be 
significantly decreased compared to the control, though these were not as dramatic 
as that seen at the 10-8M treatment (p=0.04, 0.04 and 0.01 respectively vs untreated 
control cells).   As was observed with the RANK transcript levels, when MDA-MB-
231 breast cancer cells were exposed to each of the β-oestradiol concentrations 
increases in RANKL transcript were observed. The most notable and significant 
increase in RANKL transcript occurred at β-oestradiol concentration 10-8M (p=0.006 
vs untreated control cells). RANKL transcript levels also appeared significantly 
increased at all the other concentrations tested (10-7, 10-9 and 10-10M) compared to 
the untreated MDA-MB-231 cells (p=0.009 and <0.001 respectively vs untreated 
control cells). 
When MCF-7 breast cancer cells were treated with each concentration of β-
oestradiol there appeared to be no significant overall trends observed on OPG 
transcript levels (Figure 6.5 E). At the lowest concentration tested (10-10M), OPG 
transcript was significantly reduced compared to the untreated MCF-7 breast cancer 
treated with different β-oestradiol concentrations (10-7, 10-9 and 10-10M) a general  
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Figure 6.5: RANK, RANKL and OPG transcript levels in response to β-
oestradiol treatment over a concentration gradient 
RANK  and RANKL transcript levels were significantly reduced in MCF-7 cells (A 
and C respectively) but significantly increased in MDA-MB-231 cells (B and D 
respectively) treated with different concentrations of β-oestradiol. OPG transcript 
levels fluctuated in β-oestradiol treated MCF-7 cells (E), but generally resulted in a 
significant increase in OPG transcript levels in MDA-MB-231 cells (F). Data shown 
is representative values from one independent repeat normalised against GAPDH 
with SD. *- p=<0.05, **- p=<0.01, *** - p=<0.001 
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cells (p=0.04 vs untreated control cells). In contrast, when MDA-MB-231 cells were 
significant increase in OPG expression was seen (Figure 6.5 F, p=0.02, <0.01 and 
0.01 respectively vs untreated control cells). 
 
6.4.1.2 Expression profiles of OPG, RANK and RANKL in β-oestradiol treated 
breast cancer cells in a time course 
Using the results from the concentration gradients, a time course on MCF-7 and 
MDA-MB-231 breast cancer cells with β-oestradiol treatment (10-9M) was also 
carried out, after which RANK, RANKL and OPG transcript levels were 
subsequently screened using qPCR (Figure 6.6).   
MCF-7 breast cancer cells incubated with β-oestradiol, initially resulted (0.5 hour 
and 1 hour) in a slight, though insignificant, decrease in RANK transcript expression 
compared to the control cells. However, after 2 hours incubation a significant 
increase and peak in RANK transcript levels was observed (Figure 6.6 A, p=<0.001 
vs untreated control cells).  At the following two time points, 4 hours and 24 hours, 
RANK transcript levels still remained significantly elevated compared with the 
control MCF-7 breast cancer cells (p=0.005 and 0.02 respectively), however these 
levels were not as high as those that had been observed after 2 hours. In contrast, 
the MDA-MB-231 breast cancer cells, showed a reduction in RANK transcript 
expression which was evident after 0.5 hour, however this reduction in RANK 
transcript levels did not reach  a significant level until 1 hour incubation (Figure 6.6 
B, p=0.01). This significant reduction in RANK transcript was maintained for all the 
time points studied (p=0.03, 0.005 and 0.04), but lowest levels were observed after 
4 hours incubation.   
As seen with the RANK transcript levels, incubation of MCF-7 cells with β-oestradiol 
resulted in an initial decline in RANKL transcript levels (0.5 hour and 1 hour), before  
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Figure 6.6: RANK, RANKL and OPG transcript levels in response to β-
oestradiol treatment over time 
RANK and RANKL transcript levels were significantly increased in MCF-7 cells after 
2 hours, 4 hours and 24 hours after treatment (A and C respectively). In MDA-MB-
231 cells RANK and RANKL transcript levels were significantly reduced at all the 
time points studied (B and D respectively).OPG transcript expression was 
significantly reduced in both MCF-7 (E) and MDA-MB-231 (F) treated cells. Data 
shown is representative values from one independent repeat normalised against 
GAPDH with SD. *- p=<0.05, **- p=<0.01, *** - p=<0.001 
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significantly increasing and peaking after 2 hours incubation (Figure 6.6 C, 
p=0.006). RANKL transcript levels subsequently appeared to reduce, though even 
after 4 hours incubation with β-oestradiol RANKL transcript levels remained 
significantly increased compared with control MCF-7 cells (p=0.02). MDA-MB-231 
cells incubated with β-oestradiol resulted in a significant decrease in RANKL 
transcript expression, which was maintained through each of the time points studied 
(Figure 6.6 D). The biggest decrease in RANKL transcript was observed at the first 
time point (0.5 hour, p=0.002). In each of the subsequent time points studied, small 
recoveries were seen in RANKL transcript levels, however the level of RANKL 
transcript still remain significantly lower compared to the control cells (p=0.05, 0.01 
and 0.002 respectively). 
Interestingly, OPG transcript levels were significantly affected in both MCF-7 and 
MDA-MB-231 breast cancer cells when incubated with β-oestradiol over a 24 hour 
period (Figures 6.6 E and F respectively). Though an initial increase in OPG 
transcript levels was seen at 0.5 hour in the MCF-7 breast cancer cells, most 
subsequent time points studied show a significant decrease in OPG transcript levels 
compared to the control cells (Figure 6.6 E, all p=<0.001). The minor recovery in 
OPG transcript levels observed after 4 hours incubation was also close to being 
noted as a significant decrease compared to the control cells (p=0.07). The MDA-
MB-231 cells incubated with β-oestradiol also resulted in significant decreases in 
OPG transcript levels (Figure 6.6 F). There appeared to be an initial significant 
decrease in OPG transcript levels after 0.5 and 1 hour incubations (p=0.003 and 
0.01 respectively). Interestingly, after 2 hours incubation with β-oestradiol, OPG 
levels appear to recover to similar levels observed in the control cells. However, this 
recovery is not sustained, cells incubated with β-oestradiol for 4 hours or 24 hours, 
appeared to show significant reductions which were initially observed in the time 
course experiment (p=0.02). 
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6.4.2 Role of OPG in MDA-MB-231 cells in vitro and in vivo 
6.4.2.1 Confirmation of ribozyme transgene knockdown of OPG expression in 
MDA-MB-231 breast cancer cells 
Expression of OPG was successfully targeted in MDA-MB-231 breast cancer cells 
following transfection with an anti-OPG ribozyme transgene contained within a pEF6 
plasmid (Figure 6.7). Following RNA isolation, RT-PCR and qPCR showed 
significantly reduced OPG transcript expression in MDA-MB-231OPGKD cells to the 
MDA-MB-231pEF6 control cells (Figures 6.7 A and B respectively). Western blot 
analysis subsequently confirmed the knockdown of OPG at a protein level in 
comparison to the MDA-MB-231pEF6 control cells (Figure 6.7 C).   
 
6.4.2.2 Effect of OPG suppression on MDA-MB-231 cell proliferation in vitro 
Reduced OPG expression in MDA-MB-231 breast cancer cells resulted initially in an 
increase in cell proliferation compared to the MDA-MB-231pEF6 control cells (132% 
compared to control) (Figure 6.8 A); however, this trend did not reach significance. 
This trend was not continued over a 5 day incubation period (Figure 6.8 B). MDA-
MB-231OPGKD cells actually showed no difference in cell proliferation compared to 
the MDA-MB-231pEF6 control cells (98% compared to control).   
When MDA-MB-231pEF6 control cells were treated with 40ng/ml HGF, 50µg/ml BME 
or a combination of 40ng/ml HGF and 50µg/ml BME, after 3 days incubation all 
treatments resulted in increased cell proliferation (113%, 131% and 129% of 
untreated control respectively) (Figure 6.8 C). However none of these reached 
significant levels. This trend of increased MDA-MB-231pEF6 control cell proliferation 
continued over the 5 day incubation period as well (116%, 117% and 113% of 
untreated control respectively) (Figure 6.8 D). After 5 days incubation with 40ng/ml  
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Figure 6.7: Verification of ribozyme transgene knockdown of OPG in MDA-MB-
231 cells 
Reduced expression of OPG was confirmed at a transcript level using RT-PCR (A) 
and qPCR (B) compared to the control cell line. Western blot (C) was used to 
confirm knockdown of OPG at a protein level. PCR and Western blot were 
normalised against GAPDH. Control = Nuclease free water and all gels were ran 
with a molecular weight marker used to identify band sizes.  Representative images 
and data shown. * - p=<0.05, ** - p=<0.01 and *** - p=<0.001. 
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Figure 6.8: Impact of OPG knockdown on MDA-MB-231 cell proliferation in 
vitro 
Reduced OPG expression resulted in increased MDA-MB-231 cell proliferation after 
3 days incubation (A) compared to control cells, however this trend was not 
continued over 5 days incubation (B). Treatment of the MDA-MB-231pEF6 control cell 
line with 40ng/ml HGF, 50μg/ml BME or a combination of 40ng/ml HGF and 50μg/ml 
BME resulted in an increase in cell proliferation after 3 days incubation (C), which 
reached significant levels after 5 days incubation (D). Treatment of MDA-MB-
231OPGKD cells with 40ng/ml HGF, 50μg/ml BME or a combination of 40ng/ml HGF 
and 50μg/ml BME resulted in a minor increased in cell proliferation after 3 days (E) 
which was not seen after 5 days (F). Data represents mean of 4 independent 
repeats, error bars represent SEM. * - p=<0.05, ** - p=<0.01 and *** - p=<0.001. 
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HGF or 50µg/ml BME, MDA-MB-231pEF6 control cell proliferation was shown to be 
significantly increased (p=0.029). However, in the combined treatment of 40ng/ml 
HGF and 50µg/ml BME resulted in increased MDA-MB-231pEF6 control cell 
proliferation, this also did not reach significance. 
When MDA-MB-231OPGKD cells were incubated with 40ng/ml HGF for 3 days, there 
was a small but non-significant decrease in cell growth (92% of untreated control) 
(Figure 6.8 E). When MDA-MB-231OPGKD cells were incubated with 50µg/ml BME, 
for 3 days, a very small increase in cell proliferation was observed, which was 
deemed significant (105% of untreated control, p=0.029). A similar observation was 
seen when MDA-MB-231OPGKD cells were incubated with combined treatment of 
40ng/ml HGF and 50µg/ml BME, however this did not reach significance (106% of 
untreated control). When MDA-MB-231OPGKD cells were incubated with 40ng/ml HGF 
or 50µg/ml BME for 5 days, no apparent difference was seen between the treated 
and untreated MDA-MB-231OPGKD cells (99% and 100% of untreated control 
respectively) (Figure 6.8 F). When MDA-MB-231OPGKD cells were incubated with a 
combined treatment of 40ng/ml HGF and 50µg/ml BME for 5 days, a minor 
decrease in cell MDA-MB-231OPGKD cell proliferation was observed however this 
again did not reach significance (92% of untreated control).  
 
6.4.2.3 Suppression of OPG reduces MDA-MB-231 cell-matrix adhesion in vitro 
MDA-MB-231OPGKD cells showed reduced cell-matrix adhesion in vitro compared to 
MDA-MB-231pEF6 control cells (88% compared to control), however this change did 
not reach a significant level (Figure 6.9 A). 
Treatment of MDA-MB-231pEF6 control cells with 40ng/ml HGF or 50µg/ml BME did 
not appear to have any significant impact on cell-matrix adhesion in vitro (105% and 
102% of untreated control) (Figure 6.9 B representative images from one repeat in 
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Figure 6.9 D). Interestingly when MDA-MB-231pEF6 control cells were treated with 
both 40ng/ml HGF and 50µg/ml BME a very small decrease in cell-matrix adhesion 
was observed (95% of untreated control), though again this trend was not 
significant.  
As seen with the MDA-MB-231pEF6 control cells, when MDA-MB-231OPGKD cells were 
treated with 40ng/ml HGF a small non-significant increase in cell-matrix adhesion 
was observed (107% of untreated control) (Figure 6.9 C). Interestingly, when MDA-
MB-231OPGKD cells were treated with 50µg/ml BME a small decrease in cell-matrix 
adhesion was observed (92% of untreated control), however this did not reach 
significance. Of further interest was when MDA-MB-231OPGKD cells were treated with 
a combination of 40ng/ml HGF and 50µg/ml BME cell-matrix adhesion was 
significantly decreased compared to untreated MDA-MB-231OPGKD cells (83% of 
untreated control, p=0.024). 
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 Figure 6.9: Impact of reduced OPG expression in MDA-MB-231 cells on cell-
matrix adhesion in vitro 
Reduced OPG expression resulted in a small but non-significant decrease in MDA-
MB-231 cell-matrix adhesion compared with control cells (A). When MDA-MB-
231pEF6 control cells were treated with 40ng/ml HGF or 50μg/ml BME, small 
increases in cell-matrix adhesion were seen (B), however combination of these 
treatments resulted in a decrease in cell-matrix adhesion. In the MDA-MB-231OPGKD 
cells were treated with 40ng/ml HGF cell-matrix adhesion increased, however under 
50μg/ml BME or combined HGF and BME treatment cell matrix adhesion 
decreased. Representative images from one repeat (D). Data represents mean of 4 
independent repeats, error bars represent SEM. * - p=<0.05, ** - p=<0.01 and *** - 
p=<0.001. 
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6.4.2.4 OPG suppression significantly increases MDA-MB-231 cell motility in 
vitro 
Knockdown of OPG in MDA-MB-231 cells resulted in significantly increased cell 
motility compared to the MDA-MB-231pEF6 control cells (314% compared to control) 
(Figure 6.10 A, p=0.029).  
When the MDA-MB-231pEF6 control cells were treated with 40ng/ml HGF an increase 
in cell motility was observed (133% of untreated control), however this was not 
deemed significant (Figure 6.10 B). Interestingly when the MDA-MB-231pEF6 control 
cells were treated with 50µg/ml BME a small non-significant decrease in cell motility 
was observed (93% of untreated control). However, when 40ng/ml HGF and 
50µg/ml BME were combined, MDA-MB-231pEF6 control cells showed a significant 
increase in MDA-MB-231 cell motility (117% of untreated control, p=0.029). 
MDA-MB-231OPGKD cells treated with 40ng/ml HGF or 50µg/ml BME showed a 
decrease in cell motility compared to the untreated MDA-MB-231OPGKD cells (83% 
and 85% of untreated control respectively) (Figure 6.10 C). Interestingly, when 
MDA-MB-231OPGKD cells were treated with both 40ng/ml HGF and 50µg/ml BME an 
increase in cell motility was observed (112% of untreated control); however this did 
not reach significance.  
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Figure 6.10: Effect of OPG knockdown on MDA-MB-231 cell motility 
MDA-MB-231OPGKD cells showed significantly increased motility compared with 
MDA-MB-231pEF6 control cells (A). Treatment of MDA-MB-231pEF6 control cells with 
40ng/ml HGF or a combination of 40ng/ml HGF and 50μg/ml BME increased cell 
motility (B), though solo treatment of 50μg/ml BME appeared to have little effect. 
Treatment of MDA-MB-231OPGKD cells with 40ng/ml HGF or 50μg/ml BME resulted in 
a decrease in cell motility (C), however the combined treatment of 40ng/ml HGF and 
50μg/ml BME resulted in an increase in cell motility. Representative images from 
one repeat (D). Data represents mean of 4 independent repeats, error bars 
represent SEM. * - p=<0.05, ** - p=<0.01 and *** - p=<0.001. 
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6.4.2.5 OPG suppression significantly enhanced MDA-MB-231 cell invasion in 
vitro 
 When OPG expression was reduced in MDA-MB-231 cells, cell invasion in vitro 
was significantly increased compared to the MDA-MB-231pEF6 control cells (137% of 
control) (Figure 6.11 A, p=0.037).  
When MDA-MB-231pEF6 control cells were treated with 40ng/ml HGF cell invasion 
was increased (118% of untreated control), however this result did not reach 
significance (Figure 6.11 B). A similar trend was seen when MDA-MB-231pEF6 
control cells were treated with 50µg/ml BME (126% of untreated control), a result 
which just reached significance (p=0.05). However when 40ng/ml HGF and 50µg/ml 
BME were added together to MDA-MB-231pEF6 control cells, there was no difference 
in cell invasion compared to the untreated MDA-MB-231pEF6 control cells (104% of 
untreated control cells). 
When the same treatments were added to MDA-MB-231OPGKD cells no further 
increase in cell invasion was observed. The 40ng/ml HGF treatment resulted in a 
significant decrease in MDA-MB-231OPGKD cell invasion (92% of untreated control) 
(Figure 6.11 C, p=0.002). This decrease observed in cell invasion after the HGF 
treatment resulted in levels returning to similar levels observed in untreated MDA-
MB-231pEF6 control cells as seen in the representative images (Figure 6.11 D) (Data 
not shown). Treatment of MDA-MB-231OPGKD cells with 50µg/ml BME resulted in a 
noticeable decrease in MDA-MB-231 cell invasion (83% of untreated control), as 
seen in the representative images (Figure 6.11 D); however this trend was not found 
to be significant. Treatment of MDA-MB-231OPGKD cells with 40ng/ml HGF and 
50µg/ml BME also resulted in a significant decrease in MDA-MB-231 cell invasion in 
vitro (90% of untreated control) (p=0.013).  
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Figure 6.11: Impact of reduced OPG expression on MDA-MB-231 cell invasion 
in vitro 
MDA-MB-231OPGKD cells showed significantly increased cell invasion compared with 
MDA-MB-231pEF6 control cells (A). Treatment of MDA-MB-231pEF6 control cells with 
40ng/ml HGF, 50μg/ml BME or a combination of 40ng/ml HGF and 50μg/ml BME 
increased cell invasion (B). Treatment of MDA-MB-231OPGKD cells with 40ng/ml 
HGF, 50μg/ml BME or a combination of 40ng/ml HGF and 50μg/ml BME resulted in 
a decrease in cell invasion. Representative images from one repeat (D). Data 
represents mean of 3 independent repeats, error bars represent SEM. * - p=<0.05, 
** - p=<0.01 and *** - p=<0.001. 
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6.4.2.6 OPG suppression significantly increased MDA-MB-231 cell growth in 
vivo 
A preliminary in vivo study was conducted using a xenograft model in athymic mice 
(Figure 6.12). The MDA-MB-231OPGKD cells, subcutaneously inoculated, showed a 
significant increase in growth and tumour development compared to the MDA-MB-
231pEF6 control cells (p=˂0.001). This reflected the increased MDA-MB-231 cell 
proliferation that was initially observed in vitro after 3 days incubation, though does 
not support the observations from the extended incubation period (5 days) (Figure 
6.8 A).  
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Figure 6.12: Effect of MDA-MB-231OPGKD on cell growth in vivo 
 In the xenograft model, MDA-MB-231OPGKD cells showed a significant increase in 
growth compared to the MDA-MB-231pEF6 control cells (p=˂0.001). Tumour volume 
= 0.523xWidth2xlength. N for each group = 6. 
 
 
 
 
 
 
 
 
 
 
* 
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6.4.3 Role of RANK in MDA-MB-231 cells in vitro 
6.4.3.1 Confirmation of ribozyme transgene knockdown of RANK expression 
in MDA-MB-231 breast cancer cells 
Expression of RANK was successfully targeted in MDA-MB-231 breast cancer cells 
following transfection with an anti-RANK ribozyme transgene contained within a 
pEF6 plasmid (Figure 6.13). Following RNA isolation, RT-PCR and qPCR showed 
successful knockdown of RANK expression in MDA-MB-231 cells at a transcript 
level compared to the MDA-MB-231pEF6 control cell line (Figures 6.13 A and B 
respectively). Western blot analysis subsequently confirmed the knockdown of 
RANK at a protein level compared to the MDA-MB-231pEF6 control cells (Figure 6.13 
C).   
 
6.4.3.2 RANK suppression significantly reduces MDA-MB-231 breast cancer 
cell growth in vitro 
Suppression of RANK expression in MDA-MB-231 cells resulted in a decrease in 
MDA-MB-231 cell proliferation after 3 day incubation compared with MDA-MB-
231pEF6 control cells (91% compared to control) (Figure 6.14 A), a trend which 
reached significance after 5 days incubation (53% compared to control) (Figure 6.14 
B, p=0.029).  
When MDA-MB-231pEF6 control cells were treated with 40ng/ml HGF after 3 days 
incubation, MDA-MB-231 cell proliferation was increased (113% of untreated 
control) (Figure 6.14 C). This was a trend which continued after 5 days incubation at 
which point it reach significance (Figure 6.14 D, 116% of untreated control, 
p=0.029). A similar trend was observed in MDA-MB-231pEF6 control cells treated 
with 50µg/ml BME, which after 5 days incubation resulted in MDA-MB-231pEF6  
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Figure 6.13: Verification of successful ribozyme transgene knockdown of 
RANK expression in MDA-MB-231 cells 
Reduced expression of RANK was confirmed at a transcript level using RT-PCR (A) 
and qPCR (B) compared to the control cell line. Western blot (C) was used to 
confirm knockdown of RANK at a protein level. PCR and Western blot were 
normalised against GAPDH. Control = Nuclease free water and all gels were ran 
with a molecular weight marker used to identify band sizes.   Representative images 
and data shown. * - p=<0.05, ** - p=<0.01 and *** - p=<0.001. 
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Figure 6.14: Effects of reduced RANK expression on MDA-MB-231 cell 
proliferation in vitro 
Reduced RANK expression in MDA-MB-231 cells resulted in a decrease in cell 
proliferation after 3 days incubation (A) which became significant after 5 days 
incubation (B) compared with control cells. Treatment of the MDA-MB-231pEF6 
control cell line with 40ng/ml HGF, 50μg/ml BME or a combination of 40ng/ml HGF 
and 50μg/ml BME resulted in an increase in cell proliferation after 3 days incubation 
(C), which reached significant levels after 5 days incubation (D). Treatment of MDA-
MB-231RANKKD cells with  40ng/ml HGF, 50μg/ml BME or a combination of 40ng/ml 
HGF and 50μg/ml BME resulted in an increase in cell proliferation after 3 days 
incubation (E), however this trend was not seen over a 5 day incubation period (F). 
Data represents mean of 4 independent repeats, error bars represent SEM. * - 
p=<0.05, ** - p=<0.01 and *** - p=<0.001. 
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treated cells showing a significant increase in cell proliferation (131% of untreated 
control after 3 days incubation, 117% of untreated control after 5 days incubation, 
p=0.029). The combination of 40ng/ml HGF and 50µg/ml BME, after 3 and 5 days 
incubation also resulted in increased cell proliferation (129% and 113% of untreated 
control respectively) (Figure 6.14 C and D respectively). However, neither of these 
increases reached significant levels. 
When MDA-MB-231RANKKD cells were treated with 40ng/ml HGF non-significant 
differences in cell proliferation were observed after 3 and 5 days incubation 
compared with untreated MDA-MB-231RANKKD cells (106% and 101% of untreated 
control respectively) (Figure 6.14 E and F respectively). MDA-MB-231RANKKD cells 
incubated with 50µg/ml BME for 3 days resulted in a significant increase in cell 
proliferation compared with untreated MDA-MB-231RANKKD cells (111% of untreated 
control, p=0.029). However, this trend was not continued to the 5 day incubation 
period, in the 50µg/ml BME MDA-MB-231RANKKD cell proliferation was actually 
slightly reduced compared with the untreated MDA-MB-231RANKKD cells (95% of 
untreated control) (Figure 6.14 F). When MDA-MB-231RANKKD cells were treated with 
40ng/ml HGF and 50µg/ml BME after 3 days incubation, cell proliferation was 
significantly increased compared with untreated MDA-MB-231RANKKD cells (Figure 
6.14 E, 107% of untreated control, p=0.029). This trend was not continued over the 
5 day incubation period, the combined treatment of 40ng/ml HGF and 50µg/ml BME 
resulted in a slight decrease in MDA-MB-231RANKKD cell proliferation (97% of 
untreated control), though again like the individual 50µg/ml BME treatment this 
decrease did not reach significance (Figure 6.14 F).   
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6.4.3.3 RANK suppression significantly reduces MDA-MB-231 breast cancer 
cell-matrix adhesion  
Reduced RANK expression in MDA-MB-231 cells resulted in a significant decrease 
in cell-matrix adhesion in vitro compared with MDA-MB-231pEF6 control cells (55% of 
control) (Figure 6.15 A, p=0.029, representative images Figure 6.15 D).  
Treatment of MDA-MB-231pEF6 control cells with 40ng/ml HGF or 50µg/ml BME 
resulted in minor increases in cell-matrix adhesion in vitro (105% and 102% of 
untreated control respectively) (Figure 6.15 B). Both these trends were negligible 
and non-significant compared to the untreated MDA-MB-231pEF6 control cells. 
However, when MDA-MB-231pEF6 control cells were treated with both 40ng/ml HGF 
and 50µg/ml BME a decrease in cell-matrix adhesion was observed (95% of 
untreated control), though again this difference was not great enough to be 
significant.  
MDA-MB-231RANKKD cells under the influence of 40ng/ml HGF resulted in an 
increase in cell-matrix adhesion (130% of untreated control), however this increase 
was not significant (Figure 6.15 C). When MDA-MB-231RANKKD cells were treated 
with 50µg/ml BME an increase in cell-matrix adhesion was observed (143% of 
untreated control), this was a greater increase than that seen after treatment with 
40ng/ml HGF, though again this trend did not reach significance (p=0.343). A similar 
pattern was also seen when MDA-MB-231RANKKD cells were treated with 40ng/ml 
HGF and 50µg/ml BME. An increase in cell-matrix adhesion was observed (124% of 
untreated control), though this trend was not as dramatic as that seen under the 
individual treatments, and therefore did not reach significance.  
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Figure 6.15: Effect of RANK knockdown on cell-matrix adhesion in MDA-MB-
231 cells in vitro 
Reduced RANK expression resulted in a significant decrease in MDA-MB-231 cell-
matrix adhesion compared with control cells (A). When MDA-MB-231pEF6 control 
cells were treated with 40ng/ml HGF or 50μg/ml BME, small increases in cell-matrix 
adhesion were seen (B), however combination of these treatments resulted in a 
decrease in cell-matrix adhesion. MDA-MB-231RANKKD cells treated with 40ng/ml 
HGF, 50μg/ml BME or combined HGF and BME increases in cell-matrix adhesion 
were seen compared with untreated MDA-MB-231RANKKD cells. Representative 
images from one repeat (D). Data represents mean of 4 independent repeats, error 
bars represent SEM. * - p=<0.05, ** - p=<0.01 and *** - p=<0.001. 
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6.4.3.4 RANK suppression significantly reduced MDA-MB-231 breast cancer  
cell motility in vitro  
MDA-MB-231RANKKD cells exhibited significantly decreased cell motility compared to 
MDA-MB-231pEF6 control cells (53% of control) (Figure 6.16 A, p=<0.001, 
representative images in Figure 6.16 D). Though cell motility decreased, cell 
aggregation appeared similar in both the MDA-MB-231RANKKD cells and the MDA-
MB-231pEF6 control cells. 
MDA-MB-231pEF6 control cells treated with 40ng/ml HGF, 50µg/ml BME or a 
combination of 40ng/ml HGF and 50µg/ml BME resulted in increased cell motility 
(113%, 104% and 105% of untreated control respectively), though none of these 
trends reached significance (Figure 6.16 B). Cell aggregation appeared to be a 
major trend in these treated cells (Representative images Figure 6.16 D). 
Similar responses to each treatment were seen in the MDA-MB-231RANKKD cells. 
MDA-MB-231RANKKD cell treated with 40ng/ml HGF resulted in an increase in cell 
motility compared to the untreated MDA-MB-231RANKKD cells (119% of untreated 
control); however this did not reach a significant level (Figure 6.16 C). Similar 
observations were also seen with MDA-MB-231RANKKD cells that had been treated 
with 50µg/ml BME (113% of untreated control) or a combination of 40ng/ml HGF 
and 50µg/ml BME (111% of untreated control). Both these trends did not reach 
significance. In the individual 40ng/ml HGF or 50µg/ml BME treatments MDA-MB-
231RANKKD cells appeared to be less aggregated compared to the untreated cells and 
the combined 40ng/ml HGF and 50µg/ml BME treated cells. 
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Figure 6.16: Effect of reduced RANK expression on MDA-MB-231 cell motility 
Reduced RANK expression resulted in a significant decrease in MDA-MB-231 cell 
motility compared to MDA-MB-231pEF6 control cells (A). MDA-MB-231pEF6 control 
cells treated with 40ng/ml HGF, 50µg/ml BME or a combination of 40ng/ml HGF and 
50µg/ml BME resulted in increased cell motility (B). A similar trend was observed 
when MDA-MB-231RANKKD cells were treated with the same treatments (C). 
Representative images from one repeat (D). Data represents mean of 3 
independent repeats, error bars represent SEM. * - p=<0.05, ** - p=<0.01 and *** - 
p=<0.001. 
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6.4.3.5 RANK suppression significantly reduces MDA-MB-231 breast cancer 
cell invasion in vitro 
Reduced RANK expression in MDA-MB-231 cells resulted in significantly decreased 
cell invasion in vitro compared with MDA-MB-231pEF6 control cells (64% of control) 
(Figure 6.17 A, p=0.002).   
When MDA-MB-231pEF6 control cells were treated with 40ng/ml HGF or 50µg/ml 
BME no effects on cell invasion was observed (101% and 102% compared to 
untreated control respectively) (Figure 6.17 B). However when 40ng/ml HGF and 
50µg/ml BME were added together to MDA-MB-231pEF6 control cells, cell invasion 
was significantly decreased in relation to untreated MDA-MB-231pEF6 control cells 
(82% of untreated control, p=0.031) (Figure 6.17 D). 
Interestingly, treatment of MDA-MB-231RANKKD cells with 40ng/ml HGF resulted in an 
increase in cell invasion compared to the untreated MDA-MB-231RANKKD cells (125% 
compared to untreated control), a similar pattern mirrored by MDA-MB-231RANKKD 
cells treated with 50µg/ml BME (122% of untreated control), however both these 
trends did not reach significance (p=0.23 and 0.44 respectively) (Figure 6.17 C). A 
combined treatment of 40ng/ml HGF and 50µg/ml BME also resulted in a non-
significant increase in MDA-MB-231RANKKD cell invasion (106% of untreated control); 
however this increase was not as dramatic as that observed under the individual 
treatments. 
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Figure 6.17: Effect of RANK knockdown on MDA-MB-231 cell invasion in vitro 
 MDA-MB-231RANKKD cells showed reduced cell invasion compared with MDA-MB-
231pEF6 control cells (A). When MDA-MB-231pEF6 control cells were treated with 
40ng/ml HGF or 50μg/ml BME cell invasion increased, however the combined 
40ng/ml HGF and 50μg/ml BME treatment decreased cell invasion (B).  MDA-MB-
231RANKKD cells treated with 40ng/ml HGF, 50μg/ml BME or combined 40ng/ml HGF 
and 50μg/ml BME increases in cell invasion were seen (C). Representative images 
from one repeat (D). Data represents mean of 3 independent repeats, error bars 
represent SEM. * - p=<0.05, ** - p=<0.01 and *** - p=<0.001. 
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6.5 Discussion  
With a combined effort from surgeons, oncologists and researchers primary 
treatments for breast cancer have improved, however one aspect of the disease 
which still remains poorly understood and controlled is its metastatic spread. 
Though some advances have been made in the treatment of SREs, such as the 
licensing of Denosumab, no preventative or screening tools are yet available to aid 
medics in the identification of those patients most at risk. In conducting this study 
the aim was to elucidate the potential impact targeting these molecules might have 
on breast cancer cell tumourigenesis.     
 
6.5.1 Role of OPG, RANK and RANKL in clinical breast cancer  
It is well known that breast carcinomas have the ability to metastasise to the bone; 
however, the mechanisms by which these are established remains unknown. The 
findings for OPG, RANK and RANKL expression in breast cancer tissues remain 
controversial. The clinical cohort data derived from this study indicated that RANK, 
RANKL and OPG transcripts were all reduced in tumour samples versus normal 
breast tissues. Thomas et al (1999) reported OPG mRNA expression, but no 
RANKL expression in 12 different primary breast cancer specimens. However, 
Reinholz et al (2002) reported detection of RANKL mRNA in a series of breast 
tumours. Holen et al (2005) found that there was a significant decrease in tumour 
OPG expression with increasing tumour grade. Though this study did not find an 
association between tumour grade and OPG expression a trend was identified in 
which OPG expression was decreased in tumour samples compared to normal 
breast tissue.  Van Poznak et al (2006) showed IHC staining for OPG and RANKL in 
non-neoplastic breast tissue localised to different sub-cellular compartments. Whist 
Cross et al (2006a) demonstrated that, in their large study, RANKL expression was 
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apparently lost in the majority of breast cancer cases which supports the pattern of 
reduced RANKL transcript levels seen in the tumour samples in this study. Of 
further note from the Cross et al (2006a) study was the negative association 
between RANKL and ER status. This corroborates the connection between RANKL 
and ER status found in this study.  ER levels are well known to affect the clinical 
outcome of breast cancer patients.  
In our clinical cohort, reduced expression of RANK was found to be significantly 
associated with metastases and with patients who had died from the disease.  In 
contrast RANKL expression appeared increased in patients with metastases but 
reduced in patients who had local recurrence or who had died from the disease.   
This was also supported by the Kaplien Meier curves in which both low RANK and 
low RANKL expression showed poor prognosis. This contradicts the microarray 
study by Santini et al (2011) which concludes that high RANK expression in their 
early stage breast cancer patients is predictive of worse prognosis. In contrast to the 
RANK and RANKL expression profiles, it was higher levels of OPG expression 
which correlated with a poorer overall survival in the current study, though again this 
contradicts the Santini et al (2011) and Van Poznak et al (2006) studies. Of interest 
from the Kaplein Meier survival curves was the statistically significant result that low 
RANK, low RANKL and high OPG expression resulted in poorer overall survival 
compared to those patients with high RANK, high RANKL and low OPG expression.  
 
6.5.2 Impact of β-oestradiol treatment on RANK, RANKL and OPG expression 
in vitro 
Based on the observations in the clinical data with regards to ER status and the 
correlations with RANK and RANKL, β-oestradiol treatments were carried out in 
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vitro on an oestrogen positive breast cancer cell line (MCF-7) and an oestrogen 
negative breast cancer cell line (MDA-MB-231).  
 
6.5.2.1 Concentration gradient responses to β-oestradiol treatment 
Both the ER positive and negative cell lines responded to the concentration gradient 
as expected. Both RANK and RANKL transcript levels decreased in response to the 
β-oestradiol gradient (10-7M, 10-8M, 10-9M, and 10-10M), with 10-8M appearing to 
show the greatest reduction in transcript copies compared to the control. The ER 
negative cell line showed increases in RANK and RANKL transcript copy numbers 
under increasing concentrations of β-oestradiol, both peaking at 10-8M. This 
corroborates our clinical cohort data which showed a negative correlation between 
ER positive status and RANK or RANKL transcript copies.  
In contrast, and of interest, is the apparent reversal in trend which was observed in 
the OPG transcript levels. Though 10-7M, 10-9M and 10-10M all showed decreased 
transcript copies, no apparent trend emerged in the ER positive cell line. In contrast, 
with the exception of the 10-8M β-oestradiol treatment in the ER negative cell line all 
the other concentrations responded as would be expected from the clinical data. 
Rachner et al (2008) showed, using Northern blot, that β-oestradiol could inhibit the 
production of OPG in MCF-7 cells. The data from this study generally agrees with 
this conclusion, though it appears in our data that this was most effective in the 
lowest concentration tested (10-10M). Rachner et al (2008) also, however, showed 
no effect on OPG transcripts in the MDA-MB-231 cell line, in contrast, it appears 
from our data that OPG transcript levels, for the majority of concentrations studied, 
appeared to be increased.  
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6.5.2.2 Time course responses to β-oestradiol treatment 
The time course data for the transcript levels of RANK, RANKL and OPG over a 24 
hour period after β-oestradiol stimulation is interesting. The ER positive cell line, 
MCF-7, appeared to initially respond as expected and RANK and RANKL transcript 
levels decreased, however the significant increase which was observed after 2 
hours was unexpected, especially as normal levels had not been restored after 24 
hours for the RANK expression. However, given the inhibitory effect on OPG which 
was observed after treatment with β-oestradiol by Rachner et al (2008), the 
significant decrease in OPG transcript copies after 1 hour incubation with β-
oestradiol treatment was anticipated. The interesting observation from this study 
was that the impact on OPG transcript levels was maintained throughout the 24hour 
period studied.  
The decrease in RANK and RANKL transcripts observed over the 24 hour period in 
the ER negative MDA-MB-231 cells was also unexpected, given the previous 
clinical data and concentration gradient data. These responses contradicted those 
from Rachner et al (2008) where they conclude after 6 hours treatment there was no 
change in RANKL transcript levels. qPCR may be considered a more sensitive 
technique than Northern blot, therefore the current study may have picked up the 
smaller fluctuations in the ER negative cell line. The decrease in OPG transcript 
levels over a 24hr period was also surprising in the ER negative cell line, especially 
given the increase observed previously, though at the 2 hour mark an increase was 
observed.  
Therefore this poses an interesting question into how the roles of OPG, RANK and 
RANKL, as well as the natural fluctuations of oestrogen, may evolve and impact 
breast cancer disease progression, especially under the switch from oestrogen 
dependent to oestrogen independent disease states. Further work down this avenue 
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of study is required to completely understand the role played by these molecules 
and there responsiveness to oestrogen throughout the progression of breast cancer. 
 
6.5.3 Effect of reduced OPG expression on MDA-MB-231 breast cancer cell 
behaviour 
The impact of targeting OPG was assessed using several in vitro function assays 
after successful knockdown of OPG using ribozyme transgenes. Knockdown of 
OPG in MDA-MB-231 cells appeared initially to enhance cell proliferation; however 
this was not maintained over the 5 day incubation period compared to the control 
cells. Of interest was the lack of response the treatments with HGF, BME or HGF 
and BME appeared to have on MDA-MB-231OPGKD cell proliferation. Though the 
BME treatment shows a statistically significant increase in MDA-MB-231OPGKD cell 
proliferation, this increase is only ~5% of the control and therefore may not 
represent a true substantial change. This pattern is reflected in the 5 day incubation 
graph where the control and all the treatments appeared to be similar. Some 
interest is generated in the lack of response of the MDA-MB-231OPGKD cells 
considering the control cells did respond to the treatment, though more investigation 
is required to see if this is a true trend. Similar observations were seen with MDA-
MB-231OPGKD cell-matrix adhesion, though a slight decrease in cell-matrix adhesion 
was observed compared to the control cell line it was not significant. The exogenous 
treatments added also appeared to have no noteworthy additional effects.  
Many of the previous studies looking at breast cancer and the role OPG plays have 
focused on TRAIL-induced apoptosis. Holen et al (2005) showed that in vitro MDA-
MB-231 and MDA-MB-436 cells had the ability to produce and secrete enough OPG 
(in 72hrs) to protect from TRAIL-induced apoptosis. They also noted that OPG is not 
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detected in normal breast tissue but it can be moderately detected in approximately 
40% of primary breast cancer specimens. 
Of interest was the significantly increased motility that was observed in the MDA-
MB-231OPGKD cells compared to the control cells. Interestingly this response was not 
sustained or enhanced by the pleiotropic growth factor HGF and no additional 
response was seen after treatment with BME.  Also of interest was the observation 
that MDA-MB-231OPGKD cell invasion was significantly increased compared to the 
control cells. Furthermore, the observation that all the treatments, HGF, BME and a 
combination of HGF and BME appeared to reduce MDA-MB-231OPGKD cell invasion. 
The contrast in responses compared to those seen in the MDA-MB-231pEF6 control 
cell line provides an interesting direction for further investigation. Currently our in 
vitro data suggests a role for OPG in breast cancer cell motility and invasion, where 
it may act to supress these aggressive traits and furthermore, highlights that OPG 
may be involved in regulating the response of MDA-MB-231 breast cancer cells to 
various environmental signals, such as HGF and bone like conditions. 
The preliminary xenograft model completed as part of this study, appears to 
contradict the proliferation assay that was conducted, showing the MDA-MB-
231OPGKD cells developed tumours and grow significantly faster than the controls 
(MDA-MB-231pEF6 cells). Though this may be a true trend, during the course of this 
experiment the control cells (MDA-MB-231pEF6) did not react as tumourigenically as 
in previous in vivo studied. MDA-MB-231 cells are generally considered very 
tumourigenic and larger tumour development and growth was expected, thus these 
results need to be treated with caution and confirmed through repeat 
experimentation. 
 This study has tried to address the roles OPG may play in breast cancer cell 
behaviour traits involved in metastatic spread to the bone. As a result this study has 
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highlighted the potential roles OPG may have on breast cancer cell migration and 
invasion, though further investigation is required to understand by what mechanisms 
these traits are achieved. It would also be interesting to carry out a similar model in 
the oestrogen positive MCF-7 cell line to see what impact targeting cellular 
produced OPG has on ER positive tumourigenic breast cell behaviour. 
 
6.5.4 Effect of reduced RANK expression on MDA-MB-231 breast cancer cell 
behaviour 
After suppression of RANK expression was successfully achieved in MDA-MB-231 
cells using ribozyme transgenes, the impact was assessed using several in vitro 
function assays. Knockdown of RANK expression in MDA-MB-231 cells resulted in 
significantly decreased cell proliferation, but only after 5 days incubation.  Treatment 
with HGF appeared to have little impact on MDA-MB-231RANKKD cell proliferation 
after both 3 days and 5 days incubation. Though the BME and combined HGF and 
BME treatments both gave significant results after 3 days incubation both changes 
are very slight and therefore the statistically significant values potentially do not 
represent a true substantial change.  
Reduced RANK expression in MDA-MB-231 cells resulted in reduced cell-matrix 
adhesion, cell migration and invasion in vitro. Of further interest is the impact the 
treatments appear to have on the MDA-MB-231RANKKD cell-matrix adhesion. Both 
individual HGF and BME treatments increased MDA-MB-231RANKKD cell-matrix 
adhesion and invasion, though in this study these did not yield significant results 
these trends generate interest and need further investigation to identify possible 
changes in cell surface markers and pathway(s) which might be occurring.  
The observation that targeting RANK in vitro reduces cancer cell behaviour traits is 
supported by a recent in vivo bone metastases study conducted by Blake et al 
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(2014). Blake et al (2014) showed that MDA-MB-231 cells overexpressing RANK 
resulted in greater metastatic bone colonisation and growth through RANKL 
signalling.  
Though no other previous study has reduced RANK expression in MDA-MB-231 
cells, others have studied how these cells interaction with RANKL and result in 
increased metastatic bone potential and increase migration and invasion in vitro. 
Casimiro et al (2013) showed that the bone-seeking sub-clones of MDA-MB-231 
cells which were RANK positive increased cell migration and invasion through the 
RANKL JNK and ERK 1/2 signalling. 
The interactions between OPG, RANK and RANKL are complex during breast 
cancer development and progression. Some contradictory results were seen 
between the clinical data and the in vitro single cell models. This is best highlighted 
by the role of OPG. In the clinical cohort, lower OPG levels were seen to correlate 
with good prognosis and survival, yet in the single cell model, suppression of OPG 
appeared to increase cell migration and invasion, two traits which are considered to 
reflect aggressive disease. The human body is an intricate combination of a variety 
of cell types and factors which could never be replicated in a 2-D model. Isolating 
this one molecule in a cell system has highlighted the role breast cancer cell 
produced OPG may play in breast cancer cell migration and invasiveness. It is 
unlikely that OPG produced intrinsically by breast cancer cells alone accounts for 
the diverse role that this molecule plays in breast cancer dissemination. Hence, this 
may account for the confliction between the clinical and in vitro data. With more 
evidence implicating the role of RANK in breast cancer, research to elucidate all the 
pathways affected, and how these can be targeted therapeutically in a clinical 
setting must now be of greater emphasis.  
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Chapter 7 
General Discussion 
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7.1 Bone metastases associated with breast and prostate cancer  
The skeleton is the most common organ which is affected by cancer metastases, a 
site which still causes considerable morbidity and mortality (Coleman 2006). Due to 
the circulation flow through the bone and the venous blood through the vertebral-
venous plexus of vessels from the breast and pelvis, this physical factor may play a 
role in the establishment of bone metastases particularly associated with breast and 
prostate cancer. However, as highlighted by the complexity of the metastatic 
cascade, mechanical factors cannot be the sole factor which drives the high 
incidence of bone metastases. Thus the understanding of molecular features which 
mark bone as a preferred metastatic site, has resulted in major therapeutic 
achievements, such as Denosuamab (Lacey et al 2012). However, much still 
remains unknown about the complex interplay between the cancer cells, the bone 
environment and the signalling transductions that are induced aiding cancer 
progression. 
 
7.2 Thesis Aims 
During the course of this thesis the aim was to look at the potential implications of 
targeting endogenously produced OPG, RANK and RANKL on cancer cell traits, 
including cell proliferation, migration and invasion, in breast and prostate cancer cell 
lines which generated differing osseous phenotypes.  
Given the complex nature of the bone environment, this study also aimed to look at 
the influence the stromally produced growth factor, HGF and isolated bone proteins 
(BME) might have on manipulated osseous cancer cell lines.    
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7.3 Main conclusions from this study 
7.3.1 Role of OPG in prostate cancer 
Though OPG expression has been detected in normal prostate tissue, little is known 
about the potential roles it plays in normal prostate physiology. In this study all the 
cell lines screened expressed OPG, though the LNCaP cell line exhibited reduced 
expression in comparison to all the other prostate cancer cell lines, as has been 
noted elsewhere in the literature. Combining the observations from Brown et al 
(2001a), the hypothesis by Corey et al (2005) and the in vitro observations from this 
study, this evidence supports the idea that OPG influences prostate cancer 
development and progression rather than acts a causation factor.  
This study suggests that the targeting of endogenous OPG in the PC-3 prostate 
cancer cells, can affect prostate cell proliferation, particularly over a long incubation 
period. After the targeting of endogenous OPG, the addition of external stimuli, 
despite giving some significant results after 3 days incubation, resulted in similar 
patterns seen in the control cells, therefore questioning if these are truly significant 
results. However, under long term (5 day) treatments with HGF and BME in this 
study, PC-3 cells appeared less responsive to these external stimuli than the control 
cells. Though this appears an interesting trend, these results require further 
investigation. This assay was conducted over a time period, in which PC-3 cells 
may reach confluence, given the observation that targeting endogenous OPG 
enhances cellular proliferation there needs to subsequent confirmation that 
apoptosis was not being induced due to over-confluence in these exogenously 
treated cells, thus affecting potential conclusions which can be drawn.  
The addition of a recombinant form of OPG to LNCaP cells appeared to have no 
impact on cell proliferation over long term treatment both in its own right and when 
added with other external stimuli (HGF and BME). This highlights that potentially in 
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contrast to endogenously produced OPG, exogenous OPG may play a role in 
cancer progression but not through affecting prostate cancer cell proliferation.  
Further work is needed to investigate why such differences in response to 
endogenous and exogenous OPG are seen and highlights an avenue for further 
investigation into how OPG alters, through the course of the disease, and impacts 
both tumour cells and cells in the bone environment including osteoblasts, 
osteoclasts and bone marrow stromal cells.  
OPG, either through being targeted or added, did not appear to impact either PC-3 
or LNCaP prostate cancer cell-matrix adhesion or cell motility. However, after 
targeting endogenously produced OPG, both BME and BME and HGF treatments 
resulted in significant decreases in cell-matrix adhesion and promotion in cell 
motility, though these trends did not reach significance, the individual BME 
treatment was close (p=0.084). In contrast, addition of exogenous OPG with HGF or 
a combination of HGF and BME to LNCaP cells resulted in decreases in cell-matrix 
adhesion (the latter significantly so), which was not seen under the BME treatment. 
This was accompanied by the observation that rhOPG with HGF, or a combination 
of HGF and BME promoted LNCaP cell motility, whilst a combination of rhOPG and 
BME appeared to reduce LNCaP cell migration. This data strongly suggests that 
both endogenously produced OPG and exogenously produced OPG can influence 
prostate cancer cell adhesion and motility in response to factors present in a bone 
like environment, particularly as these trends were not noted in the respective 
controls.       
Interestingly, the addition or removal of OPG appeared to impact cell invasion in 
vitro. Reducing expression levels of OPG in the aggressive androgen independent 
PC-3 cell line resulted in a more invasive phenotype, which was nullified by the 
addition of HGF. In contrast, the addition of rhOPG to the androgen dependent 
LNCaP cell line resulted in a decrease in cell invasion, which could be reversed 
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when added in combination with BME. Together this suggests that in prostate 
cancer cells, the expression of OPG can moderate invasive potential. The trends 
imply that under external stimuli, HGF and BME, or a component of the BME, may 
interfere with the anti-invasive properties of rhOPG. Of further interest are the 
changes in invasive potential between the cell lines themselves. LNCaP cells are 
androgen dependent, weakly metastatic prostate cancer cells, whilst PC-3 cells are 
androgen independent and highly metastatic. It would therefore be of interest to 
investigate what drives the potential for loss of endogenous OPG production to 
become pro-invasive, whether molecular or genetic? 
  
7.3.2 Role of RANK and RANKL in prostate cancer 
RANK expression was ubiquitous across all the prostate cancer cell lines studied, 
whilst in contrast RANKL expression seemed selective to those cell lines which 
have metastatic potential.  
Targeting of RANK expression in PC-3 cells resulted in observations of significantly 
increased cell proliferation and cell-matrix adhesion. These trends also appeared to 
be affected by the influence of external stimuli. Suppression of RANK appeared to 
make PC-3 cell proliferation less responsive to all treatments, a trend which was 
seen across both incubation periods studied. This trend was also mirrored in the 
cell-matrix adhesion assay, though no significant trends were reported in either 
group, the relevance of these observations are debateable.  
Interestingly, after targeting RANK expression in PC-3 cells, though motility did not 
appear to be affected, it allowed for an interesting observation. The PC-3RANKKD cells 
appeared more aggregated in comparison to the control cells. This provides a bit of 
a conundrum. Is it possible that these cells have migrated as a colony, or is there 
potential that after initial cells have migrated induced secretion of 
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chemoattractant(s), encourages other cells to migrate to that location? Cell 
aggregation appeared particularly apparent under the influence of the growth factor, 
HGF. This is interesting since HGF is known as a scatter factor, possibly indicating 
that these cells are less responsive to HGF. Further investigation is now needed 
into potential cell-cell contact markers which might be influenced by the suppression 
of RANK in prostate cancer cells, and subsequently if this influences other factors 
which are secreted by the cells themselves.    
Unfortunately, attempts to derive an LNCaPRANKKD cell line were unsuccessful; to 
achieving this would allow further investigation into how targeting RANK might affect 
prostate cancer cell behaviour. 
The literature suggests that immortalised prostate cancer cells which have 
metastatic osseous potential express RANKL (Corey et al 2002). The reason why 
our PC-3 prostate cancer cell line does not express any detectable levels of RANKL 
remains unknown, and attempts to generate an overexpression model were also 
unsuccessful. However, based on the observations in the literature that LNCaP cells 
are able to produce both membrane and soluble forms of RANKL, it provided a 
direction to investigate the role of targeting RANKL expression (Zhang et al 2001). 
Denosumab (neutralising RANKL monoclonal antibody, nRANKL) is not currently 
licensed by NICE for the treatment of SREs linked to prostate cancer, therefore a 
better understanding how RANKL influences prostate cancer progression, may in 
time allow for a similar, more effective therapy to become available. 
nRANKL appeared to have similar effects on LNCaP cell proliferation and cell-
matrix adhesion as those observed under the rhOPG treatment. This was to some 
extent expected due to the normal inhibitory role OPG plays physiologically on 
osteoblasts. The unexpected result came from the combination of nRANKL and 
HGF, this combination resulted in a significant decrease in LNCaP proliferation after 
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3 days incubation, an observation not noted elsewhere. This result was sustained 
over the 5 days analysed, but this result then becomes consensus with the other 
LNCaP cells treated with HGF. nRANKL and HGF in combination also appeared to 
enhance LNCaP cell motility. It would therefore be interesting to further investigate 
how the combination of nRANKL and HGF accelerate their anti-proliferative and 
pro-migratory effects in vitro. 
 
7.3.3 Role of OPG in breast cancer 
In breast cancer, the endogenous suppression of OPG in MDA-MB-321 cells, 
resulted in increased cell motility and invasive potential, however cell proliferation 
and cell-matrix adhesion appeared unaffected. Of further interest was the impact the 
external stimuli had on MDA-MB-231OPGKD cell behaviour. As was previously noted 
in the PC-3 prostate cancer cell line, HGF appeared to reduce the invasive potential 
of these cells. Therefore further investigation into how HGF moderates the invasive 
potential of OPG in both cancer types is needed. 
  
7.3.4 Role of RANK in breast cancer 
Most of the literature regarding RANK in breast cancer focuses on generating over 
expression. Suppression of RANK expression in our MDA-MB-231 cells resulted in 
the observation of reduced breast cancer cell proliferation, cell-matrix adhesion, 
motility and invasive potential, none of which were further moderated by the addition 
of external stimuli. These results are therefore contradictory to the findings in the 
clinical data and warrant further investigation, potentially using a breast cancer cell 
line with differing metastatic potential, for example MCF-7. 
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7.3.5 Roles of OPG/RANK/ RANKL in clinical breast cancer 
The clinical cohort data indicated that RANK, RANKL and OPG all demonstrate 
reduced expression in tumour samples versus normal breast tissues, however none 
of these reached significance. Transcript levels for RANK and RANKL were shown 
to be significantly lower in patients whose tumours were ERβ positive, suggesting a 
negative correlation with ER status. 
Reduced expressions of RANK and RANKL transcript were found to be significantly 
correlated with poor overall survival. In contrast to this, higher levels of OPG 
expression correlated with a poorer overall survival.  
 
7.3.6 Summary 
Taken together, these results have strongly suggested a role for OPG in prostate 
cancer (in both osteolytic and mixed osteolytic and osteoblastic) cell migration and 
invasion especially under the influence of the isolated bone proteins and HGF. In 
addition targeting of OPG in the MDA-MB-231 breast cancer cell line also appeared 
to effect tumour cell migration and invasion, though the external stimuli appeared to 
be less of a driving force. This potentially highlights that some of the characteristic 
responses induced by OPG are similar across breast and prostate cancer types.  
In contrast, the targeting of RANK in breast and prostate cancer cells resulted in 
differential effects. Suppression of prostate cell RANK in the osteolytic PC-3 model 
resulted in increased cell growth and matrix-adhesion, however, in the osteolytic 
MDA-MB-231 breast cancer model RANK suppression resulted in significant 
decreases in the cancer cell traits investigated.  
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7.4 Future perspectives 
This study has demonstrated the potential involvement of OPG/RANK/RANKL in 
breast and prostate cancer and established a role for these molecules in translating 
signals in response to HGF and bone like conditions. Whilst substantial efforts have 
been made to characterise the impact of altering expression levels in these cancer 
types and their response to external stimuli, additional work is now required to take 
forward the observations of this study. Whilst this study has identified a number of 
interesting observations, it has also generated a number of questions which require 
further scientific evaluation.  It is hoped that future work conducted following on from 
this thesis, will aid further elucidation into the importance of OPG/RANK/RANKL in 
osteotrophic prostate and breast cancer metastasis. 
Specific areas of focus for future work are: 
7.4.1 Establishment of mechanism 
Focusing on the traits, proliferation, migration and invasion, which were affected 
either directly or indirectly by OPG, some preliminary work has been conducted to 
try and establish signalling pathways which may be involved in these observations. 
The primary focus has been to look at the MMPs as they have been implicated in 
metastases and the ‘vicious’ bone cycle (Lynch 2011). In the MDA-MB-231 cells, 
MMPs 3, 7 and 9 transcript expression was analysed. Though repeats are needed, 
it appears that suppression of OPG in the MDA-MB-231 cells resulted in increased 
levels of MMP-3. This is interesting since MMP-3 has been linked to the degradation 
of collagen (types II, III, IV, IX and X), proteoglycans, fibronectin, lamin and elastin 
in rheumatoid arthritis (Burrage et al 2006). If this is reproducible it could 
subsequently be confirmed by zymography and may highlight a mechanism linking 
OPG to breast cancer cell invasion.  
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Similar patterns were not observed in the PC-3 prostate cancer cell line, when 
screened for MMP-3 and -7. Further work into the screening of the remaining MMPs 
and TIMPs are needed together with analysis of their activity in response to 
endogenous OPG suppression. In breast cancer cells the intranuclear trafficking of 
the osteoblastic transcription factor RUNX2 has been shown to be impaired, 
therefore influencing metastatic potential and invasion through regulation of MMP-9 
(Pratap et al 2009, Javed et al 2005). Whilst in prostate cancer RUNX2 has been 
shown to influence tumour cell osteomimicry (Leong et al 2010, Rucci et al 2010, 
Akech et al 2010, Brubaker et al 2003, Baniwal et al 2010). Therefore further efforts 
into elucidating the potential factors which mediate the observed responses are 
necessary, though complicated by the inter-linked network of cascades and 
transcription factors which could be influenced (Figure 7.1).     
 
7.4.2 Additional cellular models 
Due to the time constraints of this study, it was not possible to generate additional 
cell models. With more time this could be addressed. The most evident concern 
would be the lack of a reflective osteoblastic prostate cancer cell model, considering 
it is the predominant bone lesion phenotype associated with prostate cancer. Work 
into establishing the MDA-PCa-2b model was undertaken, however, the MDA-PCa-
2b model was found to be unsuitable for this purpose. Recent efforts resulted in the 
purchasing of the VCaP cell line, which has been reported to generate osteoblastic 
lesions (Kirschenbaum et al 2011). Of great interest, is that from the initial PCR 
screen which has been conducted, this prostate cancer cell line showed positive 
transcript expression for both HGF and its receptor c-MET (Data not shown). If this 
can be replicated it will allow for further investigation into not only the paracrine 
influence HGF may have on cancer cells, but also the autocrine effects. 
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Figure 7.1: Potential mechanisms of tumour and bone cell 
interactions 
These stimuli could potentially exert their effects through a variety of 
pathways by affecting signal transducers including SMADs, MAPK, FAK 
and the Rho GTPases (adapted from Weilbaecher et al 2011)  
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To fully understand in vitro the potential OPG may have on prostate cancer disease 
progression, both an immortalised normal prostate (PZHPV-7) and a primary 
prostate cancer (CAHPV-10) would also be of interest. Due to time constraints it 
was not possible to conduct this work as part of the current thesis, though these 
would represent interesting models for future study.  
The MDA-MB-231 cell line is considered ER negative, given the close nature of both 
oestrogens and breast cancer progression, and oestrogens and bone it would 
therefore also be interesting to replicate similar cell models in the ER positive MCF-
7 cell line. This is also of interest given the role androgens play in bone turnover and 
the increasing links which are being established with breast cancer progression.  
 
7.4.3 Co-culture models 
Looking at these cell models in isolation allows for intense study; however these do 
not replicate physiological models, either pre-clinical or clinical. Therefore, having 
looked at these models as part of this study, it would now be interesting to start 
establishing co-culture models with a variety of cell types from the bone 
environment. A human osteoblast cell line (hFOB1.19) is commercially available, 
however this does not appear to be the case for osteoclasts. In the literature two 
models have previously been described.  
- In some co-culture models, mouse osteoclasts are used (RAW264.7) 
(Mouline et al 2010) 
- Several research groups have reported to have isolated human pre-cursor 
osteoclasts (FLG29.1 and THP-1) and shown that it is possible to 
differentiate these in culture, though proliferation of mature osteoclasts does 
not appear to have been achieved (Gattei et al 1992, Aldinucci et al 1996, 
Jakob et al 1997, Shozu et al 1997).  
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Given that the cell models used in this study are human, it would be interesting to 
collaborate with these groups to potentially develop a co-culture model. Or to source 
these cells and experiment with the potential of co-culture looking at how these 
manipulated cancer cells effect osteoclast maturation and differentiation in vitro.  
 
7.4.4 In-vivo xenograft and bone models 
An initial xenograft model was conducted on the MDA-MB-231 cell line and though 
the results must be treated with caution they potentially highlighted something 
interesting (Figure 6.12). Unfortunately, shortly after this study had ended, the group 
project license expired. Upon renewal it would be interesting to repeat this model, 
and use the other manipulated cell lines. Efforts to establish an in-vivo bone model 
would also provide a new direction to explore the potential impact of tumour growth 
in bone and metastasis model. 
 
Many challenges remain to try and better understand the complex interplay which 
occurs between tumour cells and bone. Through a process of discovery and 
elimination it is hoped that these efforts will ultimately result in improved therapeutic 
interventions or possibly even a preventative intervention.  
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